



# HEALTH

THIS PANDEMIC HAS GIVEN US ONE IMPORTANT LESSON.  
WHEN WE **HEAL** OUR MIND, BODY, SPIRIT  
AND ENVIRONMENT WE ARE IN THE  
BEST OF **HEALTH**.

## FINANCIAL SUMMARY 10 Years' Performance

₹ In lakhs

### CAPITAL ACCOUNT

Particulars	2011-12	2012-13	2013-14	2014-15	2015-16	2016-17	2017-18	2018-19	2019-20	2020-21
Share Capital	418	418	418	418	1,253	1,253	1,253	1,253	1,253	2,505
Reserves	6,503	7,145	8,171	9,672	10,958	12,802	13,709	15,207	14,968	16,559
Borrowings	702	52	-	-	211	-	244	439	4,456	1,360
Gross Block	1,936	2,294	2,387	2,295	3,361	3,364	2,640	6,036	9,510	9,737
Net Block	1,095	1,308	1,233	982	1,850	1,759	2,262	5,502	8,404	7,142

### REVENUE ACCOUNT


Particulars	2011-12	2012-13	2013-14	2014-15	2015-16	2016-17	2017-18	2018-19	2019-20	2020-21
Total Revenue	22,908	24,490	27,055	28,874	32,973	22,454	24,863	32,537	31,117	44,250
Earnings Before Interest, Tax, Depreciation and Amortization	1,987	1,939	2,733	3,518	4,024	2,713	2,529	3,423	2,698	5,512
Profit before Tax	1,805	1,768	2,548	3,186	3,794	2,759	2,342	3,240	1,916	3,855
Profit After Tax	1,285	1,253	1,759	2,199	2,580	2,005	1,651	2,337	1,431	2,844
Earnings Per Share (₹)	15.38	15.01	21.06	26.00	10.3	8.00	6.59	9.33	5.71	5.67
Dividend Per Share (₹)	5.50	6.00	7.75	7.00	2.50	2.50	2.75	2.75	2.75	1.50

#### Notes :

- 1) EPS & DPS reported w.e.f. FY 2015-16 is after giving effect to Bonus Issue of Shares in the ratio of 2:1 i.e. 2 Bonus Shares for each Equity Share held.
- 2) EPS & DPS reported w.e.f. FY 2020-21 is after giving effect to Bonus Issue of Shares in the ratio of 1:1 i.e. 1 Bonus Shares for each Equity Share held.
- 3) Figures for the FY 2016-17 and onwards are reported as per Ind AS requirements.
- 4) The Board of Directors of the Company has recommended a final dividend of ₹ 1.50/- per equity share of face value of ₹ 5/- each (30%), subject to shareholders' approval at the 61<sup>st</sup> Annual General Meeting after giving effect to Bonus Issue of Shares in the ratio of 1:1 i.e. 1 Bonus Share for each Equity Share held.


**Total Revenue**

₹ in Lakhs




**EBITDA**

₹ in Lakhs




**Reserves**

₹ in Lakhs



**Outflow of Dividend**

₹ in Lakhs



Note: \* This includes Final Dividend of F.Y. 2018-19 of ₹ 831 lakhs and Interim Dividend of F.Y. 2019-20 of ₹ 831 lakhs.

\*\* The Board of Directors recommended a Final Dividend of ₹ 1.50/- per share i.e. 30% for the F.Y. 2020-21 subject to the approval of Shareholders.

## CONTENTS

<b>Particulars</b>	<b>Page Nos.</b>
Vice Chairman's Message to the Shareholders	3
List of Board of Directors	4
List of Senior Management and Key Managerial Personnel	6
Corporate Information	7
Notice	8
Directors' Report	24
Management Discussion and Analysis	44
Corporate Governance Report	47
Certificate on Corporate Governance	63
Independent Auditor's Report	64
Balance Sheet as on March 31, 2021	72
Statement of Profit and Loss for the year ended on March 31, 2021	73
Cash Flow Statement	74
Notes to Financial Statements	77

## Vice Chairman's Message to the Shareholders



**Mr. Bipin N. Shah**

**Vice Chairman**

Dear Shareholders,

Our Company has been bestowed with the responsibility of providing quality bulk drugs to formulation companies. We have a strong client base of 350 Indian/Multinational companies. During the financial year 2020-2021, the main challenge was to run the Company, despite several factors related to the pandemic lockdowns. These include:

- i) Picking and dropping employees
- ii) Social distancing
- iii) Sanitization
- iv) Ensuring pandemic related safety measures like wearing masks etc.

We have successfully performed throughout the year and provided timely service to all our esteemed clients.

As we reel under the effects of the second wave, we still continue to face similar challenges. With tremendous support

from staff and workers, we are confident that we will keep the wheels of production rolling.

It is my great pleasure to present to you our Company's 61<sup>st</sup> Annual Report in a nutshell.

**Our operational revenue for the financial year 2020-2021 amounted to ₹ 43,196 lakhs as against ₹ 30,696 lakhs for the previous year, an increase of 40.70%**

**Our profit before tax as compared to last year has increased by 101.25% from ₹ 1,916 lakhs to ₹ 3,855 lakhs and profit after tax has increased by 99% from ₹ 1,431 lakhs to ₹ 2,844 lakhs.**

We could achieve above good results in spite of huge depreciation of ₹ 1,508 lakhs for the financial year 2020-2021.

### **EXPANSION PROJECT:**

Our "New Expansion project" is fully operational and due to this increased capacity, we hope to continuously achieve higher topline and bottom-line.

We continue to allocate total resources towards building the API and Bulk Drugs segment. Our R&D facility at Navi Mumbai works relentlessly on the development of newer and better pharmaceutical raw materials.

### **TRANSFORMATION:**

In order to generate long term sustainable value for shareholders, businesses need to continuously involve and transform themselves to build a strong foundation for future growth.

At Anuh Pharma, we have decided on a transformational journey to ensure that the Company is aligned in tune with the times.

With warm regards,

**Mr. Bipin N. Shah**  
Vice Chairman  
Anuh Pharma Ltd.

## Board of Directors



**Mr. Jasantlal G. Shah**  
Chairman



**Mr. Bipin N. Shah**  
Vice Chairman



**Mr. Lalitkumar P. Shah**  
Director



**Mr. Bharat N. Shah**  
Director



**Mr. Arun L. Tadarwal**  
Director



**Dr. (Ms.) Mita C. Dixit**  
Director

## Board of Directors



**Mr. Harmanbhai T. Patel**  
Director



**Mr. Sandeep M. Joshi**  
Director



**Mr. Samir J. Shah**  
Director



**Mr. Ketan L. Shah**  
Director



**Mr. Ritesh B. Shah**  
Joint Managing Director



**Mr. Vivek B. Shah**  
Joint Managing Director



## Senior Management & Key Managerial Personnel



**Mr. Rajendrakumar C. Kotadia**  
Vice President - Marketing



**Dr. Rajiv P. Sutar**  
Vice President - Technical



**Mr. Darshan D. Rampariya**  
Chief Financial Officer



**Mr. Sanjay V. Barhate**  
Vice President - Quality



**Dr. Sushil J. Dheer**  
General Manager - R & D



**Mr. Tejas S. Patel**  
General Manager - QA



**Mr. Surendra U. Rai**  
Assistant General Manager - QC



**Mr. Ketan N. Shah**  
Senior Marketing Executive



**Mr. Gaurav S. Shah**  
Head Anti Malarials



**Mr. Kaushal H. Shroff**  
Senior Marketing Executive



**Mr. Nilesh S. Mohare**  
Assistant General Manager - QA



**Ms. Ashwini S. Ambrale**  
Company Secretary &  
Compliance Officer



**Mr. Bhavesh S. Mudaliar**  
Assistant General Manager  
- Production



**Mr. Babu K. Moghaveera**  
Assistant General Manager  
- Technical



**Mr. Monil R. Shah**  
Marketing & Business  
Development Executive



**ANUH PHARMA LTD.**

**CIN: L24230MH1960PLC011586**

**Sixty-First Annual Report of the Board of Directors  
with the Audited Statement of Accounts for the year ended March 31, 2021**

<b>Board of Directors</b>	: Mr. Jasvantlal Shah	Chairman - Independent Director	(DIN: 00372600)
	Mr. Bipin Shah (Appointed w.e.f. 08/01/2021)	Vice Chairman	(DIN: 00083244)
	Mr. Ritesh Shah (Re-designated w.e.f. 08/01/2021)	Joint Managing Director	(DIN: 02496729)
	Mr. Vivek Shah (Re-designated w.e.f. 08/01/2021)	Joint Managing Director	(DIN: 02878724)
	Mr. Lalitkumar Shah	Director	(DIN: 00396345)
	Mr. Bharat Shah	Director	(DIN: 00083354)
	Mr. Arun Todarwal	Independent Director	(DIN: 00020916)
	Mr. Sandeep Joshi	Independent Director	(DIN: 00516409)
	Mr. Harmanbhai Patel	Independent Director	(DIN: 07342390)
	Dr. (Ms.) Mita Dixit	Independent Director	(DIN: 08198165)
	Mr. Samir Shah	Director	(DIN: 00157396)
	Mr. Ketan Shah	Director	(DIN: 00083326)
<b>Chief Financial Officer</b>	: Mr. Darshan Rampariya		
<b>Company Secretary &amp; Compliance Officer</b>	: Ms. Ashwini Ambrale		
<b>Auditors</b>	: M/s. Jayantilal Thakkar & Co. Chartered Accountants, (Firm Registration No. 104133W)		
<b>Bankers</b>	: HDFC Bank Ltd.		
<b>Registrars and Transfer Agents</b>	: Bigshare Services Private Limited 1 <sup>st</sup> Floor, Bharat Tin Works Building, Opp. Vasant Oasis Makwana Road, Marol, Andheri East, Mumbai 400059 Tel: +91-22-6263 8200 Fax: +91-22-6263 8299 Email: investor@bigshareonline.com Web: www.bigshareonline.com		
<b>Registered Office</b>	: 3-A, Shivsagar Estate, North Wing, Dr. Annie Besant Road, Worli, Mumbai - 400018 Tel : +91-22-6622 7575 Fax: +91-22-6622 7600 Email: anuh@sk1932.com Web: www.anuhpharma.com		
<b>Factory</b>	: E-17/3, 17/4 & E-18 MIDC, Tarapur, Boisar, Dist. Palghar - 401506 Tel : +91-7410055574/75		
<b>R &amp; D Division</b>	: A-514, TTC Industrial Area, MIDC, Mahape, Navi Mumbai - 400701 Tel : +91-22-4119 3333 Fax: +91-22-4119 3300 Email: research@anuhpharma.com Web: www.aplrnd.com		

## NOTICE

SIXTY-FIRST ANNUAL GENERAL MEETING of the Members of ANUH PHARMA LIMITED will be held on Thursday, 19<sup>th</sup> August, 2021 at 11.00 AM through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") to transact the following business:

### ORDINARY BUSINESS:

1. To receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended March 31, 2021, including Audited Balance Sheet as at March 31, 2021 and the Statement of Profit & Loss for the year ended on that date together with the Reports of the Board of Directors and Auditors thereon for the said year.
2. To declare a Final Dividend of ₹ 1.50/- per Equity Share of the Company for the financial year 2020-21.
3. To appoint a Director in place of Mr. Lalitkumar P. Shah (DIN: 00396345) who retires by rotation and, being eligible offers himself for re-appointment.
4. To appoint a Director in place of Mr. Ketan L. Shah (DIN: 00083326) who retires by rotation and, being eligible offers himself for re-appointment.

### SPECIAL BUSINESS :

5. To consider and, if thought fit, to pass, with or without modification(s), the following resolution as an **Ordinary Resolution**:

**"RESOLVED THAT** pursuant to the provisions of Section 148 and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), the remuneration of ₹ 1,10,000/- plus applicable tax and reimbursement of the out of pocket expenses, if any, payable to Mr. Ankit Kishor Chande, Cost Accountant, (Certificate of Practice No. 34051) being a Cost Auditor, to conduct the audit of the Cost Accounting records related to Bulk Drugs of the Company for the financial year 2021-22, be and is hereby ratified.

**RESOLVED FURTHER THAT** Mr. Bipin Shah, Vice Chairman (DIN: 00083244), Mr. Ritesh Shah (DIN: 02496729), Mr. Vivek Shah (DIN: 02878724), Joint Managing Directors, Mr. Bharat Shah (DIN: 00083354), Mr. Ketan Shah (DIN: 00083326) Directors and the Company Secretary of the Company be and is hereby severally authorized to take all such necessary steps and actions and authorized to do all the necessary formalities and to sign and submit the necessary papers and forms with required authorities including E-Form with Registrar of Companies to give effect to this resolution."

6. To consider and, if thought fit, to pass, with or without modification(s), the following resolution as a **Special Resolution**:

**"RESOLVED THAT** pursuant to the provisions of Sections 196, 197, 203 read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modifications, amendments or re-enactments thereto for the time being in force) (hereinafter referred to as "the Act"), in pursuance of the relevant provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and as per the provisions of the Articles of Association of the Company and subject to the approvals, consents, permissions and sanctions of appropriate and/or concerned authorities and subject to such other conditions and modifications, as may be prescribed, imposed or suggested by any of such appropriate and/or concerned authorities while granting such approvals, consents, permissions and sanctions and as agreed to by the Board of Directors of the Company, (hereinafter referred to as "the Board" which term shall be deemed to include any Committee which the Board may have constituted or herein after constitute to exercise its powers including the powers conferred by this Resolution), the consent of the Members be and is hereby accorded to the appointment and re-designation of **Mr. Ritesh B. Shah (DIN: 02496729) & Mr. Vivek B. Shah (DIN: 02878724)** as Joint Managing Directors of the Company from the position of Whole Time Directors and Chief Executive Officers of the Company, for a period of 5 years with effect from 8<sup>th</sup> January, 2021 upto 7<sup>th</sup> January, 2026, whose period of office shall not be liable to retire by rotation, with the powers to the Board to alter, amend, vary and modify the terms and conditions of the said appointment.

**RESOLVED FURTHER THAT** Mr. Bipin Shah, Vice Chairman (DIN: 00083244) Mr. Bharat Shah (DIN: 00083354), Mr. Ketan Shah (DIN: 00083326) Directors and the Company Secretary of the Company be and is hereby severally authorized to take all such necessary steps and actions and authorized to do all the necessary formalities and to sign and

submit the necessary papers and forms with required authorities including E-Form with Registrar of Companies to give effect to this resolution.

**RESOLVED FURTHER THAT** a copy of the forgoing resolutions, certified as true, be given to the concerned authorities for their records.”

7. To consider and, if thought fit, to pass, with or without modification(s), the following resolution as a **Special Resolution**:

“**RESOLVED THAT** pursuant to the provisions of Section 197 read with Part I and Section I of Part II of Schedule V and other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modification or re-enactment thereof for the time being in force), applicable clauses of the Articles of Association of the Company and the recommendation of the Nomination and Remuneration Committee and as agreed by the Board of Directors, approval of the Members be and is hereby accorded for revision in the remuneration of **Mr. Ritesh B. Shah (DIN: 02496729), Joint Managing Director** of the Company for the financial year 2021-22, on the terms and conditions including remuneration as mentioned below w.e.f. 01<sup>st</sup> April, 2021:

- i) Monthly CTC of ₹ 2,30,000/- with such increments as may be decided by the Board subject to a ceiling of ₹ 5,00,000/- per month.
- ii) Commission on net profit before tax - at such rate as may be decided by the Board of Directors from time to time subject to a maximum of 0.50%.

**Part A**

1. Medical Reimbursement - Expenses incurred for self and family, including dependent parents subject to a ceiling of one month's salary in a year or three months salary over a period of three years.
2. Leave Travel Concession - For Self and family once a year incurred in accordance with the rules of the Company.
3. Personal Accident Insurance - Premium not exceeding ₹ 15,000/- p.a.
4. Entertainment Expenses - Reimbursement of entertainment expenses actually incurred in the course of business of the Company.

**Part B**

**(a) Provident Fund:**

Company's contribution subject to a ceiling as laid down by the Government from time to time.

**(b) Gratuity :**

Gratuity payable shall not exceed half a month's salary for each completed year of service and which shall be subject to the maximum amount as may be permitted under the Company's rules in relation to Gratuity prevailing from time to time.

**Part C**

The Company shall provide a car with a driver and a telephone at his residence.

The Joint Managing Director shall be entitled to earned privilege leave on full pay and allowances as per rules of the company but not more than one month's leave for every eleven months of service.

The accumulated leaves can be encashed at the end of the service.

**RESOLVED FURTHER THAT** Mr. Bipin Shah, Vice Chairman (DIN: 00083244) Mr. Bharat Shah (DIN: 00083354), Mr. Ketan Shah (DIN: 00083326) Directors and the Company Secretary of the Company be and is hereby severally

authorized to take all such necessary steps and actions and authorized to do all the necessary formalities and to sign and submit the necessary papers and forms with required authorities including E-Form with Registrar of Companies to give effect to this resolution.

**RESOLVED FURTHER THAT** a copy of the forgoing resolutions, certified as true, be given to the concerned authorities for their records.”

8. To consider and, if thought fit, to pass, with or without modification(s), the following resolution as a **Special Resolution:**

“**RESOLVED THAT** pursuant to the provisions of Section 197 read with Part I and Section I of Part II of Schedule V and other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modification or re-enactment thereof for the time being in force), applicable clauses of the Articles of Association of the Company and the recommendation of the Nomination and Remuneration Committee and as agreed by the Board of Directors, approval of the Members be and is hereby accorded for revision in the remuneration of **Mr. Vivek B. Shah (DIN: 02878724), Joint Managing Director** of the Company for the financial year 2021-22, on the terms and conditions including remuneration as mentioned below w.e.f. 01<sup>st</sup> April, 2021:

- i) Monthly CTC of ₹ 2,30,000/- with such increments as may be decided by the Board subject to a ceiling of ₹ 5,00,000/- per month.
- ii) Commission on net profit before tax - at such rate as may be decided by the Board of Directors from time to time subject to a maximum of 0.50%.

**Part A**

1. Medical Reimbursement - Expenses incurred for self and family, including dependent parents subject to a ceiling of one month's salary in a year or three months salary over a period of three years.
2. Leave Travel Concession - For Self and family once a year incurred in accordance with the rules of the Company.
3. Personal Accident Insurance - Premium not exceeding ₹ 15,000/- p.a.
4. Entertainment Expenses - Reimbursement of entertainment expenses actually incurred in the course of business of the Company.

**Part B**

**(c) Provident Fund:**

Company's contribution subject to a ceiling as laid down by the Government from time to time.

**(d) Gratuity :**

Gratuity payable shall not exceed half a month's salary for each completed year of service and which shall be subject to the maximum amount as may be permitted under the Company's rules in relation to Gratuity prevailing from time to time.

**Part C**

The Company shall provide a car with a driver and a telephone at his residence.

The Joint Managing Director shall be entitled to earned privilege leave on full pay and allowances as per rules of the company but not more than one month's leave for every eleven months of service.

The accumulated leaves can be encashed at the end of the service.

**RESOLVED FURTHER THAT** Mr. Bipin Shah, Vice Chairman (DIN: 00083244) Mr. Bharat Shah (DIN: 00083354), Mr. Ketan Shah (DIN: 00083326) Director and the Company Secretary of the Company be and is hereby severally authorized to take all such necessary steps and actions and authorized to do all the necessary formalities and to sign and submit the necessary papers and forms with required authorities including E-Form with Registrar of Companies to give effect to this resolution.

**RESOLVED FURTHER THAT** a copy of the forgoing resolutions, certified as true, be given to the concerned authorities for their records.”

For and on behalf of the Board of Directors

Sd/-  
**Ashwini Ambrale**  
Company Secretary & Compliance Officer  
(M. No.: A32456)

**Registered Office:**

CIN: L24230MH1960PLC011586  
3-A, Shiv Sagar Estate, North Wing,  
Dr. Annie Besant Road, Worli, Mumbai - 400 018  
Tel: +91-22 6622 7575; Fax: +91-22 6622 7600  
Email: anuh@sk1932.com; Web: www.anuhpharma.com;

Place : Mumbai  
Date : May 21, 2021

**NOTES:**

1. The Register of Members and Share Transfer Book of the Company shall remain closed on **Thursday, August 19, 2021** for the purpose of payment of Final Dividend and 61<sup>st</sup> Annual General Meeting of the Company.
2. In view of the continuing COVID-19 pandemic and restrictions imposed on the movement of people, the Ministry of Corporate Affairs (MCA) vide its Circular dated January 13, 2021, May 05 2020 read with Circulars dated April 08, 2020 and April 13, 2020 (collectively referred to as MCA Circulars) and Securities and Exchange Board of India (SEBI) vide its Circular No. SEBI/HO/CFD/CMD2/CIR/P/2021/11 dated January 15, 2021 regarding relaxation from compliance with certain provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 due to the CoVID-19 pandemic and SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020 have permitted the holding of the Annual General Meeting (AGM) through Video Conference/ Other Audio Visual Means, without the physical presence of the Members at a common venue.
3. The venue of the AGM shall be deemed to be the registered office of the Company at 3A, Shivsagar Estate, North Wing, Dr. Annie Besant Road, Worli, Mumbai – 400018.
4. Pursuant to the provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the Circulars issued by MCA and SEBI, 61<sup>st</sup> AGM of the Company shall be conducted through VC/OAVM. **Central Depository Services (India) Limited (CDSL)** will be providing facility for remote e-voting, participation in the AGM through VC / OAVM and e-voting during the AGM.
5. As the AGM shall be conducted through VC/ OAVM, the facility for appointment of Proxy by the Members is not available and hence, Proxy Form, Attendance Slip and Route Map are not annexed to this Notice.
6. Shareholders attending the AGM through VC/OAVM shall be reckoned for the purpose of quorum for the AGM as per Section 103 of the Companies Act, 2013 (Act)
7. Corporate members intending to authorize their representatives to participate and vote at the meeting are requested to mail to anuh@sk1932.com, a scanned copy (PDF format) of the Board Resolution authorizing their representatives to attend and vote at the AGM.

8. Shareholder holding shares in physical mode and who have not updated their email addresses with the Company are requested to update their email addresses by writing to the Company's Registrar and Share Transfer Agent, Bigshare Services Private Limited (Bigshare) at [investor@bigshareonline.com](mailto:investor@bigshareonline.com). Members are requested to submit request letter mentioning the Folio No. and Name of Shareholder along with scanned copy of the Share Certificate (front and back), self-attested copy of PAN card and Aadhaar card for updation of email address. Members holding shares in dematerialised mode are requested to register / update their email addresses with their Depository Participants.
9. The Shareholders who have not registered their email ID with the Company can access the Annual Report on the website of the Company [www.anuhpharma.com](http://www.anuhpharma.com) and website of the stock exchange i.e. BSE Limited [www.bseindia.com](http://www.bseindia.com). Shareholder who would like to obtain pdf copy on their email ID may write an email to [anuh@sk1932.com](mailto:anuh@sk1932.com). Pursuant to the Circulars mentioned above, the Company has not printed the Annual Reports and hence no hard copies of the Annual Report will be provided.
10. Members may note that the Income-tax Act, 1961, (**"the IT Act"**) as amended by the Finance Act, 2020, mandates that dividends paid or distributed by a company after April 01, 2020 shall be taxable in the hands of members. The Company shall therefore be required to deduct tax at source ("TDS") at the time of making the payment of final dividend. In order to enable us to determine the appropriate TDS rate as applicable, members are requested to submit relevant documents, as specified in the below paragraphs, in accordance with the provisions of the IT Act.

**For Resident shareholders**, taxes shall be deducted at source under section 194 of the Act, as follows:

Valid PAN of shareholder available with the Company	10% or as notified by the Government of India
Shareholders without PAN/invalid PAN with the Company*	20% or as notified by the Government of India
Shareholder who has not filed returns of tax for FY 19 and FY 20 before the due date and aggregate of tax deducted at source is ₹ 50,000 or more in each of these two years	20%**

\* Individual shareholder needs to ensure that his/her PAN is linked with Aadhaar number, on or before June 30, 2021, else his/her PAN is invalid.

\*\* TDS rate is applicable for dividend paid on or after July 1, 2021.

However, no tax shall be deducted on the dividend payable to a resident individual shareholder if the total dividend to be received by them during the financial year 2021-22 does not exceed ₹ 5,000/- and also in cases where shareholder provides form 15G (applicable to any person other than HUF or a Company or a firm)/form 15H (applicable to an individual who is 60 years and older) subject to conditions specified in the Act. Shareholders may also submit any other document as prescribed under the Act to claim a lower/nil withholding tax. PAN is mandatory for shareholders providing form 15G/form 15H or any other documents as mentioned above. The formats of form 15G/form 15H are also available on the website of our registrar and transfer agent (RTA) Bigshare Services Private Limited at [www.bigshareonline.com](http://www.bigshareonline.com).

**For non-resident shareholders**, taxes are required to be withheld in accordance with the provisions of Section 195 and other applicable sections of the IT Act, at the rates in force. The withholding tax shall be at the rate of 20% (plus applicable surcharge and cess) or as notified by the Government of India on the amount of dividend payable. However, as per Section 90 of the IT Act, non-resident shareholders have the option to be governed by the provisions of the Double Tax Avoidance Agreement (**"DTAA"**), read with Multilateral Instrument (**"MLI"**) between India and the country of tax residence of the member, if they are more beneficial to them. For this purpose, i.e. to avail the benefits under the DTAA read with MLI, non-resident shareholders will have to provide the following:

- (i) Copy of the PAN card allotted by the Indian income tax authorities duly attested by the member or details as prescribed under rule 37BC of Income-tax Rules, 1962
- (ii) Copy of Tax Residency Certificate for fiscal 2022 obtained from the revenue authorities of the country of tax residence, duly attested by member
- (iii) Self-declaration in Form 10F
- (iv) Self-declaration by the member of having no permanent establishment in India in accordance with the applicable tax treaty



- (v) Self-declaration of beneficial ownership by the non-resident shareholder
- (vi) Any other documents as prescribed under the IT Act for lower withholding of taxes if applicable, duly attested by the member.

In case of Foreign Institutional Investors / Foreign Portfolio Investors, tax will be deducted under Section 196D of the IT Act @ 20% (plus applicable surcharge and cess) or the rate provided in relevant DTAA, read with MLI, whichever is more beneficial, subject to the submission of the above documents on or before August 18, 2021. Members are requested to visit [www.anuhpharma.com](http://www.anuhpharma.com) for more instructions and information on this subject. No communication would be accepted from members after August 18, 2021 regarding tax withholding matters. Shareholders may write to [investor@bigshareonline.com](mailto:investor@bigshareonline.com) for any clarifications on this subject.

The aforementioned documents are required to be send to the Bigshare:

By Post / Courier / Hand Delivery / Email	M/s Bigshare Services Pvt. Ltd. Unit: Anuh Pharma Ltd. 1 <sup>st</sup> Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East Mumbai 400059 Tel : +91-22-62638200; Fax: +91-22-62638299 Email: <a href="mailto:investor@bigshareonline.com">investor@bigshareonline.com</a>
---	---

#### 11. PROCEDURE FOR REMOTE E-VOTING AND E-VOTING DURING THE AGM:

- (i) In compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and MCA Circulars dated April 08, 2020, April 13, 2020, May 05, 2020 and January 13, 2021 the Company is pleased to provide facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. The Company has engaged the services of Central Depository Services (India) Limited (CDSL) to provide the system of remote e-voting as well as the e-voting system on the date of the AGM.
- (ii) The Shareholder may note that the facility of participation at the AGM through VC/OAVM will be made available to at least 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
- (iii) The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of ascertaining the quorum under Section 103 of the Companies Act, 2013.
- (iv) The shareholder who is a Member as on the cut-off date shall only be entitled for availing the Remote e-voting facility or vote, as the case may be, in the Annual General Meeting.
- (v) The shareholder who is not a Member as on the cut off date should treat this Notice for information purposes only.
- (vi) The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for Remote e-voting

#### 12. THE DETAILED INTRUCTIONS FOR SHAREHOLDERS FOR REMOTE E-VOTING ARE AS UNDER:

- (i) The voting period begins on **Monday, August 16, 2021 at 09.00 AM IST and ends on Wednesday, August 18, 2021 at 05.00 PM IST**. During this period shareholders' of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date of **Wednesday, August 11, 2021** may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.
- (ii) Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.

- (iii) Pursuant to SEBI Circular No. **SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 09.12.2020**, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.

In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to **all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants**. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

- (iv) In terms of abovesaid **SEBI circular** on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Pursuant to abovesaid SEBI Circular, Login method for e-Voting and joining virtual meetings **for Individual shareholders holding securities in Demat mode** is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in Demat mode with CDSL	<ol style="list-style-type: none"> <li>1) Users of who have opted for CDSL's Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The URLs for users to login to Easi / Easiest are <a href="https://web.cdslindia.com/myeasi/home/login">https://web.cdslindia.com/myeasi/home/login</a> or <a href="http://www.cdslindia.com">www.cdslindia.com</a> and click on Login icon and select New System Myeasi.</li> <li>2) After successful login the Easi / Easiest user will be able to see the e-Voting Menu. On clicking the e-voting menu, the user will be able to see his/her holdings along with links of the respective e-Voting service provider i.e. CDSL as per information provided by Issuer / Company. Additionally, we are providing links to e-Voting Service Providers, so that the user can visit the e-Voting service providers' site directly.</li> <li>3) If the user is not registered for Easi/Easiest, option to register is available at <a href="https://web.cdslindia.com/myeasi/Registration/EasiRegistration">https://web.cdslindia.com/myeasi/Registration/ EasiRegistration</a></li> <li>4) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a link in <a href="http://www.cdslindia.com">www.cdslindia.com</a> home page. The system will authenticate the user by sending OTP on registered Mobile &amp; Email as recorded in the Demat Account. After successful authentication, user will be provided links for the respective ESP where the e-Voting is in progress during or before the AGM.</li> </ol>
Individual Shareholders holding securities in demat mode with NSDL	<ol style="list-style-type: none"> <li>1) If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: <a href="https://eservices.nsd.com">https://eservices.nsd.com</a> either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on "Access to e-Voting" under e-Voting services</li> </ol>

Type of shareholders	Login Method
	<p>and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</p> <p>2) If the user is not registered for IDeAS e-Services, option to register is available at <a href="https://eservices.nsd.com">https://eservices.nsd.com</a>. Select "Register Online for IDeAS" Portal or click at <a href="https://eservices.nsd.com/SecureWeb/IdeasDirectReg.jsp">https://eservices.nsd.com/SecureWeb/IdeasDirectReg.jsp</a></p> <p>3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <a href="https://www.evoting.nsd.com/">https://www.evoting.nsd.com/</a> either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting</p>
Individual Shareholders (holding securities in demat mode) login through their <b>Depository Participants</b>	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider's website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

**Important note:** Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

**Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL**

Login type	Helpdesk details
Individual Shareholders holding securities in Demat mode with <b>CDSL</b>	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at <a href="mailto:helpdesk.evoting@cdslindia.com">helpdesk.evoting@cdslindia.com</a> or contact at 022- 23058738 and 22-23058542-43.
Individual Shareholders holding securities in Demat mode with <b>NSDL</b>	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at <a href="mailto:evoting@nsdl.co.in">evoting@nsdl.co.in</a> or call at toll free no.: 1800 1020 990 and 1800 22 44 30

(v) Login method for e-Voting and joining virtual meeting for shareholders other than **individual shareholders & physical shareholders**.

- 1) The shareholders should log on to the e-voting website [www.evotingindia.com](http://www.evotingindia.com).
- 2) Click on "Shareholders" module.
- 3) Now enter your User ID
  - a. For CDSL: 16 digits beneficiary ID,
  - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
  - c. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.

- 4) Next enter the Image Verification as displayed and Click on Login.
- 5) If you are holding shares in demat form and had logged on to [www.evotingindia.com](http://www.evotingindia.com) and voted on an earlier e-voting of any company, then your existing password is to be used.
- 6) If you are a first-time user follow the steps given below:

	<b>For Shareholders holding shares in Demat Form other than individual and Physical Form</b>
PAN	Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) <ul style="list-style-type: none"> <li>• Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.</li> </ul>
Dividend Bank Details OR Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login. <ul style="list-style-type: none"> <li>• If both the details are not recorded with the depository or company, please enter the member id / folio number in the Dividend Bank details field as mentioned in instruction (v).</li> </ul>

- (vi) After entering these details appropriately, click on “SUBMIT” tab.
- (vii) Shareholders holding shares in physical form will then directly reach the Company selection screen. However, shareholders holding shares in demat form will now reach ‘Password Creation’ menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- (viii) For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- (ix) Click on the EVSN for the relevant Anuh Pharma Ltd. on which you choose to vote.
- (x) On the voting page, you will see “RESOLUTION DESCRIPTION” and against the same the option “YES/NO” for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- (xi) Click on the “RESOLUTIONS FILE LINK” if you wish to view the entire Resolution details.
- (xii) After selecting the resolution, you have decided to vote on, click on “SUBMIT”. A confirmation box will be displayed. If you wish to confirm your vote, click on “OK”, else to change your vote, click on “CANCEL” and accordingly modify your vote.
- (xiii) Once you “CONFIRM” your vote on the resolution, you will not be allowed to modify your vote.
- (xiv) You can also take a print of the votes cast by clicking on “Click here to print” option on the Voting page.
- (xv) If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.

**(xvi) Facility for Non – Individual Shareholders and Custodians –Remote Voting**

- Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to [www.evotingindia.com](http://www.evotingindia.com) and register themselves in the “Corporates” module.

- A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to [helpdesk.evoting@cdslindia.com](mailto:helpdesk.evoting@cdslindia.com).
- After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
- The list of accounts linked in the login should be mailed to [helpdesk.evoting@cdslindia.com](mailto:helpdesk.evoting@cdslindia.com) and on approval of the accounts they would be able to cast their vote.
- A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
- Alternatively Non Individual shareholders are required to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz; [anuh@sk1932.com](mailto:anuh@sk1932.com), if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

(xvii) If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting System, you can write an email to [helpdesk.evoting@cdslindia.com](mailto:helpdesk.evoting@cdslindia.com) or contact at 022- 23058738 and 022-23058542/43.

(xviii) All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Manager, (CDSL,) Central Depository Services (India) Limited, A Wing, 25<sup>th</sup> Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to [helpdesk.evoting@cdslindia.com](mailto:helpdesk.evoting@cdslindia.com) or call on 022-23058542/43.

**INSTRUCTIONS FOR SHAREHOLDERS ATTENDING THE AGM THROUGH VC/OAVM & E-VOTING DURING MEETING ARE AS UNDER:**

- The procedure for attending meeting & e-Voting on the day of the AGM is same as the instructions mentioned above for Remote e-voting.
- The link for VC/OAVM to attend meeting will be available where the EVSN of Company will be displayed after successful login as per the instructions mentioned above for Remote e-voting.
- Shareholders who have voted through Remote e-Voting will be eligible to attend the meeting. However, they will not be eligible to vote at the AGM.
- Shareholders are encouraged to join the Meeting through Laptops / IPads for better experience.
- Further shareholders will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
- Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
- Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending their request in advance at least **on or before Thursday, 12<sup>th</sup> August, 2021** mentioning their name, demat account number/folio number, email id, mobile number at [anuh@sk1932.com](mailto:anuh@sk1932.com). The shareholders who do not wish to speak during the AGM but have queries may send their queries in advance **on or before Thursday, 12<sup>th</sup> August, 2021** mentioning their name, demat account number/folio number, email id, mobile number at [anuh@sk1932.com](mailto:anuh@sk1932.com). These queries will be replied to by the company suitably by email.
- Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.



- (ix) Only those shareholders, who are present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system available during the EGM/AGM.
- (x) If any Votes are cast by the shareholders through the e-voting available during the AGM and if the same shareholders have not participated in the meeting through VC/OAVM facility, then the votes cast by such shareholders shall be considered invalid as the facility of e-voting during the meeting is available only to the shareholders attending the meeting.

**PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL ADDRESSES ARE NOT REGISTERED WITH THE COMPANY / DEPOSITORIES FOR OBTAINING LOGIN CREDENTIALS FOR E-VOTING:**

- a) For Physical shareholders - please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAAR (self attested scanned copy of Aadhaar Card) by an email to investor@bigshareonline.com.
- b) For Demat shareholders - Please update your email id & mobile no. with your respective Depository Participant (DP).

After due verification, RTA shall coordinate with CDSL and provide the login credentials to your registered email IDs.

- 13. The Board of Directors of the Company has appointed, Mr. Makarand M. Joshi, Practicing Company Secretary (FCS 5533, CP 3662) or failing him Ms. Kumudani Bhalerao, Practicing Company Secretary (FCS 6667, CP 6690) as the Scrutinizer for conducting the process of remote e-voting and e-voting during AGM in a fair and transparent manner.
- 14. The Scrutinizer shall submit his / her report, to the Chairman or any person authorized by him, on the voting in favour or against, if any, within forty-eight hours from the conclusion of the Meeting.
- 15. The results declared along with the consolidated Scrutinizer's Report and the recorded transcript of the meeting shall be placed on the website of the Company www.anuhpharma.com. The results shall simultaneously be communicated to the BSE Ltd.
- 16. Members holding shares in dematerialized form are requested to intimate all changes pertaining to their bank details such as bank account number, name of the bank and branch details, MICR code and IFSC code, mandates, nominations, power of attorney, change of address, change of name, e-mail address, contact numbers, etc., to their depository participant (DP). Changes intimated to the DP will then be automatically reflected in the Company's records which will help the Company and the Company's Registrars and Transfer Agents, Bigshare Services Private Limited (Bigshare) to provide efficient and better services. Members holding shares in physical form are requested to intimate such changes to Bigshare at the below new address:

By Post / Courier / Hand Delivery	M/s Bigshare Services Pvt. Ltd. Unit: Anuh Pharma Ltd. 1 <sup>st</sup> Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East Mumbai 400059 Tel : +91-22-62638200; Fax: +91-22-62638299 Email: <a href="mailto:investor@bigshareonline.com">investor@bigshareonline.com</a>
-----------------------------------	---

- 17. The Securities and Exchange Board of India ("SEBI") has mandated the submission of Permanent Account Number ("PAN") by every participant in securities market. Members holding shares in electronic form are, therefore, requested to submit their copies of PAN to their depository participants with whom they are maintaining their demat accounts. Members holding shares in physical form can submit their PAN details to Bigshare.
- 18. Members holding shares in physical form are requested to consider converting their holdings to dematerialized form to eliminate all risks associated with physical shares and for ease of portfolio management. Members can contact the Company or Bigshare for assistance in this regard.



19. Pursuant to the provisions of Regulation 40 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, securities can be transferred only in dematerialised form w.e.f. 1<sup>st</sup> April 2019. Members are requested to convert their physical holdings into demat form to avoid any possibility of loss, mutilation etc., of physical share certificates. Any shareholder who is desirous of dematerializing their securities may write to Bigshare at investor@bigshareonline.com.
20. Members of the Company are requested to note that as per the provisions of Section 124 of the Companies Act, 2013, dividends not encashed/claimed by the Member of the Company, within a period of Seven (7) years from the date of declaration of dividend, shall be transferred by the Company to the Investor Education and Protection Fund (IEPF).
21. The details of Dividends paid by the Company and the corresponding due dates for transfer of such unclaimed/unencashed dividend to the aforementioned Fund constituted by the Central Government are furnished hereunder:

Sr. Nos.	Dividend Year	Type of Dividend	Dividend declared on	Tentative Date of Dividend amount to be transferred to IEPF
1.	2014-2015	Interim	25/08/2014	30/09/2021
2.	2013-2014	Final	12/09/2014	18/10/2021
3.	2014-2015	Final	24/07/2015	29/08/2022
4.	2015-2016	Interim	11/03/2016	16/04/2023
5.	2015-2016	Final	23/09/2016	28/10/2023
6.	2016-2017	Final	22/09/2017	27/10/2024
7.	2017-2018	Final	03/08/2018	08/09/2025
8.	2018-2019	Final	22/08/2019	27/09/2026
9.	2019-2020	Interim	21/02/2020	27/03/2027

Members who have not encashed/claimed the dividend warrant(s) so far in respect of the above financial years, are therefore, requested to make their claims to Bigshare well in advance of the above tentative due dates.

22. **The Ministry of Corporate Affairs has notified provisions relating to unpaid / unclaimed dividend under Sections 124 and 125 of Companies Act, 2013 and Investor Education and Protection Fund (Accounting, Audit, Transfer and Refund) Rules, 2016. As per these Rules, dividends which are not encashed / claimed by the shareholder for a period of seven consecutive years shall be transferred to an IEPF suspense account (in the name of the Company) within 30 days of such shares becoming due for transfer to the Fund. Hence, the Company urges all the shareholders to encash / claim their respective dividend during the prescribed period. The details of the unpaid / unclaimed amounts lying with the Company are available on the website of the Company [www.anuhpharma.com](http://www.anuhpharma.com).**

**The Members/claimants whose shares and/ or unclaimed dividend have been transferred to the Fund, may claim the shares or apply for refund by making an application to IEPF Authority in Form IEPF 5 (available on [www.iepf.gov.in](http://www.iepf.gov.in)) along with requisite fees as decided by the Authority from time to time. The member/claimant can file only one consolidated claim in a financial year as per IEPF Rules. The Company and IEPF Authority shall deal with the application in the manner provided in IEPF Rules.**

23. Information pursuant to Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Secretarial Standards on General Meeting issued by the Institute of Company Secretaries of India with respect to the Director seeking variation in remuneration / re-appointment at the ensuing Annual General Meeting is annexed to this Notice. The Directors have furnished the requisite declarations for their re-appointment.
24. In terms of Section 102 of the Companies Act, 2013 and Secretarial Standard on General Meeting (SS-2), an explanatory statement setting out the material facts concerning Special Business to be transacted at the Meeting is annexed and forms part of this Notice.

**STATEMENT ANNEXED TO THE NOTICE AND SETTING OUT THE MATERIAL FACTS CONCERNING EACH ITEM OF SPECIAL BUSINESS PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013 AND SECRETARIAL STANDARD 2:****Item No. 5**

The Board, on the recommendation of the Audit Committee, has approved the appointment and remuneration of Mr. Ankit Kishor Chande, Cost Accountant, (Certificate of Practice No. 34051) as Cost Auditor to conduct the audit of the cost records of the Company for the financial year 2021-22.

In accordance with the provisions of Section 148 of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014, the remuneration payable to the Cost Auditors ₹ 1,10,000/- (Rupees One Lakh Ten Thousand only) has to be ratified by the shareholders of the Company.

Accordingly, consent of the Members is sought for passing an Ordinary Resolution as set out in Item No. 5 of the Notice for ratification of the remuneration payable to the Cost Auditor(s) for the financial year 2021-22.

The Board of Directors recommends the resolution set forth in Item No. 5 for the approval of the Members as an Ordinary Resolution.

None of the Directors and Key Managerial personnel or their relatives is interested in the above resolution.

**Item No. 6**

The Shareholders shall be informed that in appreciation and recognition of Mr. Ritesh Shah's and Vivek Shah's continuous efforts and remarkable contribution towards the growth of the Company and in view of the Board Restructuring, the Board of Directors (the 'Board') based on the recommendation of the Nomination and Remuneration Committee of the Board at its Meeting held on January 08, 2021, approved the appointment and re-designation of Mr. Ritesh B. Shah and Mr. Vivek B. Shah as Joint Managing Directors from the post of Whole Time Directors & Chief Executive Officers w.e.f. January 08, 2021, for a period of 5 years i.e. upto January 07, 2026 on the terms and conditions as enumerated in the resolution at Item No. 6 of this Notice subject to the approval of the Shareholders at the Annual General Meeting and their office shall not be liable to retire by rotation.

The Shareholders shall be further informed that we have received consent to act as a Director (Form DIR-2) from Mr. Ritesh Shah and Mr. Vivek Shah pursuant to section 152(5) and rule 8 of the Companies (Appointment and Qualification of Directors) Rules, 2014, amendments thereof.

Mr. Ritesh Shah has done B.Sc. Chemistry and MBA from Oklahoma City University (USA). He has handled international marketing for Anuh Pharma for over 16 years, currently involved in overall management of the Company. He has been doing key client visits & developing new clients for existing & new products.

Mr. Vivek Shah has done his Masters in Biotechnology (M. Sc.). He has over 10 years of experience in managing the R & D unit of Pharmaceutical Industry. He looks after EDQM review & regulatory approval, if any, required from time to time. He also manages new product development into commercialization. He engaged himself into new project conceptual planning.

Pursuant to the provisions of Sections 196, 197, 203 read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modifications, amendments or re-enactments thereto for the time being in force) (hereinafter referred to as "the Act"), in pursuance of the relevant provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and as per the provisions of the Articles of Association of the Company the above appointment and re-designation as Joint Managing Directors requires approval of the Members of the Company by way of Special Resolution. Accordingly, the resolution set out at Item No. 6 of the Notice is recommended to be passed as Special Resolution.

A copy of the resolutions passed by the Nomination and Remuneration Committee and the Board of Directors at their respective Meetings held on January 08, 2021, as referred to above, are available for inspection by the Members of the Company at the registered office of the Company between 10.00 AM to 01.00 PM on all working days (except Saturdays, Sundays and National Holidays) up to and including the date of 61<sup>st</sup> Annual General Meeting viz. August 19, 2021.

Save and except Mr. Ritesh Shah, Joint Managing Director, Mr. Vivek Shah, Joint Managing Director and Mr. Bipin Shah, Vice Chairman, none of the Directors, Key Managerial Personnel or their relatives is interested in the above resolution.

The Board recommends the Special Resolution as set out in Item No. 6 of the Notice for approval of the Members.

**Item No. 7**

Mr. Ritesh Shah, aged 40 years, was appointed and re-designated as Joint Managing Director of the Company at the Meeting of the Board held on January 08, 2021 to hold office for a period of 5 years i.e. w.e.f. January 08, 2021 upto January 07, 2026 subject to the approval of the Shareholders at the Annual General Meeting.

In appreciation and recognition of his leadership and phenomenal contribution towards the growth of the Company, the Board of Directors based on the recommendation of the Nomination and Remuneration Committee of the Board at its Meeting held on May 21, 2021, approved revision in remuneration of Mr. Ritesh Shah, Joint Managing Director of the Company with effect from April 01, 2021, on the terms and conditions as enumerated in the resolution at Item No. 7 of this Notice, subject to the approval of the Shareholders and such other approvals as may be required.

In case the Company has in any financial year no profits or if its profits are inadequate anytime during the tenure of office of Mr. Ritesh Shah, as Joint Managing Director, shall be paid the remuneration as stated in resolution at Item No. 7, with the liberty to the Board to revise, amend, alter and vary the terms and conditions relating to the remuneration payable to the Joint Managing Director in such manner as may be permitted and subject to approval of such authority(ies) as may be required, in accordance with the provisions of the Act and Schedule V thereto or any modification thereto and as may be agreed by and between the Board and Mr. Ritesh Shah, without any further approval of the Members of the Company.

Pursuant to the provisions of Section 197 read with Part I and Section I of Part II of Schedule V and other applicable provisions, if any, of the Act, (including any statutory modification or re-enactment thereof), applicable clauses of the Articles of Association of the Company, the above revision in remuneration requires approval of the Members of the Company by way of Special Resolution. Accordingly, the resolution set out at Item No. 7 of the Notice is recommended to be passed as Special Resolution.

A copy of the resolutions passed by the Nomination and Remuneration Committee and the Board of Directors at their respective Meetings held on May 21, 2021, as referred to above, are available for inspection by the Members of the Company at the registered office of the Company between 10.00 AM to 01.00 PM on all working days (except Saturdays, Sundays and National Holidays) up to and including the date of 61<sup>st</sup> Annual General Meeting viz. August 19, 2021.

Save and except Mr. Ritesh Shah, Joint Managing Director, Mr. Vivek Shah, Joint Managing Director and Mr. Bipin Shah, Vice Chairman, none of the Directors, Key Managerial Personnel or their relatives is interested in the above resolution.

The Board recommends the Special Resolution as set out in Item No. 7 of the Notice for approval of the Members.

**Item No. 8**

Mr. Vivek Shah, aged 35 years, was appointed and re-designated as Joint Managing Director of the Company at the Meeting of the Board held on January 08, 2021 to hold office for a period of 5 years i.e. w.e.f. January 08, 2021 upto January 07, 2026 subject to the approval of the Shareholders at the Annual General Meeting.

In appreciation and recognition of his leadership and phenomenal contribution towards the growth of the Company, the Board of Directors based on the recommendation of the Nomination and Remuneration Committee of the Board at its Meeting held on May 21, 2021, approved revision in remuneration of Mr. Vivek Shah, Joint Managing Director of the Company with effect from April 01, 2021, on the terms and conditions as enumerated in the resolution at Item No. 7 of this Notice, subject to the approval of the Shareholders and such other approvals as may be required.

In case the Company has in any financial year no profits or if its profits are inadequate anytime during the tenure of office of Mr. Vivek Shah, as Joint Managing Director, shall be paid the remuneration as stated in resolution at Item No. 8, with the liberty to the Board to revise, amend, alter and vary the terms and conditions relating to the remuneration payable to the Joint Managing Director in such manner as may be permitted and subject to approval of such authority(ies) as may be required, in accordance with the provisions of the Act and Schedule V thereto or any modification thereto and as may be agreed by and between the Board and Mr. Vivek Shah, without any further approval of the Members of the Company.

Pursuant to the provisions of Section 197 read with Part I and Section I of Part II of Schedule V and other applicable provisions, if any, of the Act, (including any statutory modification or re-enactment thereof), applicable clauses of the Articles of Association of the Company, the above revision in remuneration requires approval of the Members of the Company by way of Special Resolution. Accordingly, the resolution set out at Item No. 8 of the Notice is recommended to be passed as Special Resolution.

A copy of the resolutions passed by the Nomination and Remuneration Committee and the Board of Directors at their respective Meetings held on May 21, 2021, as referred to above, are available for inspection by the Members of the Company at the registered office of the Company between 10.00 AM to 01.00 PM on all working days (except Saturdays, Sundays and National Holidays) up to and including the date of 61<sup>st</sup> Annual General Meeting viz. August 19, 2021.

Save and except Mr. Ritesh Shah, Joint Managing Director, Mr. Vivek Shah, Joint Managing Director and Mr. Bipin Shah, Vice Chairman, none of the Directors, Key Managerial Personnel or their relatives is interested in the above resolution.

The Board recommends the Special Resolution as set out in Item No. 8 of the Notice for approval of the Members.

For and on behalf of the Board of Directors

Sd/-  
**Ashwini Ambrale**  
Company Secretary & Compliance Officer  
(M. No.: A32456)

Place : Mumbai  
Date : May 21, 2021

#### ANNEXURE TO THE NOTICE

Details of Directors seeking variation in remuneration / appointment / re-appointment at the forthcoming Sixty-First Annual General Meeting {in pursuance of Regulation 36 (3) of the Listing Regulations, 2015 and Secretarial Standard - 2}.

#### I. Mr. Lalitkumar P. Shah and Mr. Ketan L. Shah

<b>Name of the Director</b>	Mr. Lalitkumar P. Shah	Mr. Ketan L. Shah
<b>Designation</b>	Non-Executive Director	Non-Executive Director
<b>Director Identification Number</b>	00396345	00083326
<b>Age</b>	85 years	50 years
<b>Nationality</b>	Indian	Indian
<b>Date of first appointment on the Board</b>	29-10-1980	09-08-2016
<b>Qualifications</b>	Graduation in Pharmacy	B. Com
<b>Expertise in functional area</b>	He has 58 years experience in managing pharmaceutical business and industry	Over 22 years of experience in Production Planning, Financing Arrangements, Marketing and Raw Material Sourcing.
<b>Number of Equity Shares held in the Company</b>	4414566	239500
<b>Directorships and Committee Membership of other Board as on 31.03.2021#</b>	1 (One) Directorship & NIL	1 (One) Directorship & NIL
<b>Number of Board Meetings attended during the year</b>	2 (Two)	5 (Five)
<b>Relationship with other Directors, Manager and KMP</b>	Mr. Lalitkumar P. Shah is father of Mr. Ketan Shah (Director)	Mr. Ketan Shah is son of Mr. Lalitkumar P. Shah (Director).
<b>Remuneration Last Drawn</b>	₹ 45,000/-	₹ 1,20,000/-
<b>Remuneration sought to be paid</b>	₹ 25,000/- per Board Meeting	₹ 25,000/- per Board Meeting

**II. Mr. Ritesh B. Shah and Mr. Vivek B. Shah**

<b>Name of the Director</b>	Mr. Ritesh B. Shah	Mr. Vivek B. Shah
<b>Designation</b>	Joint Managing Director	Joint Managing Director
<b>Director Identification Number</b>	02496729	02878724
<b>Age</b>	40 years	35 years
<b>Nationality</b>	Indian	Indian
<b>Date of first appointment on the Board</b>	09-08-2016	09-08-2016
<b>Qualifications</b>	B.Sc. Chemistry and MBA from Oklahoma City University (USA)	Masters in Biotechnology (M.Sc.)
<b>Expertise in functional area</b>	Over 16 years of experience in Pharmaceutical Industry	Over 10 years of experience in managing the R & D unit of Pharmaceutical Industry
<b>Number of Equity Shares held in the Company</b>	1155404	1170000
<b>Directorships and Committee Membership of other Board as on 31.03.2021#</b>	1 (One) Directorship & NIL	1 (One) Directorship & NIL
<b>Number of Board Meetings attended during the year Relationship with other</b>	6 (Six)	6 (Six)
<b>Directors, Manager and KMP</b>	Mr. Ritesh Shah is son of Mr. Bipin Shah (Vice Chairman) and brother of Mr. Vivek Shah (Joint Managing Director)	Mr. Vivek Shah is son of Mr. Bipin Shah (Vice Chairman) and brother of Mr. Ritesh Shah (Joint Managing Director)
<b>Remuneration Last Drawn</b>	₹ 30,62,913/-	₹ 36,39,083/-
<b>Remuneration sought to be paid</b>	As per the resolution at Item no. 7 of this Notice, read with the explanatory statement thereto	As per the resolution at Item no. 8 of this Notice, read with the explanatory statement thereto

# Excludes Directorships held in private companies, foreign companies and companies under section 8 of the Companies Act, 2013 and Anuh Pharma Ltd. and excludes Committee Memberships / Chairmanships of Anuh Pharma Ltd., private companies, foreign companies and companies under section 8 of the Companies Act, 2013. Only Audit Committees and Stakeholders' Relationship Committees are considered as per the provisions of Regulation 26 of Listing Regulations, 2015.

## DIRECTORS' REPORT

To,  
The Members,

Your Directors have pleasure in placing before you the 61<sup>st</sup> Annual Report of the Company along with the Accounts for the year ended March 31, 2021:

### FINANCIAL HIGHLIGHTS

Accounting Year	(₹ in Lakhs)	
	2020-21	2019-20
Revenue from Operations	<b>43,196</b>	30,696
Other Income	<b>1,054</b>	421
Profit before interest, depreciation and taxation	<b>5,512</b>	2,698
Interest	<b>149</b>	79
Depreciation	<b>1,508</b>	703
Provision for taxation (net)	<b>1,011</b>	485
Profit after tax	<b>2,844</b>	1,431
Profit and Loss Account balance B/f	<b>5,370</b>	5,600
Income Tax adjustment of earlier years	-	0.5
Profit available for Appropriation	<b>8,214</b>	7,032
Transfer to General Reserve	<b>600</b>	-
Interim Dividend	-	689.04
Tax on Interim Dividend	-	142
Final Dividend	-	689
Tax on Final Dividend	-	142
Balance carried to the Balance Sheet	<b>7,614</b>	5,370

### DIVIDEND

For the year under review, the Directors have recommended Final Dividend of ₹ 1.50/- per share i.e. @ 30% (₹ 2.75/- per share i.e. @ 55% for the previous year) on Equity Shares of face value of ₹ 5/- each of the Company. The total dividend outgo shall be ₹ 751.68 lakhs as compared to ₹ 689.04 lakhs during the previous year.

### OPERATIONS

The revenue from operations for the year ended March 31, 2021 amounted to ₹ 43,196 lakhs as against ₹ 30,696 lakhs for the previous year. Thus the income from operations of the Company has increased by about 40.70% as compared to last year's revenue from operations.

During the year 2020-21 profit before tax as compared to last year has increased by 101.25% from ₹ 1,916 lakhs to ₹ 3,855 lakhs and profit after tax has increased by 99% from ₹ 1,431 lakhs to ₹ 2,844 lakhs.

### THE AMOUNT, IF ANY, WHICH IT PROPOSES TO CARRY TO ANY RESERVES

During the year ended March 31, 2021, the Company proposes to transfer ₹ 600 Lakhs to General Reserves.

### EXPORTS

Exports for the year ended March 31, 2021 have increased by about 49.71 % from ₹ 14,656 lakhs to ₹ 21,942 lakhs.



### **CHANGE IN THE NATURE OF BUSINESS, IF ANY**

There is no change in the nature of Business of the Company during the financial year 2020-21.

### **CURRENT OUTLOOK**

We are pleased to inform you that European Directorate of Quality Medicine has approved our following products:

- (i) Erythromycin Base
- (ii) Erythromycin Ethyl Succinate &
- (iii) Pyrazinamide

Similarly, WHO PQ Geneva authorities has given us approval for Pyrazinamide and Sulfadoxine.

Additionally, we were inspected by USFDA and are pleased to inform you that we have passed USFDA inspection without any observations.

We have also received CEP for Ambroxol Hydrochloride from EDQM.

### **MATERIAL CHANGES AND COMMITMENTS, IF ANY, AFFECTING THE FINANCIAL POSITION OF THE COMPANY WHICH HAVE OCCURRED BETWEEN THE END OF THE FY OF THE COMPANY TO WHICH THE FINANCIAL STATEMENTS RELATE AND THE DATE OF THE REPORT**

After acquiring Plot No. E-18 in the Tarapur Industrial Area of MIDC, and after receiving Environmental Clearance from Government of Maharashtra, we have successfully commissioned our new expansion project in December 2019.

### **CHANGES IN THE SHARE CAPITAL, IF ANY**

During the year ended March 31, 2021, the Company has allotted 2,50,56,000 Equity Shares each aggregating to ₹ 12,52,80,000/- in the ratio of 1:1 equity shares as fully paid-up bonus shares.

During the year ended March 31, 2021, due to unavoidable circumstances, the Company has withdrawn application for in principle approval for Issuance of upto 27,44,000 Equity Shares on preferential basis to MNB Holdings Pte. Ltd.

### **BOARD OF DIRECTORS**

In accordance with the Articles of Association of the Company and pursuant to the provisions of Section 152 of the Companies Act, 2013 and the applicable rules made thereof, Mr. Lalitkumar P. Shah and Mr. Ketan L. Shah, Directors of the Company retire by rotation at the ensuing 61<sup>st</sup> Annual General Meeting and being eligible have offered themselves for re-appointment.

Mr. Bipin N. Shah had relinquished his position from the post of Managing Director of the Company with effect from the closing of business hours of Thursday, 7<sup>th</sup> January, 2021. The Board recorded its appreciation for the dedication, assistance & guidance provided by him. In view of Board Restructuring, Mr. Bipin N. Shah was appointed as Non-Executive Director and Vice Chairman of the Company w.e.f. 8<sup>th</sup> January, 2021, whose period of office shall be liable to retire by rotation.

In view of Board Restructuring, Mr. Ritesh B. Shah & Mr. Vivek B. Shah were appointed and re-designated as Joint Managing Directors of the Company from the position of Whole Time Directors and Chief Executive Officers of the Company, for a period of 5 years with effect from 8<sup>th</sup> January, 2021 upto 7<sup>th</sup> January, 2026, subject to the approval of the Shareholders at the 61<sup>st</sup> Annual General Meeting and their office shall not be liable to retire by rotation.

### **KEY MANAGERIAL PERSONNEL**

As on March 31, 2021, Mr. Ritesh Shah, Joint Managing Director, Mr. Vivek Shah, Joint Managing Director and Mr. Darshan Rampariya, Chief Financial Officer and Ms. Ashwini Ambrale, Company Secretary & Compliance Officer were the Key Managerial Personnel of the Company under the provisions of Sections 2(51) and 203 of the Companies Act, 2013 read with the Companies (Appointment and Qualifications of Managerial Personnel) Rules, 2014.

Mr. Bipin N. Shah had relinquished his position from the post of Managing Director of the Company with effect from the closing of business hours of Thursday, 7<sup>th</sup> January, 2021 and Mr. Ritesh B. Shah & Mr. Vivek B. Shah were appointed and re-designated as Joint Managing Directors of the Company from the position of Whole Time Directors and Chief Executive Officers of the Company.

#### **DIRECTORS' RESPONSIBILITY STATEMENT**

To the best of their knowledge and belief and according to the information and explanations obtained by them, your Directors make the following statements in terms of Section 134(3) (c) read with Section 134(5) of the Companies Act, 2013-

- i) That in the preparation of the annual financial statements for the year ended March 31, 2021, the applicable accounting standards have been followed along with proper explanation relating to material departures, if any.
- ii) That the Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year viz. March 31, 2021 and of the profit or loss of the Company for the year ended on that date.
- iii) That the Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities.
- iv) That the Directors had prepared the annual accounts on a going concern basis.
- v) That proper internal financial controls were in place and that the financial controls were adequate and were operating effectively.
- vi) That the Directors had devised proper systems to ensure compliance with the provisions of all applicable laws were in place and were adequate and operating effectively.

#### **DECLARATION BY INDEPENDENT DIRECTOR(S) AND RE-APPOINTMENT, IF ANY**

The Company has received necessary declaration from each Independent Director under Section 149(7) of the Companies Act, 2013, that he/she meets the criteria of independence laid down in Section 149(6) of the Companies Act, 2013 and Regulation 16(b) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations, 2015).

In accordance with the provisions of the Companies Act, 2013, none of the Independent Directors are liable to retire by rotation.

#### **LISTING ON THE STOCK EXCHANGE**

The Company's shares are listed with BSE Limited and the Company has paid the necessary listing fees for the financial year 2021-2022.

#### **DEPOSITS**

The Company has not accepted or renewed any Deposits within the meaning of Section 73 of the Companies Act, 2013.

#### **PARTICULARS OF LOANS, GUARANTEES AND INVESTMENTS**

Details of Loans, Guarantees and Investments covered under the provisions of Section 186 of the Companies Act, 2013 are given in the notes to the Financial Statements provided in this Annual Report.

#### **PARTICULARS OF EMPLOYEES**

The Statement of particulars of employees under Section 197(12) read with Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel), Rules, 2014 is not provided with as during the financial year under review, no

employee of the Company including Managing Director and Whole Time Directors were in receipt of remuneration in excess of the limits set out in the said rules.

## MEETINGS

During the year 6 (Six) Board Meetings and 4 (Four) Audit Committee Meetings, 4 (Four) Nomination and Remuneration Committee Meetings, 2 (Two) Corporate Social Responsibility Committee Meetings and 4 (Four) Stakeholder Relationship Committee Meetings were convened and held. The details of which are given in the Corporate Governance Report that forms part of the Annual Report. The maximum interval between any two Meetings did not exceed 120 days, as prescribed under the Companies Act, 2013. The details pertaining to the composition of the Audit Committee, Nomination and Remuneration Committee, Corporate Social Responsibility Committee and Stakeholder Relationship Committee are included in the Corporate Governance Report, which is a part of this report.

## BOARD EVALUATION

Pursuant to the provisions of the Companies Act, 2013 and Regulation 17(10) of the Listing Regulations, 2015, the Board has carried out an annual performance evaluation of its own performance, the Directors individually, the Chairperson's as well as the evaluation of the working of its Audit Committee, Corporate Social Responsibility Committee, Nomination & Remuneration Committee and Stakeholder Relationship Committee. The manner in which the evaluation has been carried out has been explained in the Corporate Governance Report.

## FAMILIARISATION PROGRAM TO INDEPENDENT DIRECTORS

Familiarisation Programme has been carried out by the Company for the Independent Directors, details of which has been uploaded on the Company's website i.e. [www.anuhpharma.com](http://www.anuhpharma.com).

## BUSINESS RISK MANAGEMENT

The Company has a robust Business Risk Management (BRM) framework to identify, evaluate business risks and opportunities. This framework seeks to create transparency, minimize adverse impact on the business objectives and enhance the Company's competitive advantage. The business risk framework defines the risk management approach across the enterprise at various levels including documentation and reporting. The framework has different risk models which help in identifying risks trend, exposure and potential impact analysis at a Company level as also separately for business. The Company has adopted Financial Risk Management Policy. As on March 31, 2021, the formation of Risk Management Committee is not applicable to the Company.

## INTERNAL FINANCIAL CONTROL

The Company has in place internal financial controls with reference to the financial statements. The Company has adopted policy on internal financial control system for proper observation of internal financial controls.

## POLICIES

### Vigil Mechanism / Whistle Blower Policy

The Company has a vigil mechanism named whistle blower policy in accordance with section 177(9) of the Companies Act, 2013 and Listing Regulations, 2015, to deal with instance of fraud and mismanagement, if any. The vigil mechanism/whistle blower policy is uploaded on the Company's website i.e. [www.anuhpharma.com](http://www.anuhpharma.com).

### Nomination and Remuneration Policy

The Board has framed a Nomination and Remuneration Policy for selection and appointment of Directors, Senior Management and their remuneration on the recommendation of the Nomination & Remuneration Committee. The Nomination and Remuneration Policy is uploaded on the Company's website i.e. [www.anuhpharma.com](http://www.anuhpharma.com).

### **Policy against sexual harassment of Woman at workplace**

In order to prevent sexual harassment of women at work place a new act the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 has been notified. Under the said Act every company is required to set up an Internal Complaints Committee to look into complaints relating to sexual harassment at work place of any women employee.

A policy for prevention of Sexual Harassment of Women at workplace has been adopted and Internal Complaints Committee was also constituted by the Board of Directors of the Company. The policy and the composition of Internal Complaints Committee are uploaded on the Company's website.

The Company has complied with provisions relating to the constitution of Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

### **Policy for Preservation of Documents**

In terms of Regulation 9 of the Securities Exchange Board of India Listing Regulations, 2015 the Board has adopted this Policy for Preservation of Documents. To determine preservation period for records/documents based on their reference value and legal requirements. The Policy is uploaded on the Company's website.

### **Policy for Determination of Materiality of any Event or Information**

In pursuance of Regulation 30 of the Listing Regulations, 2015, the Company has adopted the policy for determination of materiality of any event or information based on the criteria mentioned in the said regulation ("Material Information") and that the information has been and is being promptly forwarded to the Stock Exchange. The Policy is uploaded on the Company's website.

### **Archival Policy**

This Policy is framed in compliance with the Regulation 30 of the Listing Regulations, 2015. The policy is uploaded on the Company's website.

### **AUTHORIZE KEY MANAGERIAL PERSONNEL FOR THE PURPOSE OF DETERMINING MATERIALITY OF AN EVENT OR INFORMATION**

The Company has authorized Mr. Ritesh Shah, Joint Managing Director and Ms. Ashwini Ambrale, Company Secretary and Compliance Officer of the Company for the purpose of determining the materiality of an event or information and for making disclosures to Stock exchange(s) under Regulation 30 of the Listing Regulations, 2015.

### **CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO {Section 134}**

The particulars relating to conservation of energy, technology absorption, foreign exchange earnings and outgo is annexed as "Annexure - 1" to the Directors' Report.

### **CASH FLOW STATEMENT**

As required under Regulation 34 of the Listing Regulations, a Cash Flow Statement is part of the Annual Report.

### **CORPORATE SOCIAL RESPONSIBILITY INITIATIVES**

Pursuant to Section 135 of the Companies Act, 2013 and the Rules made thereunder, the Board of Directors has constituted the Corporate Social Responsibility (CSR) Committee under the Chairmanship of Mr. Jasvantlal G. Shah, Non-Executive Independent Director. The other Members of the Committee are Mr. Bipin N. Shah, Vice Chairman and Mr. Arun L. Tadarwal, Non-Executive Independent Director. The CSR policy of the Company is uploaded on the Company's website. Other details of the CSR activities undertaken by the Company as required under Section 135 of the Companies Act, 2013 i.e. The Annual Report on CSR Activities is annexed as "Annexure - 2" to the Directors' Report.

## EXTRACT OF ANNUAL RETURN

Pursuant to Section 92(3) read with section 134(3)(a) of the Companies Act, 2013, copy of the Annual Return of the Company prepared in accordance with Section 92(1) of the Companies Act, 2013 read with Rule 11 of the Companies (Management and Administration) Rules, 2014 is placed on the website of the Company at [www.anuhpharma.com](http://www.anuhpharma.com).

## PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTY

All related party transactions that were entered into during the financial year were on an arm's length basis and were in the ordinary course of business. All Related Party Transactions are placed before the Audit Committee and the Board for approval. Policy on Transactions with Related Parties as approved by the Board is uploaded on the Company's website.

Particulars of contracts or arrangements with related parties referred to in Section 188(1) of the Companies Act, 2013, in the prescribed Form AOC-2, is annexed as "Annexure - 3" to the Directors' Report.

## RATIO OF DIRECTORS' REMUNERATION TO MEDIAN EMPLOYEES' REMUNERATION AND OTHER DISCLOSURES

The table containing the names and other particulars of ratio of Directors' Remuneration to Median Employees' Remuneration in accordance with the provisions of Section 197(12) of the Companies Act, 2013, read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, is annexed as "Annexure - 4" to the Directors' Report.

## SIGNIFICANT MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS

There are no significant material orders passed by the Regulators / Courts which would impact the going concern status of the Company and its future operations.

## MANAGEMENT DISCUSSION AND ANALYSIS

As required by Regulation 34(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), a Management Discussion and Analysis Report is a part of this report.

## CORPORATE GOVERNANCE

Your Company continues to imbibe and emulate the best corporate governance practices aimed at building trust among all stakeholders - shareholders, employees, customers, suppliers and others. Your Company believes that fairness, transparency, responsibility and accountability are the four key elements of corporate governance. The Corporate Governance Report presented in a separate section forms an integral part of this Annual Report.

## AUDITORS

In accordance with the provisions of Section 139 of the Companies Act, 2013 read with Rule 3 of the Companies (Audit and Auditors) Rules, 2014, M/s. Jayantilal Thakkar & Co., Chartered Accountants (Firm Registration Number 104133W), were appointed as Statutory Auditors of the Company in the 57<sup>th</sup> Annual General Meeting held on September 22, 2017 to hold office from the conclusion of the 57<sup>th</sup> Annual General Meeting till the conclusion of the 62<sup>nd</sup> Annual General Meeting of the Company.

The statutory auditor's report does not contain any qualifications, reservations, or adverse remarks.

## COST AUDITORS & COST AUDIT REPORT

In accordance with the provisions of Section 148 of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014, the Board has, on the recommendation of the Audit Committee, re-appointed CMA Mr. Ankit Kishor Chande, having Membership No. 34051 for conducting the audit of cost records of bulk drugs maintained by the Company for the financial year 2021-22 at a remuneration of ₹ 1,10,000/- (Rupees One Lakh Ten Thousand Only) plus service tax as applicable and re-imbursalment of out of pocket expenses as may be incurred by him for conducting the Cost Audit for the financial year 2021-22.

In view of the requirements of Section 148 of the Companies Act, 2013, the Company has obtained from the Cost Auditor written consent along with certificates with respect to compliance with the conditions specified under Rule 6(1A) of the Companies (cost records and audit) Rules, 2014.

In terms of the provisions of Section 148(3) of the Companies Act, 2013 read with Rule 14 of the Companies (Audit and Auditors) Rules, 2014, the remuneration payable to the Cost Auditor is required to be ratified by the Members of the Company. Accordingly, a resolution seeking Members' ratification for the remuneration payable to the Cost Auditor forms part of the Notice convening the ensuing Annual General Meeting.

The Company has filed the Cost Audit Report for the financial year ended March 31, 2020 submitted by Ankit Chande, Cost Auditor on September 19, 2020. The Cost Audit Report for the financial year ended March 31, 2021 shall be filed in due course.

### **SECRETARIAL AUDITOR**

The Board had appointed M/s. MMJB & Associates LLP as the Secretarial Auditors for the financial year 2020-21.

The Secretarial Audit Report (Form No. MR-3) issued by M/s. MMJB & Associates LLP, Secretarial Auditor of the Company for the year ended March 31, 2021 is annexed as "**Annexure - 5**" to the Directors' Report.

The secretarial auditor's report does not contain any qualifications, reservations, or adverse remarks.

The Annual Secretarial Compliance Report has been submitted to the stock exchange within the prescribed time.

### **REPORTING OF FRAUD BY AUDITORS**

During the year under review, the Statutory Auditors, Cost Auditors and Secretarial Auditors have not reported any instances of frauds committed in the Company by its Officers or Employees to the Audit Committee under section 143(12) of the Act, details of which needs to be mentioned in this Report.

### **ACKNOWLEDGEMENT**

Your Directors would like to express their sincere appreciation for the assistance and cooperation received from our bankers, employees, auditors and consultants during the period under review. The Directors sincerely appreciate the high degree of professionalism, commitment and dedication displayed by employees at all levels. The Directors also place on record their gratitude to the Members for their continued support and confidence.

By Order of the Board

Sd/-  
**Jasvantlal G. Shah**  
Chairman  
(DIN: 00372600)

### **Registered Office:**

3-A, Shiv Sagar Estate, North Wing,  
Dr. Annie Besant Road,  
Worli, Mumbai - 400 018

Place : Mumbai.

Date : May 21, 2021



## ANNEXURE '1' TO THE DIRECTORS REPORT

(Under Section 134 of the Companies Act 2013)

### 1. CONSERVATION OF ENERGY:

#### Form for Disclosure of Particulars with respect to Conservation of Energy.

A. Power and fuel consumption:	Current Year 2020-21	Previous Year 2019-20
<b>1. Electricity</b>		
(a) Purchased		
Units	6920880	4745492
Total amount (₹ In lakhs)	598.52	465.23
Rate/unit (In ₹ )	8.65	9.80
(b) Own generation		
Rate/Unit (₹ In lakhs)	Nil	Nil
<b>2. Coal</b>	Nil	Nil
<b>3. Light Diesel Oil</b>		
Quantity (KL)	Nil	184.80
Total cost (₹ In lakhs)	Nil	77.98
Average rate per ltr. (₹)	Nil	42.19
<b>4 Briquette</b>		
Quantity (MT)	3,745	1,014
Total cost (₹ In lakhs)	244.35	63.95
Average rate per Kg. (₹)	6.52	6.30
<b>B. Consumption per unit of production</b>		
Electricity KWH	7.46	5.78
Light Diesel Oil Ltrs.	NA	0.23
Briquette Kgs.	4.04	1.24
Coal	N.A	N.A.
Other	N.A	N.A.

#### C. Energy Conservation measures undertaken during the financial year 2020-21

- E-17 Plant steam condensate water utilised in feed for steam boiler (Minimum 15 KL steam condensate utilised for boiler feed)
- MEE Plant Vacuum pump water catch pot automation. (Per day 8 KL water saving achieved)
- Purified water system RO rejected water utilised in Utility Cooling tower (20KL MIDC water saving achieved per day)
- Stripper effluent load reduced by separating High COD & Low COD effluent streams (26 m3/day Stripper load reduced and Further ZLD treatment also reduced)
- Boiler feed water temperature increased to 80 degrees Celsius (1 % Efficiency increased which leads to saving of 140 KG Briquette per day).
- Auto tube cleaning system(ATC) installed for Brine chiller & water chiller condenser due to condenser approach maintained below 3 Degrees Celsius and 6-7 % COP increased respectively for each chiller.

- E-18 high pressure compressed air system synchronised with E-17 high pressure compressed air system due to BSD-73 Air Compressor is standby. (30 KWh, variable saving achieved)
- E-18 low pressure compressed air system synchronised with E-17 low pressure compressed air system due to ASK-27 Air Compressor is standby (12 KWh, net saving Achieved)
- E-18 brine chilling system synchronised with E-17 brine chilling system due to 95 TR Brine chilling plant is standby. (74 KWh, net saving Achieved)

## 2. TECHNOLOGY ABSORPTION

A. Research & Development (R&D)	Nil	Nil
B. Technology absorption, adoption and innovation	Nil	Nil

## 3. FOREIGN EXCHANGE EARNINGS AND OUTGO

- A. Earnings :** The FOB value of export of the Company during the year aggregated to ₹ 21,250 lakhs as against ₹ 14,237 lakhs in the previous year.
- B. Outgo :** The CIF value of outgo in foreign exchange of the Company by way of imports, payment of commission expenses aggregated to ₹ 29,273 lakhs during the year as against ₹ 22,433 lakhs in the previous year.

## ANNEXURE – ‘2’ TO THE DIRECTORS’ REPORT

### ANNUAL REPORT ON CORPORATE SOCIAL RESPONSIBILITY (CSR) ACTIVITIES

[Pursuant to Section 134(3)(o) of the Companies Act, 2013 read with the Companies (Corporate Social Responsibility Policy) Rules, 2014, as amended]

- Brief outline on CSR Policy of the Company: The CSR activities of the Company has been undertaken by the Company few directly and few through implementing agency. The Company has framed a CSR Policy in compliance with the provisions of the Companies Act, 2013 and the same is placed on the Company’s website and the web link for the same is [www.anuhpharma.com](http://www.anuhpharma.com)
- Composition of CSR Committee:

Sl. No.	Name of Director	Designation Nature / of Directorship	Number of meetings of CSR Committee held during the year	Number of meetings of CSR Committee attended during the year
1	Mr. Jasvantlal Shah	Chairman & Independent Director	2	2
2	Mr. Arun Todarwal	Member & Independent Director	2	2
3	Mr. Bipin Shah	Member & Non-Executive Director	2	2

- Provide the web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the board are disclosed on the website of the company. : [www.anuhpharma.com](http://www.anuhpharma.com)
- Provide the details of Impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social responsibility Policy) Rules, 2014, if applicable (attach the report). : The Company has been voluntarily conducting impact assessments to screen and evaluate CSR programs/projects. The Company takes cognizance of sub-rule (3) of Rule 8 of the Companies (Corporate Social Responsibility Policy) Amendment Rules, 2021 (“CSR Amendment Rules”). There are no projects undertaken or completed after the effective date of the aforementioned rules for fiscal 2021.
- Details of the amount available for set off in pursuance of sub-rule (3) of rule 7 of the Companies (Corporate Social responsibility Policy) Rules, 2014 and amount required for set off for the financial year, if any : NIL

Sl. No.	Financial Year	Amount available for set-off from preceding financial years (in ₹)	Amount required to be set- off for the financial year, if any (in ₹)
1		NIL	
	<b>TOTAL</b>		

- Average net profit of the Company as per section 135(5). : ₹ 24,82,91,114/-
- Two percent of average net profit of the company as per section 135(5) = ₹ 49,65,882/-
  - Surplus arising out of the CSR projects or programmes or activities of the previous financial years: NIL
  - Amount required to be set off for the financial year, if any: NIL
  - Total CSR obligation for the financial year (7a+7b-7c): ₹ 49,65,882/-

8. (a) CSR amount spent or unspent for the financial year:

Total Amount Spent for the Financial Year. (in ₹)	Amount Unspent (in ₹)				
	Total Amount transferred to Unspent CSR Account as per section 135(6).		Amount transferred to any fund specified under Schedule VII as per second proviso to section 135(5).		
	Amount.	Date of transfer.	Name of the Fund	Amount.	Date of transfer.
88,33,630/-	NIL				

(b) Details of CSR amount spent **against ongoing projects** for the financial year: Not Applicable

(1)	(2)	(3)	(4)	(5)		(6)	(7)	(8)	(9)	(10)	(11)	
Sl. No.	Name of the Project.	Item from the list of activities in Schedule VII to the Act.	Local area (Yes/ No).	Location of the project.		Project duration.	Amount allocated for the project (in ₹).	Amount spent in the current financial Year (in ₹).	Amount transferred to Unspent CSR Account for the project as per Section 135(6) (in ₹).	Mode of Implementation Direct (Yes/No).	Mode of Implementation – Through Implementing Agency	
				State.	District.						Name	CSR Registration number.
<b>TOTAL</b>												

(c) Details of CSR amount spent against other than ongoing projects for the financial year:

Sr. No.	Name Of The Project	Item from the list of activities in schedule VII to the Act.	Local area (Yes/ No)	Location of the project		Amount spent for the project (in ₹)	Mode of implementation - Direct (Yes/No)	Mode of implementation - Through	
				State	District			Name	CSR registration number
1	Swajan Foundation	Eradicating Hunger	Yes	Maharashtra	Mumbai	1,100,000	No	Swajan Foundation	CSR00006373
2	Bombay Round Table No. 2 Charitable Trust	Clean drinking water care/relief for elders and education for girls	Yes	Maharashtra	Mumbai	50,000	No	-	-
3	H. H. Mehta Charitable Trust	Animal Welfare	Yes	Maharashtra	Mumbai	140,000	Yes	-	-
4	Dividend From HDFC Cancer Care Fund	Providing Medical Aid	Yes	Maharashtra	Mumbai	19,980	Yes	-	-
5	Green Sole Foundation	Promoting Education	Yes	Maharashtra	Mumbai	99,500	Yes	-	-
6	The United Orphanage For Disabled	Providing Medical Aid	Yes	Tamil Nadu	Coimbatore	81,500	Yes	-	-
7	Aadarsh Goseva Avam Anusandhan Prkalp	Animal Welfare	Yes	Maharashtra	Akola	100,000	Yes	-	-
8	Rotary Club Bombay Charities Trust No. 3	Promoting Education	Yes	Maharashtra	Mumbai	25,000	No	Rotary Club Bombay Charities Trust No. 3	-
9	Friends of Tribals Society	Promoting Education	Yes	Maharashtra	Mumbai	110,000	Yes	-	-
10	Aadarsh Goseva Avam Anusandhan Prkalp	Animal Welfare	Yes	Maharashtra	Mumbai	600,000	Yes	-	-
11	MCGM – Comprehensive Thalassemia Care	Providing Medical Aid	Yes	Maharashtra	Mumbai	2,025,000	No	Sevantilal Kantilal Trust	-
12	Jain Womens Organisation	Promoting Education & Sanitization	Yes	Maharashtra	Mumbai	41,400	No	Sevantilal Kantilal Trust	-
13	Gujarat Sarvodaya Mandal	Promoting Education	Yes	Gujarat	Ahmedabad	15,000	Yes	-	-
14	Charusat Healthcare & Research Foundation	Providing Medical Aid	Yes	Gujarat	Anand	500,000	Yes	-	-
15	Rotary Club of Bombay Queen's Necklace Charitable Trust	Eradicating Hunger	Yes	Maharashtra	Mumbai	150,000	No	Rotary Club of Bombay Queen's Necklace Charitable Trust	-
16	Rotary Club of Bombay	Providing Medical Aid	Yes	Maharashtra	Mumbai	200,000	No		-
17	R.N.C Free Eye Hospital	Providing Medical Aid	Yes	Gujarat	Valsad	1,600,000	Yes	-	-
18	Vision Foundation of India	Providing Medical Aid	Yes	Maharashtra	Mumbai	400,000	Yes	-	-

Sr. No.	Name Of The Project	Item from the list of activities in schedule VII to the Act.	Local area (Yes/No)	Location of the project		Amount spent for the project (in ₹)	Mode of implementation - Direct (Yes/No)	Mode of implementation - Through	
				State	District			Name	CSR registration number
19	Sanskar Balmandir	Promoting Education	Yes	Maharashtra	Mumbai	400,000	Yes	-	-
20	The Chemists And Druggist Association	Providing Medical Aid	Yes	Maharashtra	Mumbai	51,000	Yes	-	-
21	Sevantilal Kantilal Trust	Promoting Education & Providing Medical Aid	Yes	Maharashtra	Mumbai	1,125,250	No	Sevantilal Kantilal Trust	-
<b>Total</b>						<b>88,33,630</b>			

- (d) Amount spent in Administrative Overheads: NIL
- (e) Amount spent on Impact Assessment, if applicable: Not Applicable
- (f) Total amount spent for the Financial Year (8b+8c+8d+8e): ₹ 88,33,630/-
- (g) Excess amount for set off, if any : NIL

Sl. No.	Particular	Amount (in ₹)
(i)	Two percent of average net profit of the company as per section 135(5)	NIL
(ii)	Total amount spent for the Financial Year	NIL
(iii)	Excess amount spent for the financial year [(ii)-(i)]	NIL
(iv)	Surplus arising out of the CSR projects or programmes or activities of the previous financial years, if any	NIL
(v)	Amount available for set off in succeeding financial years [(iii)-(iv)]	NIL

9. (a) Details of Unspent CSR amount for the preceding three financial years: NIL

Sl. No	Preceding Financial Year.	Amount transferred	Amount spent in the reporting Financial Year (in ₹).	Amount transferred to any fund specified under Schedule VII as per section 135(6), if any.			Amount remaining to be spent in succeeding financial years. (in ₹)
				Name of the Fund	Amount (in Rs).	Date of transfer.	
1.				NIL			
	<b>TOTAL</b>						

- (b) Details of CSR amount spent in the financial year for ongoing projects of the preceding financial year(s): Not Applicable

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
Sl. No.	Project ID.	Name of the Project.	Financial Year in which the project was commenced.	Project duration.	Total amount allocated for the project (in ₹).	Amount spent on the project in the reporting Financial Year (in Rs).	Cumulative amount spent at the end of reporting Financial Year. (in ₹)	Status of the project- Completed /Ongoing.
1.					NIL			
	<b>TOTAL</b>							

10. In case of creation or acquisition of capital asset, furnish the details relating to the asset so created or acquired through CSR spent in the financial year : **(asset-wise details)**
- (a) Date of creation or acquisition of the capital asset(s): None
  - (b) Amount of CSR spent for creation or acquisition of capital asset: Nil
  - (c) Details of the entity or public authority or beneficiary under whose name such capital asset is registered, their address etc: Not Applicable
  - (d) Provide details of the capital asset(s) created or acquired (including complete address and location of the capital asset): Not Applicable
11. Specify the reason(s), if the company has failed to spend two per cent of the average net profit as per section 135(5). – Not Applicable

Sd/-  
**Mr. Jasvantlal G. Shah**  
Chairman, CSR Committee

Sd/-  
**Mr. Ritesh B. Shah**  
Joint Managing Director

Date : May 21, 2021  
Place : Mumbai



## ANNEXURE ‘3’ TO THE DIRECTORS REPORT

### PARTICULARS OF CONTRACTS / ARRANGEMENTS MADE WITH RELATED PARTIES – FORM AOC-2

[Pursuant to Clause (h) of Sub-section (3) of Section 134 of the Companies Act, 2013, and Rule 8(2) of the Companies (Accounts) Rules, 2014]

This Form pertains to the disclosure of particulars of contracts / arrangements entered into by the Company with related parties referred to in Sub-section (1) of Section 188 of the Companies Act, 2013 including certain arm’s length transactions under third proviso thereto.

#### Details of contracts or arrangements or transactions not at arm’s length basis:

There were no contracts or arrangements or transactions entered into during the year ended March 31, 2021, which were not at arm’s length basis.

#### Details of material contracts or arrangement or transactions at arm’s length basis:

The details of material contracts or arrangement or transactions at arm’s length basis for the year ended March 31, 2021 are as follows:

Particulars of Transaction	Amt. in ₹ Lakhs			
	SKHL	EIPL	SKCPL	SKO
Sale of Goods	1815.69	-	-	-
Commission paid	-	-	73.35	-
Purchase of Goods	1.76	7.39	-	-
Reimbursement (payment) of expenses	1.63	47.22	-	41.53
Reimbursement ( receipt) of expenses	-	2.12	-	-

# Name of related party entities under direct or indirect control or substantial influence:

SKHL : S Kant Healthcare Ltd.,  
 EIPL : Eskay Iodine Pvt. Ltd.,  
 SKCPL : S. Kant Chemicals Pvt. Ltd.,  
 SKO : S K & Others

- Above mentioned transactions are based on transfer pricing guidelines of the Company.
- Appropriate approvals have been taken for related party transactions.

## ANNEXURE - '4' TO THE DIRECTORS' REPORT

### RATIO OF DIRECTORS' REMUNERATION TO MEDIAN EMPLOYEES' REMUNERATION AND OTHER DISCLOSURES

[Pursuant to Section 197 (12) of the Companies Act, 2013 and Rule 5(1) of Chapter XIII, Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

The information required under section 197 of the Act read with rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are given below:

- The ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the financial year 2020-21:

Name of the Directors	Ratio to median Remuneration
<b>Non-Executive Director</b>	
Mr. Jasvantlal Shah - Chairman	0.87
Mr. Arun Todarwal	0.87
Mr. Harmanbhai Patel	0.59
Mr. Sandeep Joshi	0.36
Mr. Lalitkumar Shah	0.11
Mr. Bharat Shah	0.54
Dr. (Ms.) Mita Dixit	0.36
Mr. Samir Shah	0.29
Mr. Ketan Shah	0.29
Mr. Bipin Shah - Vice Chairman (w.e.f. 08/01/2021)	0.23
<b>Executive Director</b>	
Mr. Bipin Shah - Managing Director (Upto 07/01/2021)	13.17
Mr. Ritesh Shah - Joint Managing Director (w.e.f. 08/01/2021)	7.52
Mr. Vivek Shah - Joint Managing Director (w.e.f. 08/01/2021)	8.93

- The percentage increase in Remuneration of each Director and Chief Financial Officer, Chief Executive Officer, Company Secretary in the financial year 2020-21:

Sr. Nos.	Names	Designations	% increase in Remuneration in the financial year
1.	Mr. Jasvantlal Shah	Chairman - Independent Director	16.39
2.	Mr. Harmanbhai Patel	Independent Director	41.67
3.	Mr. Arun Todarwal	Independent Director	16.39
4.	Mr. Sandeep Joshi	Independent Director	262.50
5.	Mr. Lalitkumar Shah	Promoter Director	(43.75)
6.	Mr. Bharat Shah	Promoter Director	109.52
7.	Dr. (Ms.) Mita Dixit	Independent Director	17.24
8.	Mr. Samir Shah	Non-executive Director	100.00
9.	Mr. Ketan Shah	Non-executive Director	0.00
10.	Mr. Bipin Shah	Managing Director (Upto 07/01/2021)	(31.75)
11.	Mr. Ritesh Shah	Joint Managing Director (w.e.f. 08/01/2021)	(13.50)
12.	Mr. Vivek Shah	Joint Managing Director (w.e.f. 08/01/2021)	1.20
13.	Mr. Darshan Rampariya	Chief Financial Officer	29.16
14.	Ms. Ashwini Ambrale	Company Secretary & Compliance Officer	20.15

3. The percentage increase in the median Remuneration of employees in the financial year 2020-21: 35.56%
4. The number of permanent employees on the rolls of Company during the year: 178
5. Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration: The average annual increase was around 10-12%. However, during the course of the year, the total increase is approximately 6.95%, after accounting for promotions and increase in hiring salaries for trainees. Increase in the managerial remuneration for the year was (12.96%).
6. The key parameters for any variable component of remuneration availed by the Directors: The Members have, through the Postal Ballot held on 10<sup>th</sup> April, 2019, approved payment of incentives to the Managing Director minimum 1% of the net profits before tax of the Company as computed under the applicable provisions of the Act.
7. The ratio of the remuneration of the highest paid director to that of the employees who are not directors but receive remuneration in excess of the highest paid director during the year: None.
8. Affirmation that the remuneration is as per the Nomination and Remuneration Policy of the Company: The Company affirms all the above Remuneration is as per the Nomination and Remuneration Policy of the Company.
9. The statement containing particulars of employees as required under section 197(12) of the Act read with Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014: Not Applicable to the Company as there are no such employees in receipt of the prescribed remuneration.

## ANNEXURE – ‘5’ TO THE DIRECTORS REPORT

### FORM NO. MR. 3 SECRETARIAL AUDIT REPORT

For the Financial Year Ended 31<sup>st</sup> March, 2021.  
*[Pursuant to section 204(1) of the Companies Act, 2013 and rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]*

To,  
The Members,  
**Anuh Pharma Limited,**  
A 3 Shiv Sagar Estate  
Dr Annie Besant Road,  
Mumbai 400018  
Maharashtra, India.

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Anuh Pharma Limited** (hereinafter called ‘the Company’). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/ statutory compliances and expressing our opinion thereon.

Based on our verification of the Company’s books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the Company has, during the audit period covering the financial year ended on 31<sup>st</sup> March, 2021 (hereinafter called the ‘**Audit Period**’) complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance- mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on 31<sup>st</sup> March, 2021 according to the provisions of:

- (i) The Companies Act, 2013 (the Act), and the rules made there under;
- (ii) The Securities Contracts (Regulation) Act, 1956 (‘SCRA’) and the rules made there under;
- (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;
- (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings; **(Not Applicable to the Company during the Audit Period)**;
- (v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 (‘SEBI Act’):-
  - a. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
  - b. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
  - c. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;
  - d. The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014; **(Not Applicable to the Company during the Audit Period)**;

- e. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; **(Not Applicable to the Company during the Audit Period);**
- f. The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
- g. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009; **(Not Applicable to the Company during the Audit Period) and;**
- h. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; **(Not Applicable to the Company during the Audit Period).**

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India;
- (ii) The Securities and Exchange Board of India (Listing Obligations and Disclosure requirements) Regulations, 2015.

During the period under review the Company has generally complied with the provisions of the Act, Rules, Regulations, Guidelines and Standards, etc. mentioned above.

**We further report that,** having regard to the compliance system prevailing in the Company and on the examination of the relevant documents and records in pursuance thereof, on test- check basis, the Company has complied with the following law applicable specifically to the Company:

- (i) The Drugs and Cosmetics Act, 1940 and Rules made thereunder;
- (ii) Drugs (Prices Control) Order, 2013 and Notifications made thereunder and;
- (iii) Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.

**We further report that**

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

All decisions at Board Meetings and Committee Meetings are carried out unanimously as recorded in the minutes of the meetings of the Board of Directors or Committee of the Board, as the case may be.

**We further report that** there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

**We further report that** during the audit period, the Company:

- a. has withdrawn application for in principle approval for Issuance of upto 27,44,000 Equity Shares to MNB Holdings Pte. Ltd due to unavoidable circumstances;

- b. has allotted 2,50,56,000 Equity Shares each aggregating to ₹ 12,52,80,000/- in the ratio of 1:1 equity shares as fully paid-up bonus shares;
- c. has obtained in principle approval of the Board of Directors and applied to the National Stock Exchange of India Limited (NSE) for the proposal for listing of Equity Shares of the Company on NSE.

For **MMJB & Associates LLP**  
Company Secretaries

Sd/-  
**Saurabh Agarwal**  
**Designated Partner**  
FCS No. 9290  
CP No. 20907  
Peer Review No. L2020MH006700  
UDIN: F009290C000356076

Date : 21.05.2021

*This report is to be read with our letter of even date which is annexed as **Annexure A** and forms an integral part of this report.*



To,  
The Members,  
Anuh Pharma Limited  
A 3 Shiv Sagar Estate Dr Annie Besant Road Mumbai 400018 Maharashtra, India.

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial record is the responsibility of the management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the company.
4. Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the company.

For **MMJB & Associates LLP**  
Company Secretaries

Sd/-  
**Saurabh Agarwal**  
**Designated Partner**  
FCS No. 9290  
CP No. 20907  
Peer Review No. L2020MH006700  
UDIN: F009290C000356076

Date : 21.05.2021

## MANAGEMENT DISCUSSION AND ANALYSIS

### INDUSTRY STRUCTURE & DEVELOPMENTS

#### Global Pharmaceutical Market

The global pharmaceutical market is now estimated to be over USD 1.4 trillion and expected to grow at CAGR of about 4% to 5%.

Though the pharmaceutical industry is developing at rapid pace, the pharmaceutical manufacturing companies are confronted with enormous challenges such as:

Cost & Pricing, New Medicines & Therapy dosages, changing regulatory landscape & growing digitization.

Indian pharma market is expected to grow to USD 60 Billion by 2022 thereby emerging as the 6<sup>th</sup> largest pharmaceutical market globally by absolute size.

#### Global Bulk Drugs Market

Three segments - Branded Prescription drugs, Over-the-Counter (OTC) drugs and Generic Prescription drugs account for a majority of global bulk drug consumption.

The total global bulk drug consumption is expected to reach USD 215 billion by 2022 at a CAGR 6.5% during the forecast period out of which 80% is used for Branded Prescription drugs, 10% for OTC drugs and 10% for Generic Prescription drugs.

#### Indian Bulk Drug Market

India is expected to be the 3<sup>rd</sup> largest global markets for Bulk Drugs with a 7.5% increase in market share. There are 1150 bulk drug units producing about 350 important Bulk Drugs. The market analyst forecast the API markets in India to grow at a CAGR of 11% over the period of 2021-2025.

### OPPORTUNITIES, THREATS AND OUTLOOK

Anuh Pharma Ltd. will be able to place itself in a strong position by expanding strategically, increasing its manufacturing capacities and enhancing capacities across the organization. The Company is looking at different opportunities in untapped markets and also across a value chain. It plans for alliances with business associates in the global market, giving a huge boost to the selective products that it already deals in.

We are fully conscious of our responsibility towards our customers. Our efforts are directed towards the fulfillment of customer satisfaction through the quality of products. As the consolidation of this industry gains momentum, the need to develop a dedicated team of skilled manpower assumes urgency and importance.

We will continue to focus on training and motivation of manpower so as to develop teams of qualified and skilled personnel to effectively discharge their responsibilities in a number of projects and activities. It is, in this context, which we have been working towards promoting the skills and professionalism of our employees to cope with and focus on the challenges of change and growth.

#### Manufacturing

Anuh Pharma Ltd. is well positioned to service its existing and potential markets through its manufacturing operations at Tarapur in Maharashtra.

The Company enjoys cGMP approvals and all the facilities are built and operated according to cGMP (current Good Manufacturing Practices).

The Company is approved by EDQM for the products Erythromycin Base, Erythromycin Ethyl Succinate, & Pyrazinamide. The Company has also got approval from WHO PQ Geneva authorities for Pyrazinamide and Sulfadoxine. The Company is also approved by COFEPRIS, Mexico for Erythromycin Stearate, Erythromycin Estolate, Erythromycin Ethyl Succinate. The Company has received USFDA and CEP for Ambroxol Hydrochloride during 2019-2020.

The Company has also received plant approvals from several MNCs.

### **Expansion**

We are pleased to inform that we have successfully commissioned our new expansion project and started commercial production in December, 2019.

### **Quality**

Quality is the key factor for any API business and Anuh Pharma Ltd. enjoys a high reputation for quality. An independent Quality Assurance team headed by Doctorate and Senior Chemists ensures this function. A number of sophisticated instruments like HPLC, GC, IR Spectrophotometer, etc., are installed in QC department.

## **MEDIUM TERM STRATEGY & LONG TERM STRATEGY**

### **Medium Term Strategy:**

Our Company has completed 32 years of start up of production.

All the manufacturing departments, marketing departments etc. are sufficiently matured to take up new challenges in the medium term.

We propose to start 4 (Four) new products in the medium term and apply for regulatory approvals like EDQM, USFDA etc.

For this purpose our R & D department is absolutely ready and they already have a few products queued up to take up for validation batches and commercial batches in the new plant commissioned in December 2019.

### **Long Term Strategy:**

India is poised to become the 2<sup>nd</sup> largest producers of API in the world.

Our Company is still dependent on Intermediates mainly from China and other countries we will definitely look forward for backward integration in long term.

We also need to improve the manufacturing processes to reduce the solvent load and formation of other by-products.

This will also help us in reducing the pollution load and ultimately reducing the final product cost.

## **RISKS AND CONCERNS**

India imports huge quantity of crude oil and variation in crude oil prices would always be an area of concern. The Company is planning to install greener technologies like briquette fired boilers, economizers etc. to save power and fuel costs.

The volatility of exchange rate of rupee against US dollar can have significant impact on the Company's profitability because approx. 50% of its sales consist of exports. However natural hedge mitigates the risk to large extent due to imports.

Macro economic conditions like currency variations, rise in crude prices and US dollar remittance issues in Africa do affect the export of our country. However, our presence is there in domestic sector such risks are mitigated to some extent.

## **FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE**

The revenue from operations for the year ended March 31, 2021 amounted to ₹ 43,196 lakhs as against ₹ 30,696 lakhs for the previous year. Thus the income from operations of the Company has increased by about 40.7 % as compared to last year's revenue from operations.

During the year 2020-21 profit before tax as compared to last year has increased by 101.25 % from ₹ 1,916 lakhs to ₹ 3,855 lakhs and profit after tax has increased by 99 % from ₹ 1,431 lakhs to ₹ 2,844 lakhs.

The details of changes in key financial ratios are explained in the table below:

<b>Ratios</b>	<b>2020-21</b>	<b>2019-20</b>
Debtors Turnover Ratio (Days)	80	94
Inventory Turnover Ratio (Days)	79	83
Interest Coverage Ratio (Times)	26.80	25.18
Current Ratio (Times)	1.70	1.37
Debt Equity Ratio (Times)	0.07	0.27
Operating Margin Ratio (%)	22.44	21.78
Net Profit Margin (%)	6.43	4.60
Return on Net Worth (RONW) (%)*	14.92	8.82

\* Return on Net Worth for the FY 2020-21 was improved compared to previous year due to increase in the sales and improvement in operational performance and efficiency.

### **INTERNAL CONTROL SYSTEMS & THEIR ADEQUACY**

The Company has strong and adequate internal control system suitable to its size and nature of business. We constantly upgrade our systems for incremental improvements.

The Audit Committee of the Board regularly reviews our system. The systems ensure protection of assets and proper recording of transactions. Internal audit is carried out by an independent chartered accountants' firm on quarterly basis.

The internal auditors' reports are regularly received by the Audit Committee. It is a regular practice to review the issues raised by Internal Auditors and statutory auditors by the Audit Committee.

### **RESEARCH & DEVELOPMENT**

During the month of April 2012 the Company had acquired an existing Research & Development Laboratory in Mahape, Navi Mumbai from a Spanish Company. This Research & Development Laboratory has three sections, i.e. Analytical Development Lab, Chemical Synthesis Lab and a Pilot Plant. Each section is equipped with latest and sophisticated equipments and machineries.

This will help us in intensifying our Research & Development activity with a view to enlarge our bulk drugs portfolio.

### **MATERIAL DEVELOPMENTS IN HUMAN RESOURCES / INDUSTRIAL RELATIONS FRONT INCLUDING NUMBER OF PEOPLE EMPLOYED**

#### **Human Resources**

Anuh Pharma Ltd. has always acknowledged importance of its human capital and fundamental source of its success. Consequently, the Company's HR department has enabled it to acquire, develop, motivate and maintain its skilled human resource.

The Company worked on its recruitment process at bringing about improvement in:

1. Speed at which talent is brought in.
2. Quality of talent with respect to competence and compatibility.
3. Cost of recruitment

### **CAUTIONARY STATEMENT**

Certain statement in the management discussion and analysis may be forward looking within the meaning of applicable securities law and regulations and actual results may differ materially from those expressed or implied. Factors that would make differences to Company's operations include competition, price realisation, forex market, changes in government policies and regulations, tax regimes, economic development within India and the countries in which the Company conducts business and other incidental factors.

# CORPORATE GOVERNANCE REPORT

Report on Corporate Governance Report pursuant to Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations, 2015) for the financial year 2020-21.

## Company's Philosophy on Code of Corporate Governance

The Company believes that Corporate Governance envisages attainment of high level of transparency, accountability, fair and equal treatment of all shareholders, compliance with regulations, and sustainable value creation for all shareholders, ethical practices and integrity thereby assisting the top management of the Company in efficient conduct of its business.

The Company believes that its systems and actions must be integrated for enhancement of corporate performance resulting in maximization of shareholders' value in the long run, protection of the interest of its shareholders and employees and maintenance of cordial relationship with its customers and bankers. The Company gives due emphasis on regulatory compliances.

## I. BOARD OF DIRECTORS

### (A) Composition and Category of Directors:

The present Board of Directors of the Company comprises of 12 (Twelve) Directors, of which 2 (Two) are Executive Directors, 5 (Five) are Non-Executive Directors and 5 (Five) are Independent Non-Executive Directors including one Woman Director with independent judgment in the deliberation and decision of the Board. The Chairman of the Board is a Non-Executive Independent Director.

### (B) Skills / Expertise / Competencies of the Board of Directors

The following are the list of core skills / expertise / competencies identified by the Board of Directors as required in the context of the Company's business and that the said skills are available with the Board Members:

- i) Knowledge on Company's businesses (Active Pharmaceutical Ingredients & Bulk Drugs), policies and culture (including the Mission, Vision and Values) major risks / threats and potential opportunities and knowledge of the industry in which the Company operates;
- ii) Behavioral skills - attributes and competencies to use their knowledge and skills to contribute effectively to the growth of the Company;
- iii) Business Strategy, Sales & Marketing, Corporate Governance, Forex Management, Administration, Decision Making;
- iv) Financial and Management skills;
- v) Technical / Professional skills and specialized knowledge in relation to Company's business

In the opinion of Board, the Independent Directors of the Company fulfill the conditions specified in SEBI (LODR) and Companies Act, 2013 and are independent of the management.

### (C) Attendance of the Directors at the Board Meetings and 60<sup>th</sup> AGM

The Board of Directors met 6 (Six) times during the year under review. The Meetings of the Board of Directors were held on various dates as follows:

(1) June 19, 2020 (2) July 03, 2020 (3) August 07, 2020 (4) November 06, 2020 (5) January 08, 2021 & (6) February 09, 2021. Detailed agenda notes and the information required to be given in terms of Business on the agenda were circulated in advance to all the Directors of the Company. The Directors including Non-Executive Directors actively participated in the Board Meeting. Attendance of Directors at the Board and Shareholders' Meeting during the financial year 2020-21:

Sr. No.	Name of the Director	Designation	Category#	No. of Board Meetings held during the year	No. of Board Meetings attended during the year	Attendance at last AGM Held on 11 <sup>th</sup> September, 2020
1.	Mr. Jasvantlal G. Shah	Chairman	INED	6	6	Yes
2.	Mr. Bipin N. Shah	Vice Chairman	NED	6	6	Yes
3.	Mr. Lalitkumar P. Shah	Director	PNED	6	2	Yes
4.	Mr. Bharat N. Shah	Director	PNED	6	6	Yes
5.	Mr. Arun L. Todarwal	Director	INED	6	6	Yes
6.	Mr. Sandeep M. Joshi	Director	INED	6	6	Yes
7.	Mr. Harmanbhai T. Patel	Director	INED	6	6	Yes
8.	Dr. (Ms.) Mita C. Dixit	Director	NED	6	6	Yes
9.	Mr. Samir J. Shah	Director	NED	6	5	Yes
10.	Mr. Ketan L. Shah	Director	NED	6	5	Yes
11.	Mr. Ritesh B. Shah	Joint Managing Director	ED	6	6	Yes
12.	Mr. Vivek B. Shah	Joint Managing Director	ED	6	6	Yes

# INED - Independent Non - Executive Director, ED – Executive Director, PNED - Promoter Non - Executive Director, NED – Non-Executive Director.

(A) The details of Directorships, relationship inter-se, shareholding in the Company, number of Directorships and Committee Chairmanships/Memberships held by them in other public companies as on March 31, 2021 are detailed below:

Sr. No.	Name of the Director <sup>1</sup>	Total No. of Directorships <sup>2</sup>	Names of the listed entities where he/she is a Director & Category	No. of Committee Memberships <sup>3</sup>	No. of Committee Chairmanships <sup>3</sup>	No. of shares held in the Company
1.	Mr. Jasvantlal G. Shah	NIL	NIL	NIL	NIL	4608
2.	Mr. Bipin N. Shah	NIL	NIL	NIL	NIL	3115860
3.	Mr. Lalitkumar P. Shah	1	NIL	NIL	NIL	4414566
4.	Mr. Bharat N. Shah	1	NIL	NIL	NIL	1979824
5.	Mr. Arun L. Todarwal	4	Independent Director in Welspun India Limited.	1	3	1100
6.	Mr. Harmanbhai T. Patel	NIL	NIL	NIL	NIL	NIL
7.	Mr. Sandeep M. Joshi	NIL	NIL	NIL	NIL	NIL
8.	Dr. (Ms.) Mita C. Dixit	1	Independent Director in Hindustan Construction Company Limited	1	NIL	70
9.	Mr. Samir J. Shah	1	NIL	NIL	NIL	842502
10.	Mr. Ketan L. Shah	1	NIL	NIL	NIL	239500
11.	Mr. Ritesh B. Shah	1	NIL	NIL	NIL	1155404
12.	Mr. Vivek B. Shah	NIL	NIL	NIL	NIL	1170000



Notes:

1. Mr. Bipin Shah & Mr. Bharat Shah are brothers, Mr. Lalitkumar Shah is father of Mr. Ketan Shah, Mr. Bipin Shah is father of Mr. Ritesh Shah and Mr. Vivek Shah and Mr. Ritesh Shah and Mr. Vivek Shah are brothers. There is no other inter-se relationship among the Directors.
2. Excludes Directorships held in private companies, foreign companies and companies under section 8 of the Companies Act, 2013 and Anuh Pharma Ltd.
3. Excludes Committee Memberships / Chairmanships of Anuh Pharma Ltd., private companies, foreign companies and companies under section 8 of the Companies Act, 2013. Only Audit Committees and Stakeholders' Relationship Committees are considered as per the provisions of Regulation 26 of the Listing Regulations, 2015.
4. All the Directors of the Company meet the criteria of maximum number of Directorships as laid down in Section 165 of the Companies Act, 2013 and Listing Regulations, 2015.

**(B) Information required under Regulation 36(3) of the Listing Regulations, 2015 on Director seeking appointment / re-appointment:**

**1) MR. LALITKUMAR P. SHAH**

<b>Name of the Director</b>	<b>Mr. Lalitkumar P. Shah</b>
DIN	00396345
A Brief Resume & nature of his expertise in specific functional areas	Mr. Lalitkumar P. Shah aged 85 has completed his graduation in Pharmacy. He has 58 years experience in managing pharmaceutical business and industry and is involved with the SK Group's various business activities like Pharmaceutical formulation / API manufacturing, exports, R&D etc. He is also involved with the charitable activities of the group through Sevantilal Kantilal Trust.
Disclosure of relationships between Directors inter-se	He is the father of Mr. Ketan L. Shah (Director)
Names of listed entities in which the person also holds the Directorship and the membership of Committees of the Board	NIL
Number of shares held	4414566

**2) MR. KETAN L. SHAH**

<b>Name of the Director</b>	<b>Mr. Ketan L. Shah</b>
DIN	00083326
A Brief Resume & nature of his expertise in specific functional areas	Mr. Ketan Shah aged 50 years is a Commerce Graduate He has hands on experience of over 2 Decades in Production Planning, Financing Arrangements, Marketing and Raw Material Sourcing. Under his management, SK group formed other Manufacturing unit in the name and style of Eskay Speciality Chemicals, which is located in Surat Special Economic Zone and is 100% export unit.
Disclosure of relationships between Directors inter-se	He is a son of Mr. Lalitkumar P. Shah (Director)
Names of listed entities in which the person also holds the Directorship and the membership of Committees of the Board	NIL
Number of shares held	239500

**3) MR. RITESH B. SHAH**

<b>Name of the Director</b>	<b>Mr. Ritesh B. Shah</b>
DIN	02496729
A Brief Resume & nature of his expertise in specific functional areas	Mr. Ritesh Shah aged 40 years, has done B.Sc. Chemistry and MBA from Oklahoma City University (USA). He has handled international marketing for Anuh Pharma for over 16 years, currently involved in overall management of the Company. He has been doing key client visits & developing new clients for existing & new products.
Disclosure of relationships between Directors inter-se	He is a son of Mr. Bipin N. Shah (Director)
Names of listed entities in which the person also holds the Directorship and the membership of Committees of the Board	NIL
Number of shares held	1155404

**4) MR. VIVEK B. SHAH**

<b>Name of the Director</b>	<b>Mr. Vivek B. Shah</b>
DIN	02878724
A Brief Resume & nature of his expertise in specific functional areas	Mr. Vivek Shah aged 35 years, has done his Masters in Biotechnology (M.Sc.). He has over 10 years of experience in managing the R & D unit of Pharmaceutical Industry. He looks after EDQM review & regulatory approval, if any, required from time to time. He also manages new product development into commercialization. He engaged himself into new project conceptual planning.
Disclosure of relationships between Directors inter-se	He is a son of Mr. Bipin N. Shah (Director)
Names of listed entities in which the person also holds the Directorship and the membership of Committees of the Board	NIL
Number of shares held	1170000

**II. AUDIT COMMITTEE**
**Terms of Reference:**

The terms of Reference to this Committee, inter-alia, covers all the matters, specified under Section 177 of the Companies Act, 2013 and also all the matters listed under the Regulation 18 of the Listing Regulations, 2015 with the Stock Exchange such as overseeing the Company's financial reporting process and disclosure of financial information to ensure presentation is correct, sufficient and credible financial statements, recommending the appointment, remuneration and terms of appointment of Auditors of the Company. The Audit Committee has powers, inter-alia, to investigate any activity within its terms of reference and to seek information from any employee of the Company as well as seek outside legal and professional advice.

The Audit Committee reviews all the information which is required to be mandatorily reviewed by it under the corporate governance.

**Composition of the Audit Committee:**

The Audit Committee of the Company comprises of Mr. Jasvantlal G. Shah, Chairman of the Committee, Mr. Arun Tadarwal and Mr. Harmanbhai T. Patel all being Independent Directors and Mr. Bipin N. Shah, who is a Vice Chairman of the Company. All the Members of the Audit Committee have knowledge on financial matters and the Chairman of the Audit Committee was a Company Secretary in various large Indian and multi-national companies.

The Company has re-appointed M/s. I. O. Dharia & Co., Chartered Accountants, (Firm Registration No. 102460W) as Internal Auditors of the Company for the financial year 2021-22 for reviewing with the management quarterly and annual financial statements and other matters as covered under the Listing Regulations, 2015 and report to the Audit Committee.

**Meetings and Attendance:**

The Audit Committee met 4 (Four) times during the year under review. The Meetings were held on various dates as follows:

- 1) June 19, 2020 (2) August 07, 2020 (3) November 06, 2020 and (4) February 09, 2021.

The attendance of each member of Audit Committee in the Committee Meetings is given below:

Name of the Director	No. of Meeting held during the year	No. of Meeting attended during the year
Mr. Jasvantlal. G. Shah	4	4
Mr. Arun L. Todarwal	4	4
Mr. Bipin N. Shah	4	4
Mr. Harmanbhai T. Patel	4	4

**III. NOMINATION AND REMUNERATION COMMITTEE:**

**Terms of Reference:**

In terms of the provisions Section 178 of the Companies Act, 2013 and Listing Regulations, 2015 the Board has constituted a Nomination and Remuneration Committee. Terms of reference of the Committee are as follows:

- a) Formulation of the criteria for determining qualifications, positive attributes and independence of a Director;
- b) Recommend to the Board a policy, relating to the remuneration of the Directors, Key Managerial Personnel and Senior Management;
- c) Formulation of criteria for evaluation of Independent Directors and the Board;
- d) Devising a policy on Board diversity;
- e) Identifying persons who are qualified to become Directors and who may be appointed in Senior Management in accordance with the criteria laid down, recommend to the Board their appointment and removal.

The Nomination and Remuneration Committee has formulated the Nomination and Remuneration Policy. The Nomination and Remuneration Policy of Anuh Pharma Limited is designed to attract, motivate and retain manpower in a competitive market. The policy reflects the Company's objectives for good Corporate Governance and compliance of Section 178 and other applicable provisions of the Companies Act, 2013.

**Composition of the Nomination and Remuneration Committee:**

This Committee consists of 3 Directors i.e.  
 Mr. Arun L. Todarwal - Chairman of the Committee  
 Mr. Jasvantlal G. Shah - Member  
 Mr. Bharat N. Shah - Member

**Meetings and Attendance:**

The Nomination and Remuneration Committee met 4 (Four) times during the year under review. The meetings were held on various dates as follows:

- (1) June 19, 2020 (2) August 07, 2020 (3) January 08, 2021 and (4) February 09, 2021

The attendance of each member of Nomination and Remuneration Committee in the Committee Meetings is given below:

Name of the Director	No. of Meeting held during the year	No. of Meeting attended during the year
Mr. Arun L. Tadarwal	4	4
Mr. Jasvantlal. G. Shah	4	4
Mr. Bharat N. Shah	4	4

#### Performance Evaluation criteria for Independent Directors:

The Nomination and Remuneration Committee has formulated the performance evaluation criteria in the Nomination and Remuneration Policy of the Company. Pursuant to the provisions of the Companies Act, 2013 and Regulation 17(10) of the Listing Regulations, 2015, the performance of the Board, its Committees, individual Directors, Chairman and Independent Directors was evaluated on the basis of a structured questionnaire as it was prepared after taking into consideration inputs received from the Directors, covering various aspects of the Board's functioning such as adequacy of the composition of the Board and its Committees, Board culture, execution and performance of specific duties, obligations and governance. The performance evaluation of the Independent Directors was carried out by the entire Board except the Independent Director being evaluated.

The Directors were asked to rate the performance on various parameters including a high degree of commitment to his responsibilities as an Independent Director, appears to be familiar with the business model of the Company and the industry it belongs to, he is aware of his role, rights and responsibilities as an Independent Director, he has been actively participating in the Board/Committee discussions and contributing to the decision-making process, he has been known to take initiative on matters of common interest of the Company and to exhibit sensitivity to the interest of all the stakeholders, he comes across as a person with expertise and experience, he keeps himself informed on the latest developments in corporate governance.

An Evaluation Report has been prepared by the Nomination and Remuneration Committee based on the evaluation done at the Independent Directors Meeting dated January 08, 2021 and Board Meeting dated January 08, 2021. The Directors expressed their satisfaction with the evaluation process.

## IV. REMUNERATION OF DIRECTORS

### Details of Remuneration

The Board, within the overall limits approved by the Members, considered the matters with regard to review and approval of remuneration payable to the Executive and Non Executive Directors of the Company. Details of remuneration to the Directors of the Company for the year ended March 31, 2021 are as follows:

Name of Director	Sitting Fees (₹)	Salary & Perquisites (₹)		2020-21
Mr. Bipin N. Shah (Upto 07/01/2021)	N.A.	Salary & Perquisites	47,02,435/-	31,73,438/-
		Commission	31,60,000/-	21,93,000/-
		<b>Total</b>	<b>78,62,435/-</b>	<b>53,66,438/-</b>
Mr. Ritesh B. Shah	N.A.	Salary & Perquisites	35,40,825/-	30,62,913/-
		Commission	NIL	NIL
		<b>Total</b>	<b>35,40,825/-</b>	<b>30,62,913/-</b>
Mr. Vivek B. Shah	N.A.	Salary & Perquisites	35,95,978/-	36,39,083/-
		Commission	NIL	NIL
		<b>Total</b>	<b>35,95,978/-</b>	<b>36,39,083/-</b>

Name of Director	Sitting Fees (₹)	Salary & Perquisites (₹)	2020-21
Mr. Jasvantlal G. Shah	3,55,000/-		
Mr. Lalitkumar P. Shah	40,000/-		
Mr. Bipin N. Shah (W.e.f. 08/01/2021)	95,000/-		
Mr. Bharat N. Shah	2,20,000/-		
Mr. Harmanbhai T. Patel	2,40,000/-		
Mr. Arun L. Tadarwal	3,55,000/-		
Mr. Sandeep M. Joshi	1,45,000/-		
Dr. (Ms.) Mita C. Dixit	1,45,000/-		
Mr. Samir J. Shah	1,20,000/-		
Mr. Ketan Shah	1,20,000/-		

The criteria of making payments to Non-Executive Directors has been mentioned in the Nomination and Remuneration Policy of the Company as formulated by the Nomination and Remuneration Committee which is placed on the website of the Company i.e. [www.anuhpharma.com](http://www.anuhpharma.com). There has been no significant change in the Nomination and Remuneration Policy since last financial year.

#### V. CORPORATE SOCIAL RESPONSIBILITY COMMITTEE:

As required by the provisions of Companies Act 2013, the Corporate Social Responsibility Committee was formed in the Board Meeting held on May 23, 2014.

This Committee consists of 3 Directors i.e.

Mr. Jasvantlal G. Shah - Chairman of the Committee  
 Mr. Arun L. Tadarwal - Member  
 Mr. Bipin N. Shah - Member

#### VI. STAKEHOLDER RELATIONSHIP COMMITTEE

The Stakeholder Relationship Committee consists of 4 (Four) Directors details of which are as follows:

Name of the Director	Designations	Composition
Mr. Lalitkumar P. Shah	Non-Executive Director	Chairman of the Committee
Mr. Bharat N. Shah	Non-Executive Director	Member
Mr. Bipin N. Shah	Vice Chairman - Non-Executive Director	Member
Mr. Jasvantlal. G. Shah	Independent Non - Executive Director	Member

No transfers were pending as on March 31, 2021. The Company has received total 2 (Two) complaints during the year under review and the same were resolved satisfactorily. No complaint was pending as on March 31, 2021.

#### Details of Compliance Officer:

**Name** : Ms. Ashwini Ambrale  
**Designation** : Company Secretary & Compliance Officer

## VII. ANNUAL GENERAL MEETINGS:

The details of the last three Annual General Meetings held are as follows:

Financial Year	Venue	Date & Time	Details of Special Resolutions passed
2017-18	Hall of Harmony, Nehru Centre, Dr. Annie Besant Road, Worli, Mumbai – 400 018	03/08/2018 At 03.00 PM	<ol style="list-style-type: none"> <li>1. Approval of revision in remuneration of Mr. Bipin N. Shah (DIN: 00083244) Managing Director of the Company</li> <li>2. Approval of revision in remuneration of Mr. Ritesh B. Shah (DIN: 02496729) Whole Time Director of the Company</li> <li>3. Approval of revision in remuneration of Mr. Vivek B. Shah (DIN: 02878724) Whole Time Director of the Company</li> </ol>
2018-19	Hall of Harmony, Nehru Centre, Dr. Annie Besant Road, Worli, Mumbai – 400 018	22/08/2019 At 03.00 PM	<ol style="list-style-type: none"> <li>1. Appointment of Mr. Harmanbhai Tulsibhai Patel (DIN: 07342390) as an Independent Director of the Company</li> <li>2. Approval of revision in remuneration of Mr. Ritesh B. Shah (DIN: 02496729) Whole Time Director of the Company</li> <li>3. Approval of revision in remuneration of Mr. Vivek B. Shah (DIN: 02878724) Whole Time Director of the Company</li> </ol>
2019-20	Through Video Conferencing / Other Audio Visual Means	11/09/2020 At 12:00 PM	<ol style="list-style-type: none"> <li>1. Continuation of Directorship of Mr. Bharat N. Shah (DIN: 00083354) who has attained the age of 75 years</li> </ol>

No Special Resolution is proposed to be passed through Postal Ballot as on the date of this Report.

## VIII. OTHER DISCLOSURES:

### Related Party Transactions

Disclosures on materially significant related party transactions i.e. transactions of the Company of material nature, with its Promoters, the Directors or the Management, their subsidiaries or relatives etc. that may have potential conflict with the interests of the Company at large. Policy on Transactions with Related Parties as approved by the Board is uploaded on the Company's website i.e. [www.anuhpharma.com](http://www.anuhpharma.com).

### Details of Non-compliance during the last three years

Details of non-compliance by the Company, penalties, and strictures imposed on the Company by the Stock Exchanges or SEBI or any statutory authority, on any matter related to capital markets, during the last three years – The appointment of Woman Director was delayed, after the resignation of the existing Woman Director, thereby non-compliance in Regulation 17(1) of SEBI (LODR) Regulation, 2015 has occurred. Therefore, the Company had paid penalty of ₹ 3,59,900/- (Incl. 18% GST)/- for a period of 61 days as per Circular No.: SEBI/HO/CFD/CMD/CIR/P/2018/77 dated May 03, 2018.

### Details of compliance with mandatory requirements and adoption of the non-mandatory requirements

The Company has complied with all the mandatory requirements of the applicable provisions of the Listing Regulations relating to Corporate Governance.

### Details of utilization of funds raised through preferential allotment or qualified institutions placement as specified under Regulation 32 (7A)

The Company has not raised any funds through preferential allotment or qualified institutions placement as specified under Regulation 32 (7A).

### Vigil Mechanism / Whistle Blower Policy

As required by the provisions of Companies Act 2013 and the Listing Regulations, 2015, the Company has established Vigil Mechanism and adopted Whistle Blower Policy to provide for adequate safeguards against victimization of employees and directors who avail of the vigil mechanism and also provide for direct access to the Chairman of the Audit Committee



or the director nominated to play the role of Audit Committee. No employee has been denied access to the Chairman of the Audit Committee.

### **Code of Conduct**

The Company is committed to conducting its business in conformity with ethical standards and applicable laws and regulations. The Code of Conduct for the Directors and Senior Management of the Company has been laid down by the Board and the same is posted on the website of the Company. All the Directors and Senior Management Personnel have affirmed their compliance with the said Code. A declaration by the Joint Managing Director of the Company to this effect is given below.

### **Declaration**

I, Ritesh Shah, Joint Managing Director of Anuh Pharma Limited, hereby declare that all the Members of the Board of Directors and the Senior Management Personnel have affirmed compliance with the Code of Conduct, applicable to them as laid down by the Board in terms of Regulation 26(3) of the Listing Regulations, 2015 entered into with the Stock Exchange for the year ended March 31, 2021.

### **Prohibition of Insider Trading**

With a view to regulate trading in securities by the Directors and Designated Persons and pursuant to the SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018, the Company put in place a framework for prohibition of insider trading in securities to strengthen the legal framework thereof the Company.

### **Familiarization Program to Independent Directors**

Familiarisation Programme has been carried out by the Company for the Independent Directors details of which has been posted on the Company's website [www.anuhpharma.com](http://www.anuhpharma.com).

### **Secretarial Standards relating to the Meetings:**

The Institute of Company Secretaries of India (ICSI) has established Secretarial Standards relating to the Meetings of the Board thereof and Annual General Meetings. Approval of the Central Government under sub-section (10) of Section 118 of the Companies Act, 2013 has been accorded to the Secretarial Standards (SS) namely SS-1 on Meetings of the Board and SS-2 on General Meetings. The Company shall follow the same.

### **CEO & CFO Certification**

The Joint Managing Directors and Chief Financial Officer of the Company have certified to the Board, inter alia the accuracy of financial statements and adequacy of internal controls for the financial reporting purpose as required under Regulation 17(8) of the Listing Regulations, 2015 for the year ended March 31, 2021. The Compliance Certificate issued by Joint Managing Director and Chief Financial Officer of the Company as per the provisions of Regulation 17(8) and Part B of Schedule II of the Listing Regulations, 2015 is annexed as '**Annexure A**' to the Corporate Governance Report.

### **Certificate from Practicing Company Secretary**

Certificate as required under Part C of Schedule V of Listing Regulations, received from Mr. Sanjay Doshi (CP No. 7595), Partner of M/s. Sanjay Doshi & Associates, Practicing Company Secretaries, that none of the Directors on the Board of the Company have been debarred or disqualified from being appointed or continuing as directors of the Company by the Securities and Exchange Board of India/ Ministry of Corporate Affairs or any such statutory authority was placed before the Board of Directors at their meeting held on May 21, 2021. The same is annexed as '**Annexure B**' to the Corporate Governance Report.

### **Environment, Health and Safety Policy**

The Company has adopted Environment, Health and Safety Policy. The same is annexed as '**Annexure C**' to the Corporate Governance Report.

### Recommendations of Committees of the Board

There were no instances during the financial year 2020-21, wherein the Board had not accepted recommendations made by any committee of the Board.

### Total fees paid to Statutory Auditors of the Company

Total fees of ₹ 7,00,000/- for financial year 2020-21, for all services, was paid by the Company to the Statutory Auditor.

### Disclosure relating to Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

The Company has in place an effective mechanism for dealing with complaints relating to sexual harassment at workplace.

The details relating to the number of complaints received and disposed of during the financial year 2020-21 are as under:

- Number of complaints filed during the financial year: NIL
- Number of complaints disposed of during the financial year: NIL
- Number of complaints pending as on end of the financial year: NIL

### Independent Directors' Meeting

During the year under review, the Independent Directors met on January 8, 2021, inter alia, to discuss and review:

- Evaluation of the performance of Non-independent Directors and the Board of Directors as a whole.
- Evaluation of the performance of the chairperson of the Company, taking into account the views of the Executive and Non-Executive Directors.
- Evaluation of the quality, content and timelines of flow of information between the Management and the Board that is necessary for the Board to effectively and reasonably perform its duties.

## MEANS OF COMMUNICATION

The quarterly/half-yearly/annual financial results are normally published in English and Marathi Newspapers viz. in Financial Express and Mumbai Lakshadeep respectively. These results are also available on the Company's website i.e. [www.anuhpharma.com](http://www.anuhpharma.com) as well as on the website of BSE Ltd. i.e. [www.bseindia.com](http://www.bseindia.com).

## GENERAL SHAREHOLDER INFORMATION

### A. Annual General Meeting

Day	:	Thursday
Date	:	August 19, 2021
Time	:	11.00 AM
Venue/Medium	:	Through Video Conferencing("VC") / Other Audio Visual Means ("OAVM")

### B. Financial Year

The Company follows Accounting financial year which starts from the 1<sup>st</sup> April and ends on 31<sup>st</sup> March.

### C. Financial Calendar for the financial year 2021-22 (Tentative)


Quarter	Period	Publications of Results
First	April 2021 - June 2021	August 14, 2021
Second	July 2021 - September 2021	November 14, 2021
Third	October 2021 - December 2021	February 14, 2022
Fourth	January 2022- March 2022 (Full Audited Accounts)	May 30, 2022

**D. Date of Book Closure** : Thursday, August 19, 2021

- E. Dividend Payment** : Final Dividend of ₹ 1.50/- per share i.e. 30% on the Equity Shares of face value of ₹ 5/- each of the Company has been recommended for the financial year 2020-21 subject to the approval of the Members at the ensuing 61<sup>st</sup> Annual General Meeting of the Company.
- E. Listing on Stock Exchanges** : The Company's Equity Shares are listed on BSE Limited and the Company has paid the necessary listing fees for the financial year 2021-22.
- F. Stock Code** : 506260 on BSE Limited
- G. ISIN Number for NSDL & CDSL** : INE489G01022
- H. Market Price Data** : High & Low during each month in the last financial year (given below).

Month	High Price (₹)	Low Price (₹)
April-2020	165.00	107.50
May-2020	197.35	140.00
June-2020	247.20	176.40
July-2020	288.00	205.75
August-2020	437.4	275.50
September-2020	422.00	182.00
October-2020	193.00	141.45
November-2020	172.80	138.00
December-2020	144.00	120.20
January-2021	142.75	124.30
Feb-2021	136.40	105.00
Mar-2021	113.40	90.00

**Share price movement vis-à-vis SENSEX:**



- I. Registrars & Transfer Agent** : **Bigshare Services Private Limited**  
 1<sup>st</sup> Floor, Bharat Tin Works Building,  
 Opp. Vasant Oasis, Makwana Road,  
 Marol, Andheri East Mumbai - 400059  
 Tel: +91-22-62638200; Fax: +91-22-62638299  
 Email: investor@bigshareonline.com  
 Website: www.bigshareonline.com
- J. Share Transfer System:**

All transfers received are processed by the Share Transfer Agents and Share Transfer Register is sent to the Company for approval. The Stakeholder Relationship Committee comprising Directors considers and approves the same. Thereafter, the Share Transfer Agents carry out necessary endorsements on the share certificates and dispatch the same to the transferees.

**K. Distribution of Shareholding:**

The Distribution of Shareholding as on March 31, 2021 was as under:

Category	No. of Shareholders	% of total Shareholders	No. of Shares Capital held	% of Shareholding
Upto 5000	18012	90.2812	14961940	5.9714
5001 - 10000	864	4.3309	6555050	2.6162
10001 - 20000	482	2.4159	7175460	2.8638
20001 - 30000	190	0.9523	4824485	1.9255
30001 - 40000	98	0.4912	3479555	1.3887
40001 - 50000	65	0.3258	2971780	1.1861
50001 - 100000	113	0.5664	8033110	3.2061
100001 and above	127	0.6366	202558620	80.8424
<b>Total</b>	<b>19951</b>	<b>100.0000</b>	<b>250560000</b>	<b>100.0000</b>

Shareholding Pattern as on March 31, 2021

Category	Total Shareholders	Shares	% of Shareholding
CLEARING MEMBER	72	119269	0.24
CORPORATE BODIES	81	573015	1.14
CORPORATE BODIES (PROMOTER CO)	1	95844	0.19
FOREIGN PROMOTERS	1	7200	0.01
IEPF	1	39882	0.08
NON NATIONALISED BANKS	1	150	0.00
NON RESIDENT INDIAN	320	335094	0.67
OTHER DIRECTORS	2	6408	0.01
PROMOTERS	10	18840862	37.60
PROMOTERS IMMEDIATE RELATIVES	34	16369342	32.67
PUBLIC	19428	13724934	27.39
<b>TOTAL</b>	<b>19951</b>	<b>50112000</b>	<b>100.00</b>

Dematerialization of Shares: 49776292 Equity Shares equivalent to 99.33% of the total paid-up Equity Capital have been in dematerialized form as on March 31, 2021.

The Company does not have outstanding global depository receipts or American depository receipts or warrants or any convertible instruments, conversion date and likely impact on equity.

**L. Credit Ratings and any revisions thereto for debt instruments or any fixed deposit programme or any scheme or proposal involving mobilization of funds, whether in India or abroad:**

The Company has not issued any debt instruments and does not have any fixed deposit programme or any scheme or proposal involving mobilization of funds in India or abroad during the financial year ended March 31, 2021.

**M. Transfer of unpaid/unclaimed dividend amounts to Investor Education and Protection Fund**

In terms of the provisions of Investor Education and Protection Fund (Accounting, Audit, Transfer and Refund) Rules, 2016 / Investor Education and Protection Fund (Awareness and Protection of Investors) Rules, 2001, the final dividend amount for the year ended March 31, 2013 and the interim dividend for the year March 31, 2014 were transferred to the Investor Education and Protection Fund and 18 shares were transferred during the financial year 2020-21 to the Investor Education and Protection Fund. The Company has appointed a Nodal Officer under the provisions of IEPF, the details of which are available on the website of the Company at [anuhpharma.com](http://anuhpharma.com).

**N. Equity shares in the suspense account**

In accordance with the requirement of Regulation 34(3) and Part F of Schedule V to the SEBI Listing Regulations, details of equity shares in the suspense account are as follows:

Sr. Nos.	Particulars	Number of Shareholders	Number of equity shares
1.	Aggregate number of shareholders and the outstanding shares in the suspense account lying as on April 1, 2020	NIL	NIL
2.	Shareholders who approached the Company for transfer of shares from suspense account during the year	NIL	NIL
3.	Shareholders whose shares are transferred to the demat account of the IEPF Authority as per Section 124 of the Act	NIL	NIL
4.	Aggregate number of shareholders and the outstanding shares in the suspense account lying as on March 31, 2021	NIL	NIL

**O. Plant Locations:**

**Factory :**

E-17/3 & 17/4, E-18 MIDC,  
Tarapur, Boisar,  
Dist. Palghar - 401 506  
Tel : +91-7410055574 / 75

**R & D Division:**

A-514, TTC Industrial Area, MIDC, Mahape,  
Navi Mumbai - 400 701  
Tel : +91-22-4119 3333  
Fax: +91-22-4119 3300  
Email: research@anuhpharma.com  
Web: www.aplmd.com

**P. Company Secretary & Compliance Officer**

Name : Ms. Ashwini Ambrale  
E-Mail ID : anuh@sk1932.com  
Tel. No. : +91-22-6622 7575  
Fax No. : +91-22-6622 7600

**Q. Address for Correspondence**

3-A, Shivsagar Estate, North Wing, Dr. Annie Besant Road, Worli, Mumbai - 400 018  
Tel. No. : +91-22-6622 7575  
Fax No. : +91-22-6622 7600  
Email : anuh@sk1932.com;  
Website : www.anuhpharma.com

By Order of the Board

**Sd/-**  
**Ashwini Ambrale**  
Company Secretary  
(M. No.: ACS 32456)

**Registered Office:**

CIN: L24230MH1960PLC011586  
3-A, Shiv Sagar Estate, North Wing,  
Dr. Annie Besant Road, Worli, Mumbai - 400 018  
Web: www.anuhpharma.com; Email: anuh@sk1932.com  
Tel: +91-22 6622 7575; Fax: +91-22 6622 7600

Place : Mumbai  
Date : May 21, 2021

## ANNEXURE A

### COMPLIANCE CERTIFICATE

*(Pursuant to the Regulation 17 (8) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015)*

- A. We hereby certify that we have reviewed financial statements and the cash flow statement for the year 2020-21 and that to the best of our knowledge and belief:
- 1) these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
  - 2) these statements together present a true and fair view of the listed entity's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- B. There are, to the best of our knowledge and belief, no transactions entered into by the listed entity during the year 2020-21 which are fraudulent, illegal or violative of the listed entity's code of conduct.
- C. We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the listed entity pertaining to financial reporting and we have disclosed to the auditors and the audit committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.
- D. We have indicated to the auditors and the Audit committee:
- 1) significant changes in internal control over financial reporting during the year 2020-21;
  - 2) significant changes in accounting policies during the year 2020-21 and that the same have been disclosed in the notes to the financial statements; and
  - 3) instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having a significant role in the listed entity's internal control system over financial reporting.

For **Anuh Pharma Limited**

Sd/-  
**Ritesh Shah**  
Joint Managing Director

For **Anuh Pharma Limited**

Sd/-  
**Vivek Shah**  
Joint Managing Director

For **Anuh Pharma Limited**

Sd/-  
**Darshan Rampariya**  
Chief Financial Officer

**ANNEXURE - B**

**CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS**

*(Pursuant to Regulation 34(3) and Schedule V Para C clause (10) (i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)*

To the Members of  
**Anuh Pharma Limited**  
 A 3 Shiv Sagar Estate, Dr. Annie Besant Road,  
 Mumbai 400018

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of **Anuh Pharma Limited** bearing **CIN L24230MH1960PLC011586** (hereinafter referred to as 'the Company'), produced before us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal [www.mca.gov.in](http://www.mca.gov.in)) as considered necessary and explanations furnished to us by the Company and its officers, we hereby certify that none of the Directors on the Board of the Company as stated below for the **financial year ending on March 31, 2021** have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, or any such other Statutory Authority.

DIN DD	Full Name	Designation	Date of Appointment
00372600	Mr. Jasvantlal Shah Girdharlal	Director	09/08/1995
00083244	Mr. Bipin Nemchand Shah	Director	01/04/2009
00396345	Mr. Lalit Popatlal Shah	Director	29/10/1980
00083354	Mr. Bharat Nemchand Shah	Director	29/10/1980
00020916	Mr. Arun Todarwal Lalchand	Director	24/10/2008
00516409	Mr. Sandeep Madhusudan Joshi	Director	22/08/2019
00157396	Mr. Samir Jayantilal Shah	Director	09/08/2016
00083326	Mr. Ketan Lalit Shah	Director	09/08/2016
02496729	Mr. Ritesh Bipin Shah	Joint Managing Director	09/08/2016
02878724	Mr. Vivek Bipin Shah	Joint Managing Director	09/08/2016
08198165	Ms. Mita Dixit	Director	08/02/2019
07342390	Mr. Harmanbhai Tulshibhai Patel	Director	22/05/2019

Ensuring the eligibility of for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification.

This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For **Sanjay Doshi & Associates**  
**[COMPANY SECRETARIES]**

Sd/-  
**Sanjay Doshi**  
**(Proprietor)**  
 FCS No: 4171  
 CP No : 7595

Place : Mumbai  
 Dated : 19.05.2021  
 UDIN : F004171C000343455



## ANNEXURE - C

### ENVIRONMENT, HEALTH AND SAFETY POLICY

We the management of Anuh Pharma Limited engaged in the Business of Manufacturing Active Pharmaceutical Ingredient (API) declare our intention and commitment to Environment, Health and Safety and compliance with all relevant statutory requirements.

We shall make all necessary arrangements to have organization set-up to carry out the declared policy by clearly assigning the responsibility at different levels to make the policy effective.

We shall strive for the involvement of entire workforce with honest intention of taking into account the health and safety performance of individuals at different levels while considering their career advancement and fixing the responsibility of the contractor ,sub contractors, transporters and other agencies entering premises for continual improvement towards our commitment.

We shall adopt relevant techniques and methods, such as safety audits and periodic risk assessment status of environment, health and safety and shall take all the required remedial measures.

We further reiterate our intention to integrate health and safety in all decisions including those dealing with purchase of Plant, Equipments, Machinery and Material as well as selection and placement of personnel and make necessary arrangement of informing ,educating ,training and retraining of our own employees at different levels and the public ,wherever required.

This policy shall be made widely known by making copies available to all workers including contract workers, apprentices, transport workers, suppliers, etc and by displaying the copies of the policy at conspicuous places in the language understood by majority of workers.

**For Anuh Pharma Ltd.**

Sd/-

**Bipin Shah**

Managing Director

(DIN: 00083244)

Format No: PA/F/032-00

Date : August 04, 2016

**CORPORATE GOVERNANCE COMPLIANCE CERTIFICATE**

To  
The Members,  
**Anuh Pharma Limited,**

We have examined the compliance of conditions of Corporate Governance by Anuh Pharma Limited (“the Company”) for the year ended on March 31, 2021, as stipulated in Regulations 17 to 27 and clauses (b) to (i) of sub-regulation (2) of Regulation 46 and Para C, D and E of Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The compliance of conditions of Corporate Governance is the responsibility of the management. Our examination was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of the Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us, and representations made by the management, we certify that the Company, to the extent applicable, has complied with the conditions of Corporate Governance as stipulated in Regulations 17 to 27, clauses (b) to (i) of sub-regulation (2) of Regulation 46 and Para C, D and E of Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We further state that such compliance is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For **MMJB & Associates LLP**  
**Company Secretaries**

**Saurabh Agarwal**  
**Designated Partner**  
FCS No. 9290  
CP No. 20907  
Peer Review No. L2020MH006700  
UDIN: F009290C000356109

Date: 21.05.2021

# INDEPENDENT AUDITORS' REPORT

TO THE MEMBERS OF  
ANUH PHARMA LIMITED

## Report on the audit of the Financial Statements

### Opinion

We have audited the accompanying financial statements of Anuh Pharma Limited ('the Company'), which comprise the balance sheet as at 31<sup>st</sup> March 2021, the statement of profit and loss (including other comprehensive income), the statement of cash flows and the statement of changes in equity for the year then ended and a summary of the significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31<sup>st</sup> March, 2021, and its profit, total comprehensive income, the changes in equity and its cash flows for the year ended on that date.

### Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing (SAs), as specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Financial Statements' section of our report. We are independent of the Company in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

### Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements for the financial year ended 31<sup>st</sup> March, 2021. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

#### Revenue recognition

The Company's performance is dependent on proper accounting of Revenue and is therefore susceptible to misstatement. Cut-off is the key assertion in so far as revenue recognition is concerned, since an inappropriate cut-off can result in material misstatement of results for the year.

#### Auditor's response

Our audit procedures with regard to revenue recognition included testing controls, automated and manual, dispatches/deliveries, inventory reconciliations and assessing the recoverability of trade receivable balances, substantive testing for cut-offs and analytical review procedures.

### Other Information

The Company's management and Board of Directors are responsible for the other information. The other information comprises the information included in the Company's annual report, but does not include the financial statements and our auditors' report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### **Management's Responsibility for the Financial Statements**

The Company's management and Board of Directors are responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the state of affairs, profit / loss (including other comprehensive income), changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

**Board of Directors are also responsible for overseeing the Company's financial reporting process.**

### **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

### Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditors' Report) Order, 2016 ("the Order") issued by the Central Government of India in terms of Section 143(11) of the Act, we give in "**Annexure A**" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

(A) As required by Section 143(3) of the Act, we report that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- (c) The Balance Sheet, the Statement of Profit and Loss (including other comprehensive income), the Statement of Changes in Equity and the Statement of Cash Flows dealt with by this Report are in agreement with the books of account.
- (d) In our opinion, the aforesaid financial statements comply with the Ind AS specified under Section 133 of the Act.
- (e) On the basis of the written representations received from the directors as on 31<sup>st</sup> March, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on 31<sup>st</sup> March, 2021 from being appointed as a director in terms of Section 164(2) of the Act.
- (f) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "**Annexure B**".
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended:

In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.

- (h) With respect to the other matters to be included in the Auditors' Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
  - i. The Company has disclosed the impact of pending litigations as at 31<sup>st</sup> March, 2021 on its financial position in its financial statements;

- ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses; and
- iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

**For JAYANTILAL THAKKAR & CO  
CHARTERED ACCOUNTANTS  
(FIRM REG. NO. 104133W)**

**PLACE: Mumbai  
DATE : 21<sup>st</sup> May, 2021**

**VIRAL A. MERCHANT  
PARTNER  
MEMBERSHIP NO. 116279  
UDIN: 21116279AAAACB7683**

## ANNEXURE 'A' TO THE INDEPENDENT AUDITOR'S REPORT

The Annexure referred to in Independent Auditors' Report to the members of the Company on the financial statements for the year ended 31<sup>st</sup> March 2021, we report that

- i. a. The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
- b. As explained to us, physical verification of the fixed assets was conducted by the management during the year. In our opinion, the frequency of physical verification is reasonable having regard to the size of the Company and the nature of its assets. No material discrepancies were noticed on such physical verification.
- c. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties are held in the name of the Company.
- ii. According to the information and explanations given to us, the physical verification of inventory has been conducted at reasonable intervals by the management. In our opinion, the discrepancies noticed on verification between the physical stocks and the book records were not material.
- iii. In our opinion and according to information and explanations given to us the Company has not granted any loans, secured or unsecured, to any companies, firms, Limited Liability Partnerships or other parties as covered in the register maintained under section 189 of the Act. Accordingly, the provisions of clause 3(iii) (a), (b) and (c) of the order are not applicable.
- iv. In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of section 185 and 186 of the Act, with respect to the loans, investments, guarantees and security made.
- v. In our opinion and according to the information and explanations given to us, the Company has not accepted any deposit within the meaning of Section 73 to 76 of the Act, and the rules framed thereunder.
- vi. We have broadly reviewed the books of accounts maintained by the Company in respect of products where, pursuant to the Rules made by the Central Government, the maintenance of cost records has been prescribed under sub-section (1) of section 148 of the Act, and are of the opinion that prima facie, the prescribed accounts and records have been made and maintained. We have not, however, made a detailed examination of the records with a view to determine whether they are accurate or complete.
- vii. a. According to the records of the company and the information and explanations given to us, the Company is generally regular in depositing with appropriate authorities undisputed statutory dues including Provident Fund, Employees' State Insurance, Income tax, Sales tax, Service tax, Custom Duty, Excise Duty, Value added tax, Goods and Services Tax, Cess and other statutory dues applicable to it. There are no undisputed statutory dues as referred to above as at 31<sup>st</sup> March, 2021 outstanding for a period of more than six months from the date on which they became payable.
- b. According to the information and explanations given to us, the dues as on March 31, 2021 in respect of Sales tax and Income Tax that have not been deposited with the appropriate authorities on account of dispute and the forum where the disputes are pending are given below:

Name of Statute	Nature of Dues	Amount (₹in lakhs)	Period to which the Amount Relates	Forum where dispute is pending
Bombay Sales Tax Act, 1959	Sales Tax (Including Interest and Penalty)	12.66	1991-1992	Bombay high court
		3.97	1992-1993	Bombay high court
Central Sales Tax Act, 1956	Sales Tax (Including Interest and Penalty)	6.48	1991-1992	Bombay high court
		3.92	1992-1993	Bombay high court
	<b>Total</b>	<b>27.03</b>		
Income Tax Act, 1961	Income Tax	27.78	AY 2018-19	CIT (Appeals)
	<b>Total</b>	<b>27.78</b>		



- viii. Based on our audit procedures and according to the information and explanations given by the management, the Company has not defaulted in repayment of loans from bank. Further as per the records of the Company, during the year there were no loans or borrowings from any financial institution, government or debenture holders.
- ix. According to the information and explanation given to us and based on our examination of the records of the Company, the Company did not raise any money by way of initial public offer or further public offer (including debt instrument) and term loans during the year. Accordingly, paragraph 3(ix) of the Order is not applicable.
- x. Based upon the audit procedures performed and to the best of our knowledge and belief and according to the information and explanations given to us no fraud by the company or any fraud on the Company by its officers or employees has been noticed or reported during the year.
- xi. According to the information and explanation given to us and based on our examination of the records of the Company, the company has paid/provided for managerial remuneration in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Act.
- xii. In our opinion and according to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, paragraph 3(xii) of the Order is not applicable.
- xiii. According to the information and explanation given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with section 177 and 188 of the Act where applicable and details of such transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- xiv. According to the information and explanation given to us and based on our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year.
- xv. According to the information and explanation given to us and based on our examination of the records of the Company, the Company has not entered into non-cash transactions with directors or persons connected with him/her. Accordingly, paragraph 3(xv) of the Order is not applicable.
- xvi. The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934.

**For JAYANTILAL THAKKAR & CO  
CHARTERED ACCOUNTANTS  
(FIRM REG. NO. 104133W)**

**PLACE: Mumbai  
DATE : 21<sup>st</sup> May, 2021**

**VIRAL A. MERCHANT  
PARTNER  
MEMBERSHIP NO. 116279  
UDIN: 21116279AAAACB7683**

## **ANNEXURE - B TO THE INDEPENDENT AUDITORS' REPORT**

### **Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")**

We have audited the internal financial controls over financial reporting of Anuh Pharma Limited ("the Company") as of 31<sup>st</sup> March, 2021 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

#### **Management's Responsibility for Internal Financial Controls**

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

#### **Auditors' Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

#### **Meaning of Internal Financial Controls over Financial Reporting**

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

#### **Inherent Limitations of Internal Financial Controls over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk

that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

**Opinion**

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an internal financial controls with reference to financial statements as at 31<sup>st</sup> March, 2021, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**For JAYANTILAL THAKKAR & CO  
CHARTERED ACCOUNTANTS  
(FIRM REG. NO. 104133W)**

**PLACE: Mumbai  
DATE : 21<sup>st</sup> May, 2021**

**VIRAL A. MERCHANT  
PARTNER  
MEMBERSHIP NO. 116279  
UDIN: 21116279AAAACB7683**

## BALANCE SHEET AS ON MARCH 31, 2021

(₹ in Lakhs)

PARTICULARS	Note No.	As at March 31, 2021	As at March 31, 2020
<b>I ASSETS</b>			
<b>1 Non-current Assets</b>			
(a) Fixed Assets			
(i) Property, Plant and equipment	2	7,111.20	8,318.77
(ii) Capital work-in-progress	2	-	-
(iii) Intangible Assets	3	23.99	28.90
(iv) Right of use assets	41	7.05	56.62
		<u>7,142.24</u>	<u>8,404.29</u>
(b) Financial Assets			
(i) Investments	4	2,037.13	1,369.52
(ii) Other Financial Assets	5	158.22	399.68
(c) Income Tax Assets	6	153.35	126.84
(d) Other Non Current Assets	7	-	41.61
<b>Total Non-Current Assets</b>		<u>9,490.94</u>	<u>10,341.94</u>
<b>2 Current Assets</b>			
(a) Inventories	8	8,142.58	6,148.75
(b) Financial Assets			
(i) Investments	9	1,101.45	6,586.24
(ii) Trade receivables	10	10,686.08	8,103.12
(iii) Cash and cash equivalents	11	219.84	184.52
(iv) Other Bank balances	12	1,789.31	67.29
(v) Loans and Advances	13	92.98	112.71
(vi) Other financial assets	14	475.24	226.89
(c) Other current assets	15	1,265.52	865.97
<b>Total Current Assets</b>		<u>23,773.00</u>	<u>22,295.49</u>
<b>TOTAL ASSETS</b>		<u>33,263.94</u>	<u>32,637.43</u>
<b>I EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
(i) Equity Share Capital	16	2,505.60	1,252.80
(ii) Other Equity	17	16,558.75	14,967.94
<b>TOTAL EQUITY</b>		<u>19,064.35</u>	<u>16,220.74</u>
<b>LIABILITIES</b>			
<b>1 NON-CURRENT LIABILITIES</b>			
(i) Lease Liabilities	18	-	7.77
(ii) Provisions	19	151.25	117.29
(iii) Deferred Tax Liabilities(Net)	20	101.41	20.73
<b>TOTAL NON-CURRENT LIABILITIES</b>		<u>252.66</u>	<u>145.79</u>
<b>2 CURRENT LIABILITIES</b>			
(a) Financial Liabilities			
(i) Borrowings	21	1,359.77	4,456.00
(ii) Lease Liabilities	22	7.77	51.69
(iii) Trade Payables:	23		
Due to Micro and Small Enterprises		55.47	50.60
Due to other than Micro and Small Enterprises		11,946.12	10,413.27
(iv) Other financial liabilities	24	468.14	800.02
(b) Other current liabilities	25	99.83	479.41
(c) Provisions	26	9.83	19.91
<b>TOTAL CURRENT LIABILITIES</b>		<u>13,946.93</u>	<u>16,270.90</u>
<b>TOTAL EQUITY AND LIABILITIES</b>		<u>33,263.94</u>	<u>32,637.43</u>
<b>SIGNIFICANT ACCOUNTING POLICIES AND NOTES TO THE ACCOUNTS</b>	1 to 50		

The Notes referred to above form an integral part of the Financial Statements.

 As per our report of even date attached  
**For JAYANTILAL THAKKAR & CO.**  
 Chartered Accountants  
 (Firm Reg. No. 104133W)

**VIRAL A. MERCHANT**  
 Partner  
 Membership No: 116279  
 Mumbai: 21<sup>st</sup> May, 2021

**For ANUH PHARMA LTD.**
**RITESH SHAH**  
 Joint Managing Director  
 (DIN: 02496729)

**DARSHAN RAMPARIYA**  
 Chief Financial Officer  
 Mumbai: 21<sup>st</sup> May, 2021

**VIVEK SHAH**  
 Joint Managing Director  
 (DIN: 02878724)

**ASHWINI AMBRALE**  
 Company Secretary

**JASVANTLAL SHAH**  
 Chairman  
 (DIN: 00372600)

## STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED ON MARCH 31, 2021

(₹ in Lakhs)

PARTICULARS	Note No.	As at	As at
		March 31, 2021	March 31, 2020
<b>I</b> Revenue from operations	27	<b>43,196.01</b>	30,695.96
<b>II</b> Other Income	28	<b>1,053.82</b>	421.23
<b>III Total Revenue (I+II)</b>		<b>44,249.83</b>	31,117.19
<b>IV Expenses :</b>			
Cost of materials consumed	29	<b>32,400.19</b>	23,965.58
Purchases of Stock-in-Trade	30	<b>348.31</b>	401.45
Changes in inventories of finished goods and work-in-progress	31	<b>231.31</b>	(1,350.76)
Employee benefits expense	32	<b>1,429.12</b>	1,336.23
Finance Cost	33	<b>149.45</b>	79.22
Depreciation and other amortization expense	2, 3& 41	<b>1,507.58</b>	703.26
Other Expenses	34	<b>4,328.73</b>	4,066.65
<b>Total Expenses</b>		<b>40,394.69</b>	29,201.63
<b>V Profit before tax (III-IV)</b>		<b>3,855.14</b>	1,915.56
<b>VI Tax expense:</b>			
- Current tax		<b>930.83</b>	370.00
- Deferred tax		<b>65.01</b>	130.70
- MAT Credit (Entitlement)/ Utilised		<b>15.67</b>	(15.67)
		<b>1,011.51</b>	485.03
<b>VII Profit after Tax (V-VI)</b>		<b>2,843.63</b>	1,430.53
<b>VIII Other comprehensive Income (OCI) ( net of tax)</b>			
(i) Items that will not be reclassified to profit or loss			
- Remeasurement of Defined Benefit Plans		-	(13.01)
- Income tax on above		-	3.79
(ii) Items that will be reclassified to profit or loss		-	-
<b>Total Other comprehensive Income</b>		-	(9.22)
<b>Total comprehensive income for the period (VII + VIII)</b>		<b>2,843.63</b>	1,421.31
<b>IX Earnings per equity share:</b>			
Basic and Diluted	40	<b>5.67</b>	2.85
<b>SIGNIFICANT ACCOUNTING POLICIES AND NOTES TO THE ACCOUNTS</b>	1 to 50		

The Notes referred to above form an integral part of the Financial Statements.

As per our report of even date attached  
**For JAYANTILAL THAKKAR & CO.**  
 Chartered Accountants  
 (Firm Reg. No. 104133W)

**VIRAL A. MERCHANT**  
 Partner  
 Membership No: 116279

Mumbai: 21<sup>st</sup> May, 2021

**For ANUH PHARMA LTD.**

**RITESH SHAH**  
 Joint Managing Director  
 (DIN: 02496729)

**DARSHAN RAMPARIYA**  
 Chief Financial Officer  
 Mumbai: 21<sup>st</sup> May, 2021

**VIVEK SHAH**  
 Joint Managing Director  
 (DIN: 02878724)

**ASHWINI AMBRALE**  
 Company Secretary

**JASVANTLAL SHAH**  
 Chirman  
 (DIN: 00372600)

## CASH FLOW STATEMENT

(₹ in Lakhs)

Particulars	Year ended on	Year ended on
	March 31,2021	March 31,2020
	Audited	Audited
<b>(A) CASH FLOW FROM OPERATING ACTIVITIES:</b>		
NET PROFIT BEFORE TAX	3,855.14	1,915.56
<u>Adjustment for:</u>		
Depreciation and Amortization	1,507.58	703.26
Finance Costs	149.45	79.22
Interest Income	(63.07)	(41.03)
Market to Market (gain) / loss on investment	(109.55)	398.56
Market to Market (gain) / loss on Derivative	0.31	-
Provision for Gratuity & Leave Encashment	52.44	29.51
Doubtful Debts Provision written back	(0.49)	-
Bad Debts Written Off	38.90	-
Provision for Doubtful Debts	-	16.94
Dividend Income	(141.29)	(213.61)
Loss/(Profit) on Sale of fixed assets	3.21	(0.02)
Loss/(Profit) on Sale of Investment	(694.82)	(142.93)
	<u>742.67</u>	<u>829.90</u>
<b>OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES</b>	<b>4,597.81</b>	<b>2,745.46</b>
<u>Adjustment for:</u>		
Trade and Other Receivables	(2,582.46)	(649.67)
Inventories	(1,993.83)	(1,863.67)
Other Financial Assets	(1,727.70)	(5.05)
Loans and Advances	19.73	(78.57)
Other Current Assets	(399.56)	400.57
Trade Payables	1,537.72	4,572.27
Other Financial Liabilities	72.82	17.20
Other current Liabilities	(379.58)	294.09
Gratuity & Leave Encashment paid	(45.42)	(30.11)
	<u>(5,498.28)</u>	<u>2,657.06</u>
<b>CASH GENERATED FROM OPERATIONS</b>	<b>(900.47)</b>	<b>5,402.52</b>
Direct Taxes paid	(973.00)	(509.46)
<b>NET CASH FROM OPERATIONS</b>	<b>(1,873.47)</b>	<b>4,893.06</b>
<b>(B) CASH FLOW FROM INVESTING ACTIVITIES:</b>		
(Purchase)/Sale of Investments [net]	5,621.56	(4,345.95)
Purchase of Property,Plant and Equipment and Capital Work in Progress	(615.38)	(3,562.93)
Sale of Property,Plant and Equipment	10.95	1.20
Interest Income	61.87	41.11
Dividend Income	141.29	213.61
<b>NET CASH USED IN INVESTING ACTIVITIES</b>	<b>5,220.29</b>	<b>(7,652.96)</b>

Particulars	Year ended on	Year ended on
	March 31,2021	March 31,2020
	Audited	Audited
<b>(C) CASH FLOW FROM FINANCING ACTIVITIES:</b>		
Total proceeds from Borrowings (net of repayments):		
Secured Loans/Short Term Borrowings	(3,096.23)	4,017.43
Payment of Lease Liabilities	(55.02)	(78.32)
Finance Costs	(162.40)	(56.53)
Dividend paid (including tax thereon)	2.15	(1,665.40)
<b>NET CASH FROM FINANCING ACTIVITIES</b>	<b>(3,311.50)</b>	<b>2,217.18</b>
<b>NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS (A + B + C)</b>	<b>35.32</b>	<b>(542.72)</b>
CASH AND CASH EQUIVALENT AS AT THE BEGINNING OF THE PERIOD	<b>184.52</b>	727.24
CASH AND CASH EQUIVALENT AS AT THE END OF THE PERIOD	<b>219.84</b>	184.52

As per our report of even date attached  
**For JAYANTILAL THAKKAR & CO.**  
Chartered Accountants  
(Firm Reg. No. 104133W)

**VIRAL A. MERCHANT**  
Partner  
Membership No: 116279  
Mumbai: 21<sup>st</sup> May, 2021

**For ANUH PHARMA LTD.**

**RITESH SHAH**  
Joint Managing Director  
(DIN: 02496729)

**DARSHAN RAMPARIYA**  
Chief Financial Officer  
Mumbai: 21<sup>st</sup> May, 2021

**VIVEK SHAH**  
Joint Managing Director  
(DIN: 02878724)

**ASHWINI AMBRALE**  
Company Secretary

**JASVANTLAL SHAH**  
Chirman  
(DIN: 00372600)



## STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED AS AT MARCH 31, 2021

### (a) Equity share capital

	No. of Shares	(₹ in Lakhs)
Balance as at 1 <sup>st</sup> April 2019	2,50,56,000	1,252.80
Changes in equity share capital	-	-
Balance as at 31 <sup>st</sup> March 2020	2,50,56,000	1,252.80
Changes in equity share capital	2,50,56,000	1,252.80
<b>Balance as at 31 March 2021</b>	<b>5,01,12,000</b>	<b>2,505.60</b>

### (b) Other Equity

(₹ in Lakhs)

Particulars	Reserves and Surplus			Statement of other comprehensive Income	Total other equity
	Capital Reserve	General Reserve	Retained earnings	Remeasurements of the net defined benefit Plans	
<b>Balance as at 1<sup>st</sup> April 2019</b>	<b>7.50</b>	<b>9,593.08</b>	<b>5,600.62</b>	<b>6.28</b>	<b>15,207.48</b>
Total Comprehensive					
Profit for the year	-	-	1,430.53	-	1,430.53
Other comprehensive income for the year	-	-	-	(9.22)	(9.22)
Income Tax of Earlier Years	-	-	0.49	-	0.49
Transactions with owners of the company					
Final Dividend on Equity Shares	-	-	(689.04)	-	(689.04)
Tax on Final Dividend	-	-	(141.63)	-	(141.63)
Interim Dividend on Equity Shares	-	-	(689.04)	-	(689.04)
Tax on Interim Dividend	-	-	(141.63)	-	(141.63)
Transferred from Retained Earnings	-	-	-	-	-
Transferred to General Reserve	-	-	-	-	-
<b>Balance as at 31<sup>st</sup> March 2020</b>	<b>7.50</b>	<b>9,593.08</b>	<b>5,370.30</b>	<b>(2.94)</b>	<b>14,967.94</b>
Total Comprehensive					
Profit for the year	-	-	2,843.63	-	2,843.63
Other comprehensive income for the year	-	-	-	-	-
Income Tax of Earlier Years	-	-	(0.02)	-	(0.02)
Transactions with owners of the company					
Final Dividend on Equity Shares	-	-	-	-	-
Tax on Final Dividend	-	-	-	-	-
Interim Dividend on Equity Shares	-	-	-	-	-
Tax on Interim Dividend	-	-	-	-	-
Transferred from Retained Earnings	-	600.00	-	-	600.00
Transferred to General Reserve	-	-	(600.00)	-	(600.00)
Issue of fully paid-up bonus Equity Shares	-	(1,252.80)	-	-	(1,252.80)
<b>Balance as at 31<sup>st</sup> March 2021</b>	<b>7.50</b>	<b>8,940.28</b>	<b>7,613.91</b>	<b>(2.94)</b>	<b>16,558.75</b>

The Notes referred to above form an integral part of the Financial Statements.

As per our report of even date attached  
**For JAYANTILAL THAKKAR & CO.**  
Chartered Accountants  
(Firm Reg. No. 104133W)

**VIRAL A. MERCHANT**  
Partner  
Membership No: 116279

Mumbai: 21<sup>st</sup> May, 2021

**For ANUH PHARMA LTD.**

**RITESH SHAH**  
Joint Managing Director  
(DIN: 02496729)

**DARSHAN RAMPARIYA**  
Chief Financial Officer  
Mumbai: 21<sup>st</sup> May, 2021

**VIVEK SHAH**  
Joint Managing Director  
(DIN: 02878724)

**ASHWINI AMBRALE**  
Company Secretary

**JASVANTLAL SHAH**  
Chirman  
(DIN: 00372600)

# Notes on Financial Statements for the Financial year ended on March 31, 2021

## NOTES FORMING PART OF THE FINANCIAL STATEMENTS

### 1(a) General information

Anuh Pharma Limited ('the Company') is engaged in the business of manufacturing and selling of "Bulk drugs and chemicals".

The company is a public limited company incorporated and domiciled in India and has its registered office at 3-A, Shivsagar Estate, North Wing, Dr. Annie Besant Road, Worli, Mumbai- 400018, Maharashtra, India.

### 1(b) Significant Accounting policies

#### (a) Basis of preparation

- (i) The financial statements have been prepared in compliance with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 (the Act) [Companies (Indian Accounting Standards) Rules, 2015] and other relevant provisions of the Act.
- (ii) The financial statements have been prepared on the historical cost basis except for the following assets and liabilities which have been measured at fair value:
  - 1. Financial instruments measured at fair value through profit and loss
  - 2. Defined benefit plans – plan assets measured at fair value

#### (b) Foreign currency translation

##### (i) Functional and presentation currency

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity operates ('the functional currency'). The financial statements are presented in Indian rupee (₹), which is the company's functional and presentation currency.

##### (ii) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates.

#### (c) Revenue recognition

The Company has adopted Ind AS 115, Revenue from Contract with Customers.

Revenue is measured at the fair value of the consideration received or receivable. Revenue from sale of goods is recognised; when the significant risks and rewards in respect of ownership of products are transferred by the Company, the entity retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold and no significant uncertainty exist regarding the amount of consideration that will be derived from the sale of goods as well as regarding its ultimate collection. Amounts disclosed as revenue are net of variable consideration on account of various Discounts, Rebates, incentives offered by the Company as a part of the contract.

The Company recognises revenue when the amount of revenue can be reliably measured, it is probable that future economic benefits will flow to the entity.

## Notes on Financial Statements for the Financial year ended on March 31, 2021

### Sale of goods

Revenue is measured at the fair value of the consideration received or receivable. Revenue from sale of goods is recognised when the significant risks and rewards in respect of ownership of products are transferred by the Company. The entity retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold and no significant uncertainty exist regarding the amount of consideration that will be derived from the sale of goods as well as regarding its ultimate collection. Amounts disclosed as revenue are inclusive of excise duty and net of returns.

The Company recognizes revenue when the amount of revenue can be reliably measured, it is probable that future economic benefits will flow to the entity.

### Dividend income

Dividend is recognized as revenue when the right to receive payment has been established.

### Interest income

Interest income is recognized on time proportion basis taking into account the amount outstanding and rate applicable.

## (d) Property, Plant and Equipment (PPE)

### i. Recognition and measurement

All items of PPE are measured at cost less accumulated depreciation and any accumulated impairment losses, if any.

The cost of an item of PPE comprises:

- a) its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates.
- b) any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Income and expenses related to the incidental operations, not necessary to bring the item to the location and condition necessary for it to be capable of operating in the manner intended by management, are recognised in profit or loss.

The Company has elected to continue with the carrying value of all its property, plant and equipment as recognized in the financial statements as at the date of transition to Ind AS, measured as per the previous GAAP and use that as the deemed cost as at the transition date pursuant to the exemption under Ind AS 101.

Any gain or loss on disposal of an item of PPE is recognised in profit and loss.

### ii. Subsequent expenditure

Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the Company.

### iii. Depreciation

Depreciable amount for assets is the cost of an asset, or other amount substituted for cost, less its estimated residual value.

## Notes on Financial Statements for the Financial year ended on March 31, 2021

Depreciation on PPE (other than leasehold land) has been provided based on useful life of the assets in accordance with Schedule II to the Companies Act, 2013, on written down value method except, useful life of Support structure for Plant differently based on an independent technical evaluation as 30 years. For the following assets, based on independent technical evaluation, which is different from the useful life and residual values as per Schedule II of the Companies Act, 2013, as under:

Category	Useful Life	Residual Value
Motor Car	5 years	25% of Cost
Support structure for plant	30 years	1% of Cost

Leasehold land (other than perpetual leasehold land) are amortised over the lease period.

Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

Profit and loss on disposals are determined by comparing proceeds with carrying amount. These are included in statement of profit and loss.

### (e) Intangible assets

Intangible Assets are stated at cost of acquisition net of recoverable taxes less accumulated amortisation/depletion. All costs, including financing costs till commencement of commercial production, net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to the intangible assets are capitalised.

The Company has elected to continue with the carrying value of all its intangible assets as recognized in the financial statements as at the date of transition to Ind AS, measured as per the previous GAAP and use that as the deemed cost as at the transition date pursuant to the exemption under Ind AS 101

Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific to which it relates.

### (f) Impairment of non-financial assets

Assets that have a definite useful life are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Management periodically assesses using, external and internal sources, whether there is an indication that an asset may be impaired.

The recoverable amount is higher of the asset's net selling price or value in use, which means the present value of future cash flows expected to arise from the continuing use of the asset and its eventual disposal. An impairment loss for an asset is reversed if, and only if, the reversal can be related objectively to an event occurring after the impairment loss was recognized. The carrying amount of an asset is increased to its revised recoverable amount, provided that this amount does not exceed the carrying amount that would have been determined (net of any accumulated amortization or depreciation) had no impairment loss been recognized for the asset in prior years.

### (g) Borrowing cost

Borrowing costs attributable to the acquisition/construction of qualifying assets are capitalized and form part of the cost of the qualifying assets. A qualifying asset is an asset that necessarily takes a substantial period of time to get ready for its intended use. All other borrowing costs are charged to revenue as an expense.

### (h) Leases

The Company evaluates if an arrangement qualifies to be a lease as per the requirements of Ind AS 116. Identification of a lease requires significant judgment. The Company uses significant judgement in assessing the lease term

## Notes on Financial Statements for the Financial year ended on March 31, 2021

(including anticipated renewals) and the applicable discount rate. The Company determines the lease term as the non-cancellable period of a lease, together with both periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option; and periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option. In assessing whether the Company is reasonably certain to exercise an option to extend a lease, or not to exercise an option to terminate a lease, it considers all relevant facts and circumstances that create an economic incentive for the Company to exercise the option to extend the lease, or not to exercise the option to terminate the lease. The Company revises the lease term if there is a change in the non-cancellable period of a lease. The discount rate is generally based on the incremental borrowing rate specific to the lease being evaluated or for a portfolio of leases with similar characteristics.

### (i) Income Tax

Provision for income tax is made for both current and deferred taxes. Provision for current income tax is made on the current tax rates based on the assessable income. The Company provides for deferred tax based on the tax effect of timing differences resulting from the recognition of items in the financial statements and in estimating its current tax provision. Deferred tax assets are recognized where there is certainty that there will be sufficient future taxable income available against which such deferred tax assets can be realized.

### (j) Inventories

Inventories are measured at lower of cost and net realisable value after providing for obsolescence, if any. Cost of inventories comprises of cost of purchase, cost of conversion and other cost including manufacturing overheads incurred in bringing them to their respective present location and condition. Cost of raw materials, work-in-progress, packing materials, trading and other products are determined on first-in-first-out basis.

### (k) Research and development

Revenue expenditure on Research and Development is charged to Profit and Loss Account as incurred. Capital expenditure on assets acquired for Research and Development is added to PPE.

### (l) Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

#### Financial assets

##### Classification

The Company shall classify financial assets as subsequently measured at amortised cost and fair value through profit and loss (FVTPL) on the basis of its business model for managing the financial assets and the contractual cash flow characteristics of the financial asset.

##### Cash and cash equivalents

The Company considers all highly liquid financial instruments, which are readily convertible into known amounts of cash that are subject to an insignificant risk of change in value and having original maturities of three months or less from the date of purchase, to be cash equivalents. Cash and cash equivalents consist of balances with banks which are unrestricted for withdrawal and usage.

##### Financial assets at amortised cost

Financial assets are subsequently measured at amortised cost if these financial assets are held within a business whose objective is to hold these assets to collect contractual cash flows and the contractual terms of the financial assets give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

## Notes on Financial Statements for the Financial year ended on March 31, 2021

### Financial assets at fair value through profit or loss

Financial assets are measured at fair value through profit or loss unless they are measured at amortised cost or at fair value through other comprehensive income on initial recognition. The transaction costs directly attributable to the acquisition of financial assets and liabilities at fair value through profit or loss are immediately recognised in statement of profit and loss.

### Impairment of financial assets

In accordance with Ind-AS 109, the Company applies expected credit loss (ECL) model for measurement and recognition of impairment loss on the following financial assets and credit risk exposure:

- a) Financial assets that are debt instruments, and are measured at amortised cost e.g. Bonds, securities and deposits.
- b) Trade receivables - The application of simplified approach does not require the Company to track changes in credit risk. Rather, it recognises impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

### Financial liabilities

#### Classification

The Company classifies all financial liabilities as subsequently measured at amortised cost, except for financial liabilities at fair value through profit and loss.

#### Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss.

The Company's financial liabilities include trade and other payables, loans and borrowings.

#### Offsetting of financial instruments

Financial assets and liabilities are offset and the net amount is reported in the balance sheet where there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the normal course of business and in the event of default, insolvency or bankruptcy of the Company or the counterparty.

#### Derivative financial instruments

The Company uses derivative financial instruments, such as foreign exchange forward contracts to manage its exposure to foreign exchange risks. For contracts where hedge accounting is not followed, such derivative financial instruments are initially recognised at fair value on the date on which a derivative contract is entered into and are subsequently re-measured at fair value through profit and loss. Derivatives are carried as financial assets when the fair value is positive and as financial liabilities when the fair value is negative.

### (m) Employee benefits

#### i. Short term employee benefits

Short term employee benefits consisting of wages, salaries, social security contributions, ex-gratia and accrued leave, are benefits payable and recognised in 12 months. Short-term employee benefits expected to be paid in exchange for the services rendered by employees are recognised undiscounted during the year as the related service are rendered by the employee.

## Notes on Financial Statements for the Financial year ended on March 31, 2021

### ii. Defined contribution plans

Company's contribution for the year paid/payable to defined contribution retirement benefit schemes are charged to Statement of Profit and Loss.

The Company's contribution towards provident fund and employee state insurance scheme for certain eligible employees are considered to be defined contribution plan for which the Company made contribution on monthly basis.

### iii. Defined benefit plans

Company's liabilities towards defined benefit plans and other long term benefits viz. gratuity and compensated absences expected to occur after twelve months, are determined using the Projected Unit Credit Method. Actuarial valuations under the Projected Unit Credit Method are carried out at the balance sheet date. Actuarial gains and losses are recognised in the Statement of other comprehensive income in the period of occurrence of such gains and losses. The retirement benefit obligation recognised in the balance sheet represents the present value of the defined benefit obligation as adjusted for unrecognised past service cost, and as reduced by the fair value of scheme assets, if any.

### (n) Provisions , Contingent Liabilities and Contingent Assets

A provision is recognised if as a result of a past event, the Company has a present obligation (legal or constructive) that can be estimated reliably and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are recognised at the best estimate of the expenditure required to settle the present obligation at the balance sheet date. If the effect of time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability.

A contingent liability exists when there is a possible but not probable obligation, or a present obligation that may, but probably will not, require an outflow of resources, or a present obligation whose amount cannot be estimated reliably. Contingent liabilities do not warrant provisions but are disclosed unless the possibility of outflow of resources is remote. Contingent assets are neither recognised nor disclosed in the financial statements. However, when the realisation of income is virtually certain, then the related asset is not a contingent asset and its recognition is appropriate.

### (o) Earnings per share (EPS)

Basic EPS is computed using the weighted average number of equity shares outstanding during the period. Diluted EPS is computed using the weighted average number of equity and dilutive equity equivalent shares outstanding during the period except where the results would be anti-dilutive.

### (p) Key estimates and assumptions

The preparation of financial statements in accordance with Ind AS requires use of estimates and assumptions for some items, which might have an effect on their recognition and measurement in the balance sheet and statement of profit and loss. The actual amounts realised may differ from these estimates.

Estimates and assumptions are required in particular for:

- Determination of the estimated useful lives of tangible assets and intangible assets and the assessment as to which components of the cost may be capitalized.

Useful lives of tangible assets and intangible assets are based on the life prescribed in Schedule II of the Companies Act, 2013. In cases, where the useful lives are different from that prescribed in Schedule II, they are based on management estimate, taking into account the nature of the asset, the estimated usage of the asset, the operating conditions of the asset, past history of replacement, anticipated technological changes,



## Notes on Financial Statements for the Financial year ended on March 31, 2021

manufacturers' warranties and maintenance support. Assumptions also need to be made, when the Company assesses, whether an asset may be capitalized and which components of the cost of the asset may be capitalised.

- Recognition and measurement of defined benefit obligations

The obligation arising from defined benefit plan is determined on the basis of actuarial assumptions. Key actuarial assumptions include discount rate, trends in salary escalation and vested future benefits and life expectancy. The discount rate is determined by reference to market yields at the end of the reporting period on government bonds. The period to maturity of the underlying bonds correspond to the probable maturity of the post-employment benefit obligations.

- Provisions and contingent liabilities

The Company exercises judgment in measuring and recognising provisions and the exposures to contingent liabilities related to pending litigation or other outstanding claims subject to negotiated settlement, mediation, arbitration or government regulation, as well as other contingent liabilities. Judgment is necessary in assessing the likelihood that a pending claim will succeed, or a liability will arise, and to quantify the possible range of the financial settlement. Because of the inherent uncertainty in this evaluation process, actual losses may be different from the originally estimated provision.

### (q) Rounding of amounts

All amounts disclosed in the financial statements and notes have been rounded off to the nearest lakhs (upto 2 decimal) as per the requirement of Schedule III, unless otherwise stated.

## Notes on Financial Statements for the Financial year ended on March 31, 2021

### NOTE NO.2 PROPERTY, PLANT AND EQUIPMENTS AND CAPITAL WORK IN PROGRESS AS AT 31<sup>st</sup> MARCH, 2021

(₹ in Lakhs)

Property, Plant and Equipment	GROSS BLOCK (AT COST)			DEPRECIATION (INCLUDING AMORTISATION)			NET BLOCK		
	Balance As at 01.04.2020	Additions During the year 2020-21	Deductions During the year - 2020-21	Balance As at 31.03.2021	For the Year	Deductions During the year	Total upto 31.03.2021	As At 31.03.2021	As At 31.03.2020
<b>Tangible Assets:</b>									
<b>(a) Land</b>									
-Freehold									
-Leasehold	974.77	-	-	974.77	17.13	-	85.65	889.12	906.25
-Leasehold - (Perpetual Lease)	155.88	-	-	155.88	-	-	-	155.88	155.88
<b>(b) Buildings</b>									
Building on Leasehold Land	216.23	-	-	216.23	19.17	-	106.26	109.97	129.14
Office Premises (see Note 2.1 below)	94.85	-	-	94.85	5.61	-	28.52	66.33	71.94
Guest House	104.20	-	-	104.20	27.85	-	33.56	70.64	76.35
Building-Stripper - ETP	15.44	-	-	15.44	5.03	-	6.51	8.93	10.41
Building- Admin Block	162.72	-	-	162.72	11.19	-	24.88	137.84	149.03
Factory Building	864.67	3.09	-	867.76	119.05	-	149.73	718.03	833.99
<b>(c) Plant and Equipment</b>									
Production Plant and Machinery	2,447.04	23.66	6.00	2,464.70	279.13	1.29	725.13	1,739.57	2,167.91
Safety Equipment - Production Plant	-	15.51	-	15.51	-	1.54	1.54	13.97	-
ZLD Plant	589.67	4.07	-	593.74	43.40	-	156.38	437.36	546.27
Laboratory Equipments	329.84	2.75	-	332.59	181.06	-	236.62	95.97	148.78
Material Storage & Handling Equipments	21.59	-	-	21.59	5.86	-	9.04	12.55	15.73
Support Structure - Plant	2,066.33	17.71	-	2,084.04	73.31	-	358.59	1,725.45	1,993.02
Boiler	165.29	2.79	-	168.08	8.48	-	41.12	126.96	156.81
Electrical installation - Plant	327.29	92.34	-	419.63	17.52	-	94.07	325.56	309.77
<b>(d) Furniture and Fixtures</b>	<b>216.29</b>	<b>0.28</b>	<b>-</b>	<b>216.57</b>	<b>68.03</b>	<b>-</b>	<b>122.79</b>	<b>93.78</b>	<b>148.26</b>
<b>(e) Vehicles</b>	<b>90.02</b>	<b>45.08</b>	<b>27.00</b>	<b>108.10</b>	<b>39.05</b>	<b>17.55</b>	<b>37.27</b>	<b>70.83</b>	<b>50.97</b>
<b>(f) Office Equipment</b>	<b>35.28</b>	<b>7.12</b>	<b>-</b>	<b>42.40</b>	<b>20.85</b>	<b>-</b>	<b>33.05</b>	<b>9.35</b>	<b>14.43</b>
<b>(g) Others:</b>									
-Electric Installations	82.90	32.13	-	115.03	41.55	-	63.25	51.78	41.35
-Air Conditioners	457.24	0.65	-	457.89	79.19	-	218.75	239.14	378.05
-Computer	42.41	11.72	-	54.13	27.98	-	41.94	12.19	14.43
<b>TOTAL PROPERTY, PLANT AND EQUIPMENT</b>	<b>9,459.95</b>	<b>258.90</b>	<b>33.00</b>	<b>9,685.85</b>	<b>1,452.32</b>	<b>18.84</b>	<b>2,574.65</b>	<b>7,111.20</b>	<b>8,318.77</b>
<b>CAPITAL WORK IN PROGRESS</b>									

## Notes on Financial Statements for the Financial year ended on March 31, 2021

### NOTE NO.2 PROPERTY, PLANT AND EQUIPMENTS AND CAPITAL WORK IN PROGRESS AT 31<sup>ST</sup> MARCH 2020

Property, Plant and Equipment	GROSS BLOCK (AT COST)			DEPRECIATION (INCLUDING AMORTISATION)			NET BLOCK		
	Balance As at 01.04.2019	Additions During the year 2019-20	Deductions During the year 2019-20	Balance As at 31.03.2020	For the Year	Deductions During the year	Total upto 31.03.2020	As At 31.03.2020	As At 31.03.2019
<b>Tangible Assets:</b>									
<b>(a) Land</b>									
-Freehold									
-Leasehold	974.77	-	-	974.77	17.13	-	68.52	906.25	923.38
-Leasehold - (Perpetual Lease)	155.88	-	-	155.88	-	-	-	155.88	155.88
<b>(b) Buildings</b>									
Building on Leasehold Land	211.58	4.65	-	216.23	22.29	-	87.09	129.14	146.79
Office Premises (see Note 2.1 below)	77.35	17.50	-	94.85	5.95	-	22.91	71.94	60.39
Guest House	104.20	-	-	104.20	6.17	-	27.85	76.35	82.52
Building-Stripper - ETP	15.44	-	-	15.44	1.73	-	5.03	10.41	12.14
Building- E18 - Admin Block	162.72	-	-	162.72	12.10	-	13.69	149.03	161.14
Factory Building - E18	-	864.67	-	864.67	30.68	-	30.68	833.99	-
<b>(c) Plant and Equipment</b>									
Plant & Machinery - Stripper - ETP	207.60	2,239.43	-	2,447.04	143.01	-	279.14	2,167.91	71.48
ZLD Plant/ETP	33.44	556.23	-	589.67	33.33	-	43.40	546.27	23.37
Laboratory Equipments	241.58	88.26	-	329.84	74.39	-	181.06	148.78	134.91
Material Storage & Handling Equipments	6.96	14.65	-	21.59	1.77	-	5.86	15.73	2.86
Support Structure Plant - E18	-	2,066.33	-	2,066.33	73.31	-	73.31	1,993.02	-
Boiler	-	165.29	-	165.29	8.48	-	8.48	156.81	-
Electrical installation plant	-	327.29	-	327.29	17.52	-	17.52	309.77	-
<b>(d) Furniture and Fixtures</b>	<b>128.28</b>	<b>87.98</b>	-	<b>216.26</b>	<b>56.19</b>	-	<b>68.03</b>	<b>148.26</b>	<b>116.42</b>
<b>(e) Vehicles</b>	<b>77.48</b>	<b>17.27</b>	<b>4.73</b>	<b>90.02</b>	<b>14.11</b>	<b>3.54</b>	<b>39.05</b>	<b>50.97</b>	<b>48.99</b>
<b>(f) Office Equipment</b>	<b>25.62</b>	<b>9.66</b>	-	<b>35.28</b>	<b>12.05</b>	-	<b>20.85</b>	<b>14.43</b>	<b>16.83</b>
<b>(g) Others:</b>									
-Electric Installations	70.95	11.96	-	82.90	18.06	-	41.55	41.35	52.88
-Air Conditioners	80.74	376.50	-	457.24	21.72	-	79.19	378.05	59.02
-Computer	26.53	15.91	-	42.41	12.99	-	27.98	14.43	13.55
<b>TOTAL PROPERTY, PLANT AND EQUIPMENT</b>	<b>2,601.12</b>	<b>6,863.56</b>	<b>4.73</b>	<b>9,459.95</b>	<b>626.19</b>	<b>3.54</b>	<b>1,141.18</b>	<b>8,318.77</b>	<b>2,082.55</b>
<b>CAPITAL WORK IN PROGRESS</b>									<b>3,385.29</b>

## Notes on Financial Statements for the Financial year ended on March 31, 2021

2.1 Office Premises includes value of shares of a co-operative society.

2.2 Some of the Motor Vehicles are held in the name of the Director of the Company.

2.3 From April 1, 2014, Depreciation on Tangible Fixed Assets is provided on pro-rata basis on the written down value method over the useful lives of assets as prescribed in Part C of Schedule II of the Companies Act, 2013. The Management of the Company estimates the useful lives and residual value for the following assets, based on independent technical evaluation, which is different from the useful lives and residual values as per Part C of Schedule II of the Companies Act, 2013, as under:

2.4 Useful life of fixed assets differently based on an independent technical evaluation as under:

Category	Useful Life	Residual Value
Motor Car	5 years	25% of Cost
Support Structure for plant	30 years	1% of Cost

### NOTE NO.3 INTANGIBLE ASSETS AS AT 31<sup>st</sup> MARCH, 2021

Intangible Assets	GROSS BLOCK (AT COST)				DEPRECIATION (INCLUDING AMORTISATION)				NET BLOCK	
	Balance As at 01.04.2020	Additions During the year 2020-21	Deductions During the year 2020-21	Balance As at 31.03.2021	Balance upto 01.04.2020	For the Year	Deductions During the year	Total upto 31.03.2021	As At 31.03.2021	As At 31.03.2020
Computer software	50.10	0.78	-	50.88	21.20	5.69	-	26.89	23.99	28.90
<b>TOTAL INTANGIBLE</b>	<b>50.10</b>	<b>0.78</b>	<b>-</b>	<b>50.88</b>	<b>21.20</b>	<b>5.69</b>	<b>-</b>	<b>26.89</b>	<b>23.99</b>	<b>28.90</b>

### NOTE NO.3 INTANGIBLE ASSETS AS AT 31<sup>st</sup> MARCH, 2020

Intangible Assets	GROSS BLOCK (AT COST)				DEPRECIATION (INCLUDING AMORTISATION)				NET BLOCK	
	Balance As at 01.04.2019	Additions During the year 2019-20	Deductions During the year 2019-20	Balance As at 31.03.2020	Balance upto 01.04.2019	For the Year	Deductions During the year	Total upto 31.03.2020	As At 31.03.2020	As At 31.03.2019
Computer software	50.10	-	-	50.10	15.53	5.67	-	21.20	28.90	34.57
<b>TOTAL INTANGIBLE</b>	<b>50.10</b>	<b>-</b>	<b>-</b>	<b>50.10</b>	<b>15.53</b>	<b>5.67</b>	<b>-</b>	<b>21.20</b>	<b>28.90</b>	<b>34.57</b>

### NOTE 4: INVESTMENTS

Particulars	(₹ in Lakhs)	
	As at March 31, 2021	As at March 31, 2020
Other Investments		
(a) Investments in bonds	180.75	180.75
(b) Investments in Mutual Funds	1,856.38	1,188.77
<b>Total</b>	<b>2,037.13</b>	<b>1,369.52</b>

## Notes on Financial Statements for the Financial year ended on March 31, 2021

### Details of Other Investments

Sr. No.	Name of the Body Corporate/ Mutual Fund	No. of Shares / Units		Amount (₹ in Lakhs)	
		As at March 31, 2021	As at March 31, 2020	As at March 31, 2021	As at March 31, 2020
(1)	(2)	(3)	(4)	(5)	(6)
<b>(i)</b>	<b>Investments in Bonds</b>				
	<b>(Others, Quoted , Fully paid up) (At Amortised Cost)</b>				
	Indian Railway Finance Corporation Ltd. 8.10% Tax Free 15 Years Bonds of ₹ 1000 each	4,350	4,350	43.50	43.50
	National Highway Authority of India 8.30% Tax Free 15 Years Bonds of ₹ 1000 each	2,472	2,472	24.72	24.72
	Power Finance Corporation Ltd. 8.30% Tax Free 15 Years Bonds of ₹ 1000 each	5,696	5,696	56.96	56.96
	Indian Railway Finance Corporation Ltd. 7.28% Tax Free 15 Years Bonds of ₹ 1000 each	4,530	4,530	45.30	45.30
	Power Finance Corporation Ltd. 7.35% Tax Free 15 Years Bonds of ₹ 1000 each	1,027	1,027	10.27	10.27
	<b>Total</b>			<b>180.75</b>	180.75
<b>(ii)</b>	<b>Investments in Mutual Funds (see Note 10.1)</b>				
	<b>( Others , Unquoted Fully Paid-up) (At Fair Value through Profit and Loss Account)</b>				
	HDFC Corporate Bond Fund Direct Growth	20,48,817.5730	-	515.96	-
	HDFC FMP 1158D February 2018(1) Series 39-Growth option - Direct of HDFC Mutual fund	-	20,00,000.0000	-	237.72
	HDFC Balanced Advantage Fund (Earswhile HDFC Prudence Fund ) Dividend option of-Direct HDFC Mutual Fund	46,75,512.2730	46,75,512.2730	1,340.42	951.05
	<b>Total</b>			<b>1,856.38</b>	1,188.77
	<b>Grand Total</b>			<b>2,037.13</b>	1,369.52

4.1 The current portion of Long Term Investments is reflected under Current Investments (see Note 9).

### NOTE NO.5 : OTHER FINANCIAL ASSETS

Particulars	(₹ in Lakhs)	
	As at March 31, 2021	As at March 31, 2020
(a) Security Deposits	108.22	99.68
(b) Earmarked deposit balances with bank	50.00	300.00
	<u>158.22</u>	<u>399.68</u>

### NOTE NO.6 : INCOME TAX ASSETS

Income Tax Assets (Net of Provision for Income Tax)	153.35	126.84
	<u>153.35</u>	<u>126.84</u>

## Notes on Financial Statements for the Financial year ended on March 31, 2021

(₹ in Lakhs)

Particulars	As at	
	March 31, 2021	March 31, 2020
<b>NOTE NO.7 : OTHER NON CURRENT ASSETS</b>		
Capital Advances	-	41.61
	-	41.61

### NOTE NO.8 : INVENTORIES

(At lower of Cost and Net Realisable Value)

(a) Raw materials	5,295.18	3,080.94
(b) Work-in-Progress	314.65	378.14
(c) Finished Goods	2,499.67	2,667.50
(d) Light Diesel Oil	7.77	5.70
(e) Packing Materials	9.08	7.15
(f) Sundry Goods Items	16.23	9.32
	<b>8,142.58</b>	<b>6,148.75</b>

### NOTE 9 : INVESTMENTS

(a) Investments in bonds	494.46	-
(b) Investments in Mutual Funds		
(i) Current Investments	355.11	5,346.64
(ii) Current portion/maturity of Long-term Investments	251.88	1,239.60
<b>Total</b>	<b>1,101.45</b>	<b>6,586.24</b>

### Details of Current Investments

Sr. No.	Name of the Body Corporate/ Mutual Fund Particulars	No. of Shares / Units		Amount (Rs. in Lakhs)	
		As at March 31, 2021	As at March 31, 2020	As at March 31, 2021	As at March 31, 2020
(1)	(2)	(3)	(4)	(5)	(6)
<b>(i) Investment in Bonds</b>					
	Tata Capital (TCFSL Market Linked NCD Tranche "A" 2018-19)	42	-	494.46	-
	<b>Total</b>			<b>494.46</b>	<b>-</b>
	<b>Investments in Mutual Funds</b>				
	(Others , Unquoted Fully Paid-up) (At Fair Value through Profit and Loss Account)				
<b>(i) Current Investments</b>					
	HDFC Floating Rate Income Fund- Short Term Plan- Wholesale Option- Growth of HDFC Mutual Fund-	-	8,70,875.3250	-	4,522.95

## Notes on Financial Statements for the Financial year ended on March 31, 2021

Sr. No.	Name of the Body Corporate/ Mutual Fund Particulars	No. of Shares / Units		Amount (Rs. in Lakhs)	
		As at March 31, 2021	As at March 31, 2020	As at March 31, 2021	As at March 31, 2020
	Idfc Ultra Short Term Fund- Dp Growth	32,345.2970	-	355.11	
	HDFC Arbitrage Fund- Wholesale Plan- Montly Dividend- Direct Plan	-	30,86,113.4110	-	823.69
	<b>Total</b>			<b>355.11</b>	<b>5,346.64</b>
(ii)	<b>Current portion/maturity of Long-term Investments</b>				
	<b>(Others , Unquoted Fully Paid-up) (At Fair Value through Profit and Loss Account)</b>				
	HDFC FMP 1218D December 2016(1) Series 37- Growth option - Direct of HDFC Mutual fund	-	50,00,000.0000	-	647.72
	HDFC FMP 1199D January 2017(1) Series 37- Growth option - Direct of HDFC Mutual fund	-	20,00,000.0000	-	256.70
	HDFC FMP 1158D February 2018(1) Series 39- Growth option - Direct of HDFC Mutual fund	20,00,000.0000	-	251.88	-
	HDFC Charity Fund for Cancer Cure- Arbitrage Plan- Regular 100% Dividend Donation Payout option -of HDFC Mutual fund	-	3,00,000.0000	-	30.14
	HDFC Credit Risk Fund (Earswhile Corporate Debt Opportunities Fund) - Growth option of-Direct HDFC Mutual Fund	-	17,48,790.0000	-	305.04
	<b>Total</b>			<b>251.88</b>	<b>1,239.60</b>
	<b>Grand Total</b>			<b>1,101.45</b>	<b>6,586.24</b>

### NOTE NO.10 : TRADE RECEIVABLE

Particulars	(₹ in Lakhs)	
	As at March 31, 2021	As at March 31, 2020
(a) Secured Considered good	589.49	799.65
(b-i) Unsecured Considered good #	10,096.60	7,303.47
(b-ii) Unsecured Trade receivables which have significant increase in credit risk	25.09	25.59
(c) Trade receivables - credit impaired	-	-
	<b>10,711.17</b>	<b>8,128.71</b>
Less: Provision for Doubtful Debts	25.09	25.59
	<b>10,686.08</b>	<b>8,103.12</b>
# Includes Receivable from Related parties (Refer Note no. 37)	<b>375.88</b>	<b>613.45</b>



## Notes on Financial Statements for the Financial year ended on March 31, 2021

Particulars	(₹ in Lakhs)	
	As at March 31, 2021	As at March 31, 2020
<b>NOTE NO.11 : CASH AND CASH EQUIVALENTS</b>		
-Balances with banks	217.79	182.47
-Cash on hand	2.05	2.05
	<u>219.84</u>	<u>184.52</u>
<b>NOTE NO.12 : OTHER BANK BALANCE</b>		
(i) In Fixed Deposits (under lien)		
Within 3 months maturity	-	-
With more than 3 months but upto 12 months maturity	1,769.86	50.00
	<u>1,769.86</u>	<u>50.00</u>
(ii) In Unclaimed Dividend Accounts	19.45	17.29
<b>TOTAL</b>	<u>1,789.31</u>	<u>67.29</u>
<b>NOTE NO.13 : LOANS AND ADVANCES</b>		
(Unsecured, considered good)		
Loans and Advances to Employees	62.93	59.14
Loans and Advances to others	30.05	53.57
	<u>92.98</u>	<u>112.71</u>
<b>NOTE NO.14 : OTHER FINANCIAL ASSETS</b>		
Interest Receivable	2.38	5.00
Interest accrued but not due on non current investments	6.49	6.61
Interest accrued but not due on fixed deposits	3.00	1.68
Export Incentives receivable	463.37	213.60
Other receivable	-	-
	<u>475.24</u>	<u>226.89</u>
<b>NOTE NO.15 : OTHER CURRENT ASSETS</b>		
Prepaid Expenses	44.00	27.41
Other Advances recoverable	1.42	1.42
Advance to suppliers	12.36	32.41
Balances with Government Authorities	46.60	326.61
GST /VAT /Excise /Service Tax Receivables	1,161.14	478.12
	<u>1,265.52</u>	<u>865.97</u>

## Notes on Financial Statements for the Financial year ended on March 31, 2021

### NOTE NO.16 : EQUITY SHARE CAPITAL

Share Capital	(₹ in Lakhs)	
	As at March 31, 2021	As at March 31, 2020
<b>Authorised</b>		
10,20,00,000 ,Equity Shares of ₹ 5 each	5,100.00	5,100.00
<b>Issued</b>		
5,01,12,000 (Previous year 2,50,56,000) Equity Shares of ₹ 5 each Subscribed & Paid up	2,505.60	1,252.80
5,01,12,000 (Previous year 2,50,56,000) Equity Shares of ₹ 5 each fully paid-up	2,505.60	1,252.80
<b>Total</b>	<b>2,505.60</b>	<b>1,252.80</b>

#### 16.1 Reconciliation of number of Shares outstanding at the beginning and end of the year

Particulars	2020-21		2019-20	
	Number	₹	Number	₹
<b>Equity Shares :</b>				
Shares outstanding at the beginning of the year	2,50,56,000	1,252.80	2,50,56,000	1,252.80
Issue of Bonus Shares (Fully paid up)	2,50,56,000	1,252.80	-	-
Shares outstanding at the end of the year	5,01,12,000	2,505.60	2,50,56,000	1,252.80

#### 16.2 Shareholders holding more than 5% of the Share Capital

Name of Shareholder	As at March 31, 2021	As at March 31, 2020
<b>Equity Shares :</b>		
Bharti Bipin Shah	97,37,400	48,68,700
% Holding	19.43	19.43
Bipin Nemchand Shah (HUF)	42,47,100	21,23,550
% Holding	8.48	8.48
Lalitkumar Popatlal Shah	38,39,760	19,19,880
% Holding	7.66	7.66
Bipin Nemchand Shah	31,15,860	15,59,930
% Holding	6.22	6.23
Prafulla Lalitkumar Shah	27,36,000	13,68,000
% Holding	5.46	5.46

16.3 Particulars	2020-21	2019-20	2018-2019	2017-2018	2016-2017
<b>Equity Shares :</b>					
Fully paid-up pursuant to contract(s) without payment being received in cash	-	-	-	-	-
Fully paid-up by way of bonus shares	2,50,56,000	-	-	-	1,67,04,000
Shares bought back	-	-	-	-	-

## Notes on Financial Statements for the Financial year ended on March 31, 2021

16.4 The company has only one class of Equity Shares having a par value of ₹ 5 per share. Each holder of equity share is entitled to one vote per share. The company declares and pays dividend in Indian rupees. The dividend proposed by the Board of Directors is subject to approval of the shareholders in the ensuing Annual General Meeting.

16.5 The shareholders of the Company had approved the sub-division of Equity Shares of the Company having nominal/face value of ₹ 10 each into Equity Shares having nominal/face value of ₹ 5 each at the Extraordinary General Meeting (“EGM”) held on June 9, 2006.

Consequently, the Authorised, Issued and Paid-up Share Capital were divided from ₹ 10 per Equity share to ₹ 5 per Equity Share.

### NOTE NO. 17 : OTHER EQUITY

Particulars	(₹ in Lakhs)	
	As at March 31, 2021	As at March 31, 2020
a. Capital Reserves		
Opening Balance	7.50	7.50
Add: Addition during the year		
Closing Balance	<u>7.50</u>	<u>7.50</u>
b. General Reserve		
Opening Balance	9,593.08	9,593.08
Add: Transfer from Statement of Profit and Loss in current year	600.00	-
Less: Utilised for issue of fully paid-up bonus Equity Shares	<u>1,252.80</u>	<u>-</u>
Closing Balance	<u>8,940.28</u>	<u>9,593.08</u>
c. Surplus		
Opening balance	5,370.30	5,600.62
Add: Net Profit/(Net Loss) for the current year	2,843.63	1,430.53
Add: Income tax adjustments of earlier years	(0.02)	0.49
Less: Appropriations:		
Final Dividend	-	(689.04)
Tax on Final Dividend	-	(141.63)
Interim Dividend	-	(689.04)
Tax on Interim Dividend	-	(141.63)
Transfer to General Reserve	<u>(600.00)</u>	<u>-</u>
Closing Balance	<u>7,613.91</u>	<u>5,370.30</u>
Other Comprehensive Income (OCI) :		
Remeasurement of the net defined benefit plans		
Opening Balance	(2.94)	6.28
Movement during the year	<u>(0.00)</u>	<u>(9.22)</u>
Closing Balance	<u>(2.94)</u>	<u>(2.94)</u>
<b>Total</b>	<u><b>16,558.75</b></u>	<u><b>14,967.94</b></u>

### NOTE NO.18 : LEASE LIABILITIES

Lease Liabilities	-	7.77
<b>Total</b>	<u>-</u>	<u>7.77</u>

## Notes on Financial Statements for the Financial year ended on March 31, 2021

Particulars	(₹ in Lakhs)	
	As at March 31, 2021	As at March 31, 2020
<b>NOTE NO.19 : PROVISIONS</b>		
- Provision for employee benefits		
Gratuity	95.98	74.08
Leave Encashment	55.27	43.21
<b>Total</b>	<b>151.25</b>	<b>117.29</b>
<b>NOTE NO.20 : DEFERRED TAX LIABILITY</b>		
Deferred Tax Liability	199.76	134.75
Less:		
Deferred Tax Assets	98.35	98.35
MAT credit entitlement	-	15.67
<b>Total</b>	<b>101.41</b>	<b>20.73</b>
<b>NOTE NO.21 : BORROWINGS</b>		
Secured Loan From Banks:		
Export Packing Credit	1,359.77	4,456.00
<b>Total</b>	<b>1,359.77</b>	<b>4,456.00</b>
<b>NOTE NO.22 : LEASE LIABILITIES</b>		
Lease Liabilities	7.77	51.69
<b>Total</b>	<b>7.77</b>	<b>51.69</b>
<b>NOTE NO.23 : TRADE PAYABLES</b>		
Due to Micro and Small Enterprises	55.47	50.60
Due to other than Micro and Small Enterprises	11,946.12	10,413.27
<b>Total</b>	<b>12,001.59</b>	<b>10,463.87</b>
<b>NOTE NO.24 : OTHER FINANCIAL LIABILITIES</b>		
Interest accrued but not due on borrowings	-	16.27
Unpaid dividends (see Note below)	19.45	17.29
Derivative Liability	0.31	-
Outstanding Creditors for Capital Goods	82.74	479.47
Other Payable	365.64	286.99
<b>Total</b>	<b>468.14</b>	<b>800.02</b>

24.1 There is no amount due and outstanding to be credited to the Investor Education & Protection Fund.

## Notes on Financial Statements for the Financial year ended on March 31, 2021

Particulars	(₹ in Lakhs)	
	As at March 31, 2021	As at March 31, 2020
<b>NOTE NO.25 : OTHER CURRENT LIABILITIES</b>		
Duties & Taxes (including tds,gst,vat,excise,service tax, TCS etc)	24.04	29.55
Advance received from customers	65.99	439.10
Other Payble	9.80	10.76
	<b>99.83</b>	<b>479.41</b>
<b>NOTE NO.26 : PROVISIONS</b>		
Provision for employee benefits		
Leave Encashment	4.67	6.21
Gratuity	5.16	13.70
	<b>9.83</b>	<b>19.91</b>
<b>NOTE NO.27 : REVENUE FROM OPERATIONS</b>		
Particulars	(₹ in Lakhs)	
	Year ended March 31, 2021	Year ended March 31, 2020
Sale of Products	42,730.33	30,273.03
Bulk drugs and Chemicals		
Other operating revenues (Gross)	465.68	422.93
Total Revenue From Operations	<b>43,196.01</b>	<b>30,695.96</b>
<b><u>DISAGGREGATION OF REVENUE</u></b>		
Revenue based on Geography		
- Export	21,941.80	14,655.90
- Domestic #	21,254.21	16,040.06
Revenue from operations	<b>43,196.01</b>	<b>30,695.96</b>
# ( Including export incentive on account of MEIS licence)		
<b><u>Reconciliation of Revenue from operations with contract price</u></b>		
Contract Price	44,036.93	31,785.55
Less:		
Sales returns	840.92	1,089.59
Total Revenue from operations	<b>43,196.01</b>	<b>30,695.96</b>

## Notes on Financial Statements for the Financial year ended on March 31, 2021

Particulars	(₹ in Lakhs)	
	Year ended March 31, 2021	Year ended March 31, 2020
<b>NOTE NO.28 : OTHER INCOME</b>		
Interest Income (Gross):		
(i) On Fixed deposits with Bank	48.71	26.67
(ii) On Non Current Investments (tax-free)	14.36	14.36
(iii) On Others	6.41	5.87
	<u>69.48</u>	<u>46.90</u>
Dividend Income from Investments in Mutual Funds :	141.29	213.61
Net gain/(loss) on sale of investments:		
(i) From Current Investments	423.10	82.82
(ii) From Non Current Investments	271.72	60.11
	<u>694.82</u>	<u>142.93</u>
Mark to Market Gain on Mutual Fund Investments (IND AS)	109.55	-
Profit on sale of Fixed Assets	-	0.02
Foreign Exchange Loss/(Gain)	30.16	-
Other non-operating income:		
Miscellaneous Income	8.03	17.77
Doubtful Debts Provision written back	0.49	-
	<u>8.52</u>	<u>17.77</u>
<b>Total</b>	<u><u>1,053.82</u></u>	<u><u>421.23</u></u>
<b>NOTE NO.29 : COST OF MATERIAL CONSUMED</b>		
Cost of Raw Material Consumed	32,180.50	23,813.25
Packing Material Consumed	188.65	127.37
Consumable Stores Consumed	31.03	24.96
<b>Total of Material Consumed</b>	<u><u>32,400.19</u></u>	<u><u>23,965.58</u></u>
<b>NOTE NO.30 : PURCHASE OF STOCK IN TRADE</b>		
Purchases		
Bulk drugs and Chemicals	348.31	401.45
<b>Total</b>	<u><u>348.31</u></u>	<u><u>401.45</u></u>

## Notes on Financial Statements for the Financial year ended on March 31, 2021

Particulars	(₹ in Lakhs)	
	Year ended March 31, 2021	Year ended March 31, 2020
<b>NOTE NO. 31: CHANGES IN INVENTORIES OF FINISHED GOODS AND WORK IN PROGRESS</b>		
Opening Stock :		
Work-in-Progress	2,667.50	461.79
Finished Goods	378.14	1,233.09
	<u>3,045.64</u>	<u>1,694.88</u>
Less : Closing Stock		
Work-in-Progress	314.65	2,667.50
Finished Goods	2,499.67	378.14
	<u>2,814.32</u>	<u>3,045.64</u>
Net (Increase) / Decrease in Inventories	<u>231.31</u>	<u>(1,350.76)</u>
<b>NOTE NO.32 : EMPLOYEE BEBEFIT EXPESNES</b>		
-Salaries and wages	1,328.60	1,244.49
-Contribution to provident and other funds	71.83	62.27
- Staff welfare expenses	28.69	29.47
	<u>1,429.12</u>	<u>1,336.23</u>
<b>NOTE NO.33 : FINANCE COST</b>		
(a) Interest expenses	146.13	69.48
(b) Interest on lease liabilities	3.32	9.74
	<u>149.45</u>	<u>79.22</u>
<b>NOTE NO. 34 : OTHER EXPENSES</b>		
Laboratory Expenses	113.20	88.87
Power and Fuel	865.75	631.31
Rent Expenses	27.61	4.27
Repairs and Maintenance to:		
Machineries	201.33	188.56
Building	32.57	32.54
Others	79.99	84.84
Insurance Charges	62.83	52.71
Rates and Taxes	6.01	5.60
Processing & Micronising Charges	1,027.37	891.06
Foreign Exchange Loss/(Gain)	-	336.49
Testing Charges	1.89	6.28
Travelling & Conveyance Expenses	51.22	36.60
Shipment and Export Expenses	328.19	169.88
Freight and Forwarding	64.40	54.37
Motor Vehicle Expenses	51.03	42.71
Bank Charges	53.57	46.57
Telephone & Courier Expenses	12.31	18.39



## Notes on Financial Statements for the Financial year ended on March 31, 2021

(₹ in Lakhs)

Particulars	Year ended	Year ended
	March 31, 2021	March 31, 2020
Brokerage and Commission	314.29	310.13
Membership Fees and Subscription	1.42	1.11
Sales Promotion Expenses	1.79	30.91
Professional Charges	55.18	48.65
Director Sitting Fees	18.40	12.75
Miscellaneous Expenses	818.93	519.57
(Gain)/loss on sale of Fixed Assets	3.21	-
Mark to Market loss on Mutual Fund Investments	-	398.56
Bad Debts Written Off	38.90	-
Provision for Doubtful Debts	-	16.95
Corporate Social Responsibility ("CSR") Expenditure [See Note no. 48]	90.09	30.24
Auditor's Remuneration [See Note no. 45]	7.25	6.73
<b>Total</b>	<b>4,328.73</b>	<b>4,066.65</b>

### NOTE NO.35

#### Financial instruments – Fair values and risk management

##### A. Accounting classification and fair values

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy. It does not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value.

(₹ in Lakhs)

Financial assets	As at 31 March 2021						
	Carrying amount			Fair value			
	Fair value through profit and loss	Amotised Cost	Total	Level 1	Level 2	Level 3	Total
Cash and cash equivalents (Including other bank balances)	-	2,009.15	2,009.15	-	-	-	-
Mutual Fund	2,463.37	-	2,463.37	-	2,463.37	-	2,463.37
Loans	-	92.98	92.98	-	-	-	-
Trade and other receivables	-	10,686.08	10,686.08	-	-	-	-
Other financial assets	-	633.46	633.46	-	-	-	-
Bonds	-	566.99	566.99	-	-	-	-
Security deposit	-	108.22	108.22	-	-	-	-
<b>TOTAL</b>	<b>2,463.37</b>	<b>14,096.88</b>	<b>16,560.25</b>	<b>-</b>	<b>2,463.37</b>	<b>-</b>	<b>2,463.37</b>
<b>Financial liabilities</b>							
Other financial liabilities	-	468.14	468.14	-	-	-	-
Short term borrowings	-	1,359.77	1,359.77	-	-	-	-
Trade and other payables	-	12,001.59	12,001.59	-	-	-	-
Lease liability	-	7.77	7.77	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>13,837.27</b>	<b>13,837.27</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>

## Notes on Financial Statements for the Financial year ended on March 31, 2021

(₹ in Lakhs )

Financial assets	As at 31 March 2020						
	Carrying amount			Fair value			
	Fair value through profit and loss	Amotised Cost	Total	Level 1	Level 2	Level 3	Total
Cash and cash equivalents (Including other bank balances)	-	251.82	251.82	-	-	-	-
Mutual Fund	7,775.01	-	7,775.01	-	7,775.01	-	7,775.01
Loans	-	112.71	112.71	-	-	-	-
Trade and other receivables	-	8,103.12	8,103.12	-	-	-	-
Other financial assets	-	526.89	526.89	-	-	-	-
Bonds	-	180.75	180.75	-	-	-	-
Security deposit	-	99.68	99.68	-	-	-	-
<b>TOTAL</b>	<b>7,775.01</b>	<b>9,274.97</b>	<b>17,049.98</b>	<b>-</b>	<b>7,775.01</b>	<b>-</b>	<b>7,775.01</b>
<b>Financial liabilities</b>							
Other financial liabilities	-	800.02	800.02	-	-	-	-
Short term borrowings	-	4,456.00	4,456.00	-	-	-	-
Trade and other payables	-	10,463.87	10,463.87	-	-	-	-
Lease liability	-	59.46	59.46	-	-	-	-
<b>TOTAL</b>	<b>-</b>	<b>15,779.35</b>	<b>15,779.35</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>

Fair values for financial instruments carried at amortised cost approximates the carrying amount, accordingly the fair values of such financial assets and financial liabilities have not been disclosed separately.

### B. Measurement of fair values

Ind AS 107, 'Financial Instrument - Disclosure' requires classification of the valuation method of financial instruments measured at fair value in the Balance Sheet, using a three level fair-value-hierarchy (which reflects the significance of inputs used in the measurements). The hierarchy gives the highest priority to un-adjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and lowest priority to un-observable inputs (Level 3 measurements). Fair value of derivative financial assets and liabilities are estimated by discounting expected future contractual cash flows using prevailing market interest rate curves. The three levels of the fair-value-hierarchy under Ind AS 107 are described below:

Level 1 : Level 1 Hierarchy includes financial instruments measured using quoted prices.

Level 2 : The fair value of financial instruments that are not traded in an active market are determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

Level 3 : If one or more of the significant inputs are not based on observable market data, the instrument is included in level 3. e.g. unlisted equity securities.

Transfers between Levels

There have been no transfers between Levels during the reporting periods

The following tables show the valuation techniques used in measuring Level 2 and Level 3 fair values, as well as the significant unobservable inputs used.

Financial instruments measured at fair value

## Notes on Financial Statements for the Financial year ended on March 31, 2021

Type	Valuation technique	Significant unobservable inputs	Inter-relationship between significant unobservable inputs and fair value measurement
<b>Level 2:</b>			
Mutual Fund	Net Asset Value	Not applicable	Not applicable
Forward Contracts	Market valuation techniques The Company has used discounted mark to market of forward contracts using current forward rates for remaining tenure of the forward contract as provided by respective banks	Not applicable	Not applicable

There are no transfers between the levels

### C. Financial risk management

The Company has exposure to the following risks arising from financial instruments:

- Credit risk ;
- Liquidity risk ; and
- Market risk

#### i. Risk management framework

The Company's board of directors has overall responsibility for the establishment and oversight of the Company risk management framework. The board of directors is responsible for developing and monitoring the Company risk management policies.

The Company's risk management policies are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities. The Company, through its training and management standards and procedures, aims to maintain a disciplined and constructive control environment in which all employees understand their roles and obligations.

The audit committee oversees how management monitors compliance with the company's risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Company. The audit committee is assisted in its oversight role by internal audit. Internal audit undertakes both regular and adhoc reviews of risk management controls and procedures, the results of which are reported to the audit committee.

#### ii. Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's receivables from customers and investments in debt securities, cash and cash equivalents, mutual funds, bonds etc.

The carrying amount of financial assets represents the maximum credit exposure.

#### Trade and other receivables

Around 51% of the sales are export sales. For major part of the sales, customer credit risk is managed by requiring domestic and export customers to pay advances before transfer of ownership, therefore substantially eliminating the Company's credit risk in this respect.

## Notes on Financial Statements for the Financial year ended on March 31, 2021

Based on prior experience and an assessment of the current economic environment, management believes that no provision is required for credit risk wherever credit is extended to customers.

Management believes that the unimpaired amounts that are past due by more than 6 months are still collectible in full, based on historical payment behaviour.

### Provision for doubtful debts movement

Particulars	(₹ in Lakhs )
Balance as at March 31, 2019	8.64
Impairment loss recognised	16.95
Amounts written off	-
Balance as at March 31, 2020	25.59
Impairment loss recognised	25.59
Amounts written off	(26.09)
<b>Balance as at March 31, 2021</b>	<b>25.09</b>

### Concentration of credit risk

At 31<sup>st</sup> March 2021, the carrying amount of the Company's most significant customer is ₹ 4342 lakhs (31<sup>st</sup> March, 2020 : ₹ 1,218 lakhs)

### Loan to others

The credit worthiness of the counter party is evaluated by the management on an ongoing basis and is considered to be good. The Company did not have any amounts that were past due but not impaired. The Company has no collateral in respect of these loans.

### Investment in mutual funds and bonds

The investment in mutual funds, Government bonds are entered into with credit worthy fund houses, Government of India and financial institution respectively. The credit worthiness of these counter parties are evaluated by the management on an ongoing basis and is considered to be good. The Company does not expect any losses from non-performance by these counter-parties.

### Cash and cash equivalents

Credit risk from balances with banks is managed by the Company's treasury department in accordance with the company's policy. Investment of surplus funds are made in mainly in mutual funds with good returns and within approved credit ratings.

Other than trade and other receivables, the Company has no other financial assets that are past due but not impaired.

### iii. Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company manages its liquidity risk by ensuring, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risk to the Company's reputation.

The Company has obtained fund and non-fund based working capital lines from one bank. The Company also constantly monitors funding options available in the debt and capital markets with a view to maintaining financial flexibility.

## Notes on Financial Statements for the Financial year ended on March 31, 2021

As at 31<sup>st</sup> March, 2021, the Company had working capital of ₹ 9826.07 lakhs, including cash and cash equivalents of ₹ 219.84 lakhs and highly marketable current investments of ₹ 1101.45 lakhs.

As at 31<sup>st</sup> March, 2020, the Company had working capital of ₹ 6024.59 lakhs, including cash and cash equivalents of ₹ 184.52 lakhs and highly marketable current investments of ₹ 6586.24 lakhs.

### Exposure to liquidity risk

The table below analyses the Company's financial liabilities into relevant maturity groupings based on their contractual maturities :

(₹ in Lakhs )

As at 31 <sup>st</sup> March 2021	Contractual cash flows					
	Carrying amount	Total	1 year or less	1-2 years	2-5 years	More than 5 years
<b>Non-derivative financial liabilities</b>						
Secured borrowings	1,359.77	1,359.77	1,359.77	-	-	-
Trade and other payables	12,001.59	12,001.59	12,001.59	-	-	-
Other financial liabilities	448.39	448.39	448.39	-	-	-
Unpaid Dividend	19.45	19.45	19.45	-	-	-
Derivative Liability	0.31	0.31	0.31			

As at 31 <sup>st</sup> March 2020	Contractual cash flows					
	Carrying amount	Total	1 year or less	1-2 years	2-5 years	More than 5 years
<b>Non-derivative financial liabilities</b>						
Secured borrowings	4,456.00	4,456.00	4,456.00	-	-	-
Trade and other payables	10,463.87	10,463.87	10,463.87	-	-	-
Other financial liabilities	766.46	766.46	766.46	-	-	-
Unpaid Dividend	17.29	17.29	17.29	-	-	-
Interest accrued but not due	16.27	16.27	16.27			

### iv. Market risk

Market risk is the risk of loss of future earnings, fair values or future cash flows that may result from adverse changes in market rates and prices (such as interest rates, foreign currency exchange rates ) or in the price of market risk-sensitive instruments as a result of such adverse changes in market rates and prices. Market risk is attributable to all market risk-sensitive financial instruments, all foreign currency receivables and payables and all short term and long-term debt. The Company is exposed to market risk primarily related to foreign exchange rate risk, interest rate risk and the market value of its investments. Thus, the Company's exposure to market risk is a function of investing and borrowing activities and revenue generating and operating activities in foreign currencies.

#### a) Currency risk

The company is exposed to currency risk to the extent that there is a mismatch between the currencies in which sales, purchase, other expenses and borrowings are denominated and the functional currency of the company. The functional currency of the company is Indian Rupees (INR). The currencies in which these transactions are primarily denominated is USD.

## Notes on Financial Statements for the Financial year ended on March 31, 2021

### Exposure to currency risk

The summary quantitative data about the Company's exposure to currency risk as reported to the management of the Company is as follows:

(₹ in Lakhs )

Particulars	As at 31 <sup>st</sup> March 2021		As at 31 <sup>st</sup> March 2020	
	EUR	USD	EUR	USD
Financial assets (A)				
Trade receivables	-	4,427.93	-	2,865.28
	-	4,427.93	-	2,865.28
Financial liabilities(B)				
Secured Loans	-	-	-	-
Trade payables	-	10,027.65	-	8,516.86
	-	10,027.65	-	8,516.86
Net statement of financial position exposure (A-B)	-	(5,599.72)	-	(5,651.57)

### Sensitivity analysis

The strengthening / weakening of the respective foreign currencies with respect to functional currency of Company would result in increase or decrease in profit or loss and equity as shown in table below. This analysis assumes that all other variables, in particular interest rates, remain constant. The following analysis has been worked out based on the exposures as of the date of statements of financial position.

(₹ in Lakhs )

Particulars	Profit / (loss)		
	Strengthening / Weakening %	Strengthening	Weakening
As at 31 <sup>st</sup> March, 2021			
EUR	2%	-	-
USD	3%	(167.99)	167.99

(₹ in Lakhs )

Particulars	Profit / (loss)		
	Strengthening / Weakening %	Strengthening	Weakening
As at 31 <sup>st</sup> March, 2020			
EUR	2%	-	-
USD	3%	(169.55)	169.55

(Note: The impact is indicated on the profit/loss before tax basis)

### b) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in interest rates.

## Notes on Financial Statements for the Financial year ended on March 31, 2021

For details of the Company's short-term loans and borrowings, including interest rate profiles, refer to Note of these financial statements.

Particulars	(₹ in Lakhs )	
	As at 31 <sup>st</sup> March, 2021	As at 31 <sup>st</sup> March, 2020
Fixed-rate instruments		
Financial assets	2,445.07	230.75
Financial liabilities	(1,359.77)	(4,456.00)
	<b>1,085.30</b>	<b>(4,225.25)</b>

### Interest rate sensitivity - fixed rate instruments

The company's fixed rate borrowings are carried at amortised cost. They are therefore not subject to interest rate risk as defined in IND AS 107, since neither the carrying amount nor the future cash flow will fluctuate because of a change in market interest rates.

### NOTE NO.36

#### Hedge accounting

As part of its risk management strategy, the company endeavors to hedge its net foreign currency exposure of highly forecasted sale transactions for the next 10 to 12 months in advance. The company uses forward contracts to hedge its currency exposure. Such contracts are designated as cash flow hedges.

The forward contracts are generally denominated in the same currency in which the sales realization is likely to take place.

For derivative contracts designated as hedge, the Company documents, at inception, the economic relationship between the hedging instrument and the hedged item, the hedge ratio, the risk management objective for undertaking the hedge and the methods used to assess the hedge effectiveness.

Financial contracts designated as hedges are accounted for in accordance with the requirements of Ind AS 109 depending upon the type of hedge.

The Company applies cash flow hedge accounting to hedge the variability in the future cash flows attributable to foreign exchange risk.

Hedge effectiveness is ascertained at the time of inception of the hedge and periodically thereafter. The Company assesses hedge effectiveness both on prospective and retrospective basis. The prospective hedge effectiveness test is a forward looking evaluation of whether or not the changes in the fair value or cash flows of the hedging position are expected to be highly effective on offsetting the changes in the fair value or cash flows of the hedged position over the term of the relationship. On the other hand, the retrospective hedge effectiveness test is a backward-looking evaluation of whether the changes in the fair value or cash flows of the hedging position have been highly effective in offsetting changes in the fair value or cash flows of the hedged position since the date of designation of the hedge.

Hedge effectiveness is assessed through the application of critical terms match method. Any ineffectiveness in a hedging relationship is accounted for in the statement of profit and loss.

The company has formally designated and documented hedge relationship from 1 April 2016.

a) Disclosure of effects of hedge accounting on financial position



## Notes on Financial Statements for the Financial year ended on March 31, 2021

As at 31<sup>st</sup> March, 2021

Type of risk/hedge position	Hedged item	Description of hedging strategy	Hedging instrument	Description of hedging instrument	Type of hedging relationship
Forward contract	Foreign currency risk of highly probable forecast transactions using forward contracts	Mitigate the impact of fluctuations in foreign exchange rates	Currency forward	Company enters into a forward derivative contract to hedge the foreign currency risk of highly probable forecast transactions using forward contracts. These are customized contracts transacted in the over-the-counter market.	Cash flow hedge

The tables below provide details of the derivatives that have been designated as cash flow hedges for the periods presented:

As at 31<sup>st</sup> March 2021

Particulars	Notional principal amounts	Derivative Financial Instruments - Assets	Derivative Financial Instruments - Liabilities	Line item in Balance Sheet position where the hedging instrument is included	Maturity date	Average strike price/ rate
Foreign exchange forward contracts	2.00 Lakhs USD	Nil	0.31	Nil	FY 2021-22	1 USD = INR 73.1025

Particulars	Change in fair value for the year	Change in fair value for the year recognized in OCI	Ineffectiveness recognized in profit or loss	Line item in profit or loss that includes hedge ineffectiveness	Amount reclassified from the hedge reserve to profit or loss	Line item in profit or loss affected by the reclassification
Foreign exchange forward contracts	FY 2020-21	Nil	0.31	Not applicable	Nil	Not applicable

### NOTE NO.37

#### I) Related Party Disclosures \*

(Where transactions have taken place)

##### a) Key Management Personnel (KMP)

Bipin N. Shah (Managing Director upto 07<sup>th</sup> January 2021/ Vice Chairman w.e.f. 8<sup>th</sup> January, 2021), Ritesh B. Shah (Whole Time Director & Chief Executive officer upto 07<sup>th</sup> January 2021/ Joint Managing Director w.e.f. 8<sup>th</sup> January, 2021), Vivek B. Shah (Whole Time Director & Chief Executive officer R&D upto 07<sup>th</sup> January 2021/ Joint Managing Director w.e.f. 8<sup>th</sup> January, 2021), Darshan Rampariya (Chief Financial Officer) and Ashwini Ambrale (Company Secretary and Compliance Officer).

##### b) Relatives of Key Management Personnel :

Bharat N. Shah, Bipin N. Shah (HUF)

##### c) Other Related Parties -(Enterprises-KMP having significant influence/owned by major shareholders)

S. Kant Pharma Pvt. Ltd (proprietor of Eskay Fine Chemicals), S Kant Healthcare Ltd, S.K. Age Exports, Bharti & Co., Sevantilal Kantilal & Co., Sevantilal Kantilal Pvt. Ltd., Sevak Pharma Pvt. Ltd., S.K. Pharma (Jogeshwari), S.K. Brothers, S.K. Distributors, Eskay Speciality Chemicals, Sevantilal Kantilal Trust, S.K. Logistics, Eskay Iodine Pvt. Ltd., S.Kant Chemicals Pvt. Ltd. and Ital Pharmachem Pvt. Ltd., S K & Others

## Notes on Financial Statements for the Financial year ended on March 31, 2021

### II Related Party Transactions

₹ in Lakhs

Transactions	As at 31 <sup>st</sup> March 2021			As at 31 <sup>st</sup> March 2020		
	Key Management Personnel	Relatives of (KMP)	Other related Party	Key Management Personnel	Relatives of (KMP)	Other related Party
<b>Income</b>						
Sale of Goods/ Materials	-	-	1,815.69	-	-	1,286.44
Testing Charges Received	-	-	0.08	-	-	-
<b>Expenses</b>						
Commission Paid	-	-	73.35	-	-	39.73
Rent Paid	-	-	-	-	-	0.30
Purchases of Raw Material/ Trading Purchase	-	-	9.14	-	-	17.51
Reimbursement (receipt) of Exhibition / Other Expenses	-	-	2.12	-	-	12.50
Reimbursement (Payment) of Society Maint. Charges	-	-	90.38	-	-	71.34
Managing Director's Remuneration	53.66	-	-	78.62	-	-
Director's Sitting Fees	-	2.20	-	-	1.05	-
Salary Paid	98.46	-	-	96.34	-	-
CSR Expenditure	-	-	31.92	-	-	14.19

₹ in Lakhs

Particulars	Key Management Personnel		Relatives of (KMP)		Other related Party	
	As at 31 <sup>st</sup> March 2021	As at 31 <sup>st</sup> March 2020	As at 31 <sup>st</sup> March 2021	As at 31 <sup>st</sup> March 2020	As at 31 <sup>st</sup> March 2021	As at 31 <sup>st</sup> March 2020
<b>Outstanding Balances</b>						
Short Term Provision	24.08	21.93	-	-	-	-
<b>Assets</b>						
Trade Receivables	-	-	-	-	375.88	613.45
<b>Liabilities</b>						
Trade Payables	-	-	-	-	15.19	10.86

## Notes on Financial Statements for the Financial year ended on March 31, 2021

### Disclosure in Respect of Related Party Transaction during the year :

₹ in Lakhs

Particulars	Key Management Personnel		Relatives of Key Management Personnel		Entities under direct or indirect control or substantial influence		Total	
	As at 31 <sup>st</sup> March 2021	As at 31 <sup>st</sup> March 2020	As at 31 <sup>st</sup> March 2021	As at 31 <sup>st</sup> March 2020	As at 31 <sup>st</sup> March 2021	As at 31 <sup>st</sup> March 2020	As at 31 <sup>st</sup> March 2021	As at 31 <sup>st</sup> March 2020
<b>(i) Transactions during the year:</b>								
<b>Income</b>								
Sales								
a) S. Kant Healthcare Ltd.	-	-	-	-	1,815.69	1,208.04	1,815.69	1,208.04
b) S. K. Age Exports	-	-	-	-	-	78.40	-	78.40
Total	-	-	-	-	1,815.69	1,286.44	1,815.69	1,286.44
Testing Charges Received								
a) Eskay Iodine Pvt. Ltd.	-	-	-	-	0.08	-	0.08	-
Total	-	-	-	-	0.08	-	0.08	-
<b>Expenses</b>								
Commission Paid								
a) S. Kant Chemicals Pvt. Ltd	-	-	-	-	73.35	39.73	73.35	39.73
Rent Paid								
a) S. K. Logistics	-	-	-	-	-	0.30	-	0.30
Purchases of Raw Material/ Trading Purchase								
a) Eskay Iodine Pvt. Ltd.	-	-	-	-	7.39	16.94	7.39	16.94
b) S. Kant Healthcare Ltd.	-	-	-	-	1.76	0.57	1.76	0.57
Total	-	-	-	-	9.14	17.51	9.14	17.51
Reimbursement (receipt) of Exhibition /Other Expenses								
a) Eskay Iodine Pvt. Ltd.	-	-	-	-	2.12	12.50	2.12	12.50
Total	-	-	-	-	2.12	12.50	2.12	12.50
Reimbursement (Payment) of Society Maint. Charges / Travelling Exp / Office Sharing Exp.								
a) S. Kant Healthcare Ltd.	-	-	-	-	1.63	1.67	1.63	1.67
b) Eskay Iodine Pvt. Ltd.	-	-	-	-	47.22	47.22	47.22	47.22
c) S K &Others	-	-	-	-	41.53	22.45	41.53	22.45
Total	-	-	-	-	90.38	71.34	90.38	71.34
Managing Director's Remuneration**								
a) Bipin N. Shah	53.66	78.62	-	-	-	-	53.66	78.62
Director's Sitting Fees								
a) Bharat N. Shah	-	-	2.20	1.05	-	-	2.20	1.05
Salary Paid**								
a) Vivek B. Shah	36.39	35.96	-	-	-	-	36.39	35.96
b) Ritesh B. Shah	30.63	35.41	-	-	-	-	30.63	35.41
c) Darshan Rampariya	24.07	18.84	-	-	-	-	24.07	18.84
d) Ashwini Ambrale	7.37	6.13	-	-	-	-	7.37	6.13
Total	98.46	96.34	-	-	-	-	98.46	96.34

## Notes on Financial Statements for the Financial year ended on March 31, 2021

₹ in Lakhs

Particulars	Key Management Personnel		Relatives of Key Management Personnel		Entities under direct or indirect control or substantial influence		Total	
	As at 31 <sup>st</sup> March 2021	As at 31 <sup>st</sup> March 2020	As at 31 <sup>st</sup> March 2021	As at 31 <sup>st</sup> March 2020	As at 31 <sup>st</sup> March 2021	As at 31 <sup>st</sup> March 2020	As at 31 <sup>st</sup> March 2021	As at 31 <sup>st</sup> March 2020
(i) Transactions during the year:								
CSR Expenditure								
a) Sevantilal Kantilal Trust	-	-	-	-	31.92	14.19	31.92	14.19
<b>Year end balances</b>								
<b>Assets</b>								
Trade Receivables								
a) S. Kant Healthcare Ltd.	-	-	-	-	375.88	613.45	375.88	613.45
<b>Total</b>	-	-	-	-	<b>375.88</b>	<b>613.45</b>	<b>375.88</b>	<b>613.45</b>
<b>Liabilities</b>								
Trade Payables								
a) Eskay Iodine Pvt. Ltd.	-	-	-	-	-	3.25	-	3.25
b) S. Kant Chemicals Pvt Ltd.	-	-	-	-	25.10	24.62	25.10	24.62
c) S K &Others	-	-	-	-	(9.91)	(17.01)	(9.91)	(17.01)
<b>Total</b>	-	-	-	-	<b>15.19</b>	<b>10.86</b>	<b>15.19</b>	<b>10.86</b>
Short Term Provisions								
a) Bipin N. Shah	24.08	21.93	-	-	-	-	24.08	21.93
<b>Total</b>	<b>24.08</b>	<b>21.93</b>	-	-	-	-	<b>24.08</b>	<b>21.93</b>

\*\*Excluding Provision for gratuity and leave encashment

### Terms and conditions of transactions with related parties

All the related party transactions were made on terms equivalent to those that prevail in an arm's length transactions.

\* Parties identified by the Management and relied upon by the auditors.

\$ All the related party transactions were made on terms equivalent to those that prevail in an arm's length transactions.

No amount in respect of related parties have been written off/back or are provided for.

### NOTE NO.38

#### i) Tax Reconciliation

(a) The Income tax expense consists of the following:

Particulars	(₹ in Lakhs)	
	Year ended 31 <sup>st</sup> March, 2021	Year ended 31 <sup>st</sup> March, 2020
Current income tax	930.83	370.00
MAT credit entitlement	15.67	(15.67)
Deferred tax expense	65.01	130.70
<b>Tax expense for the year</b>	<b>1,011.51</b>	<b>485.03</b>

## Notes on Financial Statements for the Financial year ended on March 31, 2021

### (b) Amounts recognised in other comprehensive income

(₹ in Lakhs)

Particulars	Year ended 31 <sup>st</sup> March, 2021	Year ended 31 <sup>st</sup> March, 2020
Items that will not be reclassified to profit or loss		
Remeasurement of post employment benefit obligations		
Before tax	-	(13.01)
Tax (expense) benefit	-	3.79
Net of tax	-	(9.22)

The reconciliation of estimated income tax expenses at statutory income tax rate to income tax expense reported in statement of Profit and loss is as follows:

(₹ in Lakhs)

Particulars	Year ended 31 <sup>st</sup> March, 2021	Year ended 31 <sup>st</sup> March, 2020
Profit before tax	3,855.14	1,915.56
Indian statutory income tax rate	29.120%	29.120%
Expected income tax expenses	1,122.62	557.81
Tax effect of adjustments to reconcile expected income tax expense to reported income tax expenses:-		
Income exempt from income taxes	(3.65)	(76.58)
Additional allowances/deductions	(11.39)	(82.56)
Effect of non-deductible expenses / non taxable Income (Net) for the purpose of Income Tax	(96.07)	86.36
Total Income Tax expenses	1,011.51	485.03
Effective Tax Rate	26.238%	25.321%

### ii) Deferred Tax Disclosure

#### (a) Movement in deferred tax balances

(₹ in Lakhs)

Particulars	Net balance as at 1 <sup>st</sup> April, 2020	Recognised in profit or loss	Recognised in OCI	Net Deferred tax asset as at 31 <sup>st</sup> March, 2021
Deferred tax asset/ (liabilities)				
Property, plant and equipment	(139.17)	(63.13)	-	(202.30)
Employee benefits	60.38	7.54	-	67.92
Other items	42.39	(9.42)	-	32.97
MAT Credit entitlement	15.67	(15.67)	-	-
Tax assets/ (liabilities)	(20.73)	(80.68)	-	(101.41)

## Notes on Financial Statements for the Financial year ended on March 31, 2021

### (b) Movement in deferred tax balances

(₹ in Lakhs)

Particulars	Net balance as at 1 <sup>st</sup> April, 2019	Recognised in profit or loss	Recognised in OCI	Net Deferred tax asset as at 31 <sup>st</sup> March, 2020
Deferred tax asset/ (liabilities)				
Property, plant and equipment	12.03	(151.20)	-	(139.17)
Employee benefits	47.07	9.52	3.79	60.38
Other items	31.41	10.98	-	42.39
MAT Credit entitlement	-	15.67	-	15.67
Tax assets/ (liabilities)	90.51	(115.03)	3.79	(20.73)

The company offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax authority.

Significant management judgement is required in determining provision for income tax, deferred income tax assets and liabilities and recoverability of deferred income tax assets. The recoverability of deferred income tax assets is based on estimates of taxable income in which the relevant entity operates and the period over which deferred income tax assets will be recovered.

### NOTE NO. 39

#### Capital Management

The Company's policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. Management monitors the return on capital as well as the level of dividends to ordinary shareholders.

The Company monitors capital using a ratio of 'net debt' to 'equity'. For this purpose, net debt is defined as total debt, comprising loans and borrowings less cash and cash equivalents and current investments.

The Company's net debt to equity ratio as at 31<sup>st</sup> March 2021 and 31<sup>st</sup> March 2020 was as follows.

(₹ in Lakhs)

Particulars	As at 31 <sup>st</sup> March, 2021	As at 31 <sup>st</sup> March, 2020
Current Borrowings	1,359.77	4,456.00
<b>Gross Debt</b>	<b>1,359.77</b>	<b>4,456.00</b>
Less - Cash and Cash Equivalents	219.84	184.52
Less - Current Investments	1,101.45	6,586.24
<b>Net debt</b>	<b>38.48</b>	<b>(2,314.76)</b>
<b>Total equity</b>	<b>19,064.35</b>	<b>16,220.74</b>
<b>Net debt to Equity ratio*</b>	<b>0.0020</b>	<b>-</b>

\*Since Net debt to Equity ratio result is negative, the same is shown as nil.

## Notes on Financial Statements for the Financial year ended on March 31, 2021

### NOTE NO.40

#### Earning Per Share (EPS):

Basic EPS and Diluted EPS amounts are calculated by dividing the profit for the year attributable to equity holders of the company by the weighted average number of Equity shares outstanding during the year.

Particulars	Year ended	Year ended
	31 <sup>st</sup> March, 2021	31 <sup>st</sup> March, 2020
Profit attributable to equity holders (₹ in Lakhs )	<b>2,843.63</b>	1,430.53
Weighted average number of shares outstanding during the year	<b>5,01,12,000</b>	5,01,12,000
Nominal Value of Equity Shares (in ₹)	<b>5</b>	5
Earning Per Share Basic and Diluted (in ₹)	<b>5.67</b>	2.85

On 22<sup>nd</sup> September ,2020 ,the Company allotted 2,50,56000 Equity Shares of ₹ 5 each as fully paid-up Bonus Equity Shares in the ratio of 1:1 to all registered shareholders as on record date by capitalisation of reserves. Consequently, in accordance with Ind AS 33 "Earnings per Share" figure for the year ended 31<sup>st</sup> March 2020 have been adjusted to give effect to allotment of the Bonus Shares.

### NOTE NO.41

#### Right Of Use Assets:

The Company has lease contracts for various item of buildings in its operation. Lease of building generally have lease term between 1 to 2 years. The Companies obligation under it leases are secured by the lessor title to the lease assets. Generally the Company is restricted from assigning and sub leasing the lease assets. There are no major lease contracts that include extension and termination options and variable lease payments. The effective rate of interest for lease liabilities is 10%.

Set out below are the carrying amounts of rights-of-use assets recognised and the movement during the period:

Particulars	₹ in lakhs	
	As at 31 <sup>st</sup> March, 2021	As at 31 <sup>st</sup> March, 2020
Opening Balance	<b>56.62</b>	128.04
Addition	-	-
Less: Depreciation expenses	<b>49.57</b>	71.42
Closing Balance	<b>7.05</b>	56.62

Set out below are the carrying amounts of lease liabilities and the movements during the period:

Particulars	₹ in lakhs	
	As at 31 <sup>st</sup> March, 2021	As at 31 <sup>st</sup> March, 2020
Opening Balance	<b>59.46</b>	128.04
Additions	<b>0.00</b>	0.00
Accretion of Interest	<b>3.32</b>	9.74
Less: Payments	<b>55.02</b>	78.32
Closing Balance	<b>7.77</b>	59.46
Current	<b>7.77</b>	51.69
Non-Current	<b>0.00</b>	7.77



## Notes on Financial Statements for the Financial year ended on March 31, 2021

The following are the amounts recognised in profit and loss :

Particulars	₹ in lakhs	
	Year ended 31 <sup>st</sup> March, 2021	Year ended 31 <sup>st</sup> March, 2020
Depreciation expenses of right of use assets	49.57	71.42
Interest expenses on lease liabilities	3.32	9.74
Expenses relating to short term lease and low value leased (included in other expenses accrued in current year and paid in earlier year)	27.61	4.27
<b>Total amount recognised in profit and loss</b>	<b>80.50</b>	<b>85.43</b>

The Company had total cash outflow for lease of ₹ 82.63 lakhs during the year ended on 31<sup>st</sup> March, 2021 (previous year ₹ 82.59 lakhs).

### NOTE NO.42

As at 31<sup>st</sup> March, 2020, the Company has certain dues to suppliers registered under Micro, Small and Medium Enterprises Development Act, 2006 ('MSMED Act'). The disclosures pursuant to the said MSMED Act are as follows:

	₹ in lakhs	
	As at 31 <sup>st</sup> March 2021	As at 31 <sup>st</sup> March 2020
a) The principal amount remaining unpaid to any supplier at the end of the year	55.47	50.60
b) Interest due remaining unpaid to any supplier at the end of the year	-	-
c) The amount of interest paid by the buyer in terms of section 16 of the MSMED Act, 2006, along with the amount of the payment made to the supplier beyond the appointed day during the year	-	-
d) The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act, 2006	-	-
e) The amount of interest accrued and remaining unpaid at the end of each accounting year	-	-
f) The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprises, for the purpose of disallowance of a deductible expenditure under section 23 of the MSMED Act, 2006	-	-

Disclosure of payable to vendors as defined under the "Micro, Small and Medium Enterprise Development Act, 2006" is based on the information available with the Company regarding the status of registration of such vendors under the said Act, as per the intimation received from them on requests made by the Company. There are no overdue principal amounts / interest payable amounts for delayed payments to such vendors at the Balance Sheet date. There are no delays in payment made to such suppliers during the year or for any earlier years and accordingly there is no interest paid or outstanding interest in this regard in respect of payment made during the year or on balance brought forward from previous year.

### NOTE NO.43

#### Employee Benefit obligations

##### (A) Defined Contribution Plan

The Company has various schemes for long-term benefits such as provident fund and superannuation. In case of funded schemes, the funds are recognised by the Income tax authorities and administered through trustees /appropriate authorities. The Company's defined contribution plans are superannuation and employees' pension scheme (under the

## Notes on Financial Statements for the Financial year ended on March 31, 2021

provisions of the Employees' Provident Funds and Miscellaneous Provisions Act, 1952) since the Company has no further obligation beyond making the contributions. The liability of the Company on the exempt Provident Fund managed by the trustees is restricted to the interest shortfall if any.

Particulars	(₹ in Lakhs)	
	Year ended 31 <sup>st</sup> March 2021	Year ended 31 <sup>st</sup> March 2020
Charge to the Statement of Profit and Loss based on contributions:		
Employees' Provident fund	42.80	36.59

### (B) Defined Benefit Plan

"In accordance with the provisions of the Payment of Gratuity Act, 1972, the Company has a defined benefit plan which provides for gratuity payments. The plan provides a lump sum gratuity payment to eligible employees at retirement or termination of their employment. The amounts are based on the respective employee's last drawn salary and the years of employment with the Company.

Liabilities in respect of the gratuity plan are determined by an actuarial valuation, based upon which the Company makes annual contributions to the Group Gratuity cum Life Assurance Schemes administered by the LIC of India, a funded defined benefit plan for qualifying employees. Trustees administer the contributions made by the Company to the gratuity scheme.

The most recent actuarial valuation of the defined benefit obligation along with the fair valuation of the plan assets in relation to the gratuity scheme was carried out as at March 31, 2021. The present value of the defined benefit obligations and the related current service cost and past service cost, were measured using the Projected Unit Credit Method.

Based on the actuarial valuation obtained in this respect, the following table sets out the details of the employee benefit obligation and the plan assets as at balance sheet date:

Particulars	(₹ in Lakhs)	
	As at 31 March 2021	As at 31 March 2020
	Gratuity (Funded plan)	Gratuity (Funded plan)
<b>(i) Change in Defined Benefit Obligation</b>		
Opening defined benefit obligation	186.43	151.31
Amount recognised in profit and loss		
Current service cost	19.61	14.14
Interest cost	11.22	10.22
Amount recognised in other comprehensive income		
Actuarial loss / (gain) arising from:		
Demographic assumptions	-	-
Financial assumptions	3.95	15.26
Experience adjustment	(3.18)	(1.95)
Other (Past Service cost)	-	-
Benefits paid	(21.17)	(2.55)
Closing defined benefit obligation	<u>196.86</u>	<u>186.43</u>
<b>(ii) Change in Fair Value of Assets</b>		
Opening fair value of plan assets	98.65	81.75
Adjustment to Opening fair value of plan assets	(4.88)	(2.45)

## Notes on Financial Statements for the Financial year ended on March 31, 2021

Particulars	(₹ in Lakhs)	
	As at 31 March 2021	As at 31 March 2020
	Gratuity (Funded plan)	Gratuity (Funded plan)
Amount recognised in profit and loss		
Interest income	5.81	5.32
Amount recognised in other comprehensive income		
Actuarial gain / (loss)		
Return on Plan Assets, Excluding Interest Income	0.77	0.31
Other (transfer in fund)	-	0.15
Contributions by employer	16.54	16.13
Benefits paid	(21.17)	(2.55)
Closing fair value of plan assets	<u>95.72</u>	<u>98.65</u>
<b>(iii) Plan assets comprise the following</b>		
	<u>Unquoted</u>	Unquoted
Insurance fund (100%)	<u>95.72</u>	98.65
<b>(iv) Principal actuarial assumptions used</b>	%	%
Discount rate	6.33	6.53
Employee Attrition Rate [Past Service (PS)]:		
0 to 5	15.00	15.00
5 to 10	10.00	10.00
10 to 19	5.00	5.00
19 to 51	5.00	5.00
Future Salary growth rate	10.00	10.00
<b>(v) Amount recognised in the Balance Sheet</b>		
	<u>As at 31<sup>st</sup> March, 2021</u>	As at 31 <sup>st</sup> March, 2020
Present value of obligations as at year end	<u>196.86</u>	186.43
Fair value of plan assets as at year end	<u>95.72</u>	98.65
Net (asset) / liability recognised as at year end	<u>101.14</u>	<u>87.78</u>
Recognised under :		
Short term provisions	5.16	13.70
Long term provisions	<u>95.98</u>	74.08
	<u>101.14</u>	<u>87.78</u>
<b>(vi) Sensitivity analysis</b>		

Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant, would have affected the defined benefit obligation by the amounts shown below.

## Notes on Financial Statements for the Financial year ended on March 31, 2021

(₹ in Lakhs)

Particulars	As at 31 <sup>st</sup> March, 2021		As at 31 <sup>st</sup> March, 2020	
	Increase	Decrease	Increase	Decrease
Discount rate (1% movement) - Gratuity	(178.30)	218.69	(170.73)	204.87
Future salary growth (1% movement) - Gratuity	215.01	(180.98)	201.65	(173.05)

The above sensitivity analyses have been calculated to show the movement in defined benefit obligation in isolation and assuming there are no other changes in market conditions at the reporting date. In practice, generally it does not occur. When we change one variable, it affects to others. In calculating the sensitivity, project unit credit method at the end of the reporting period has been applied.

### (vii) Expected future cash flows

(₹ in Lakhs)

Particulars	Less than a year	Between 1-2 years	Between 2-5 years	Over 5 years	Total
As at 31 <sup>st</sup> March , 2021					
Defined benefit obligations (Gratuity)	10.04	9.96	40.94	82.46	143.41

(₹ in Lakhs )

Particulars	Less than a year	Between 1-2 years	Between 2-5 years	Over 5 years	Total
As at 31 <sup>st</sup> March , 2020					
Defined benefit obligations (Gratuity)	29.09	9.00	31.98	75.01	145.08

### Other long-term employee benefits:

Compensated absences are payable to employees at the rate of daily basic salary and other components for each day of accumulated leave partially at the year end and partially on death or on resignation or upon retirement. The charge towards compensated absences for the year ended 31<sup>st</sup> March, 2020 based on actuarial valuation using the projected accrued benefit method is ₹ 39.08 lakhs (31<sup>st</sup> March 2019 : ₹ 29 lakhs)."

## Notes on Financial Statements for the Financial year ended on March 31, 2021

### NOTE NO.44

#### Contingent Liabilities and Commitments

Particulars	(₹ in Lakhs)	
	As at 31 <sup>st</sup> March 2021	As at 31 <sup>st</sup> March 2020
<b>(i) Contingent Liabilities</b>		
a) Guarantees given by the Company's bankers on behalf of the Company for the Company	25.00	25.00
b) other money for which the Company is contingently liable:		
(1) Letter of Credit outstanding	2,259.02	3,255.40
(2) Sales Tax (See Note 44.1)	27.03	27.03
(3) Income Tax (See Note 44.2)	27.78	-
	<b>2,338.83</b>	<b>3,307.43</b>
<b>(ii) Commitments</b>		
a) Estimated amount of contracts remaining to be executed on capital account and not provided for	-	-
b) Other commitments (see Note 44.3)	-	-
	<b>2,338.83</b>	<b>3,307.43</b>

44.1 The figure of ₹ 27.03 lakhs is as per the orders dated April 10, 2003 of the Assistant Commissioner of Sales Tax (Appeals), Thane. Thereafter, the Company had preferred an appeal before the Maharashtra Sales Tax Tribunal, which has passed its orders on August 27, 2009. However, the Company has not yet received the revised assessment orders giving effect to the above referred Tribunal orders. The Company has filed a Writ Petition before the Honourable High Court of Bombay contesting the Tribunal order.

44.2 The figure of ₹ 27.78 lakhs is as per the orders dated March 31, 2021 of Assessing Officer, National e- Assessment Centre, Delhi for Assessment year 2018-19. The Company had preferred an appeal before the Commissioner of Income-tax (Appeals).

44.3 The Company has imported certain raw materials and chemicals under the Advance Authorisation/License scheme without payment of duty subject to fulfilment of specified export obligations. However, the Company has yet to fulfil certain portion of these export obligations within the stipulated validity period. On a forward basis, the Company's management is confident of fulfilling these export obligations within the stipulated validity period and hence, no provision for the duty payable, in case the export obligation is not fulfilled, has been made in the accounts.

### NOTE NO.45

#### Payment to Auditors

Particulars	(₹ in Lakhs)	
	Year ended 31 <sup>st</sup> March 2021	Year ended 31 <sup>st</sup> March 2020
Statutory Auditors		
- Audit Fees	6.50	6.00
- For Quarterly-Limited Review/Audit	0.50	0.50
- For Other services - Certification, etc.	0.25	0.23
<b>Total</b>	<b>7.25</b>	<b>6.73</b>

## Notes on Financial Statements for the Financial year ended on March 31, 2021

### NOTE NO.46

#### Expenditure on In-house research and Development facility

Particulars	(₹ in Lakhs)	
	Year ended 31 <sup>st</sup> March 2021	Year ended 31 <sup>st</sup> March 2020
Research and Development Cost/Expenditure		
- Revenue	311.21	300.36
- Capital	2.41	14.58
Total of Research and Development Cost/Expenditure	<b>313.62</b>	309.47

During the financial year 2012-2013, the Company had set up an in-house Research and Development facility at A-514, TTC Industrial Area, Mahape, Navi Mumbai 400701. This facility has commenced research and development work on May 1, 2012. The facility has been recognised by the Department of Scientific and Industrial Research, Ministry of Science and Technology, Government of India vide its letter dated December 31, 2012 upto December 31, 2015 and vide its letter dated April 1, 2015 upto March 31, 2018 and vide its letter dated April 10, 2018 upto March 31, 2021.

### NOTE NO.47

#### Nature of Security in respect of Short Term secured Loan

Particulars	(₹ in Lakhs)	
	As at 31 <sup>st</sup> March, 2021	As at 31 <sup>st</sup> March, 2020
Export Packing Credit (In INR)	1,359.77	4,456.00
(Secured by way of hypothecation of Inventories, Receivables, other current assets and on all the present and future movable Plant and Machinery of the Company.)		

### NOTE NO.48

#### CORPORATE SOCIAL RESPONSIBILITY (CSR) ACTIVITY:

Particulars	(₹ in Lakhs)	
	As at 31 <sup>st</sup> March, 2021	As at 31 <sup>st</sup> March, 2020
Total Expenditure towards CSR activity	90.09	30.24
Amount required to be spent u/s 135 of Companies Act 2013	49.66	51.70
Excess/(Short)	<b>40.43</b>	(21.46)

In terms of Amendment to Companies (Corporate Social Responsibility Policy) Amendment Rules, 2021 (the CSR Rules 2021) effective from 22<sup>nd</sup> January, 2021, if a company fails to spend prescribed CSR amount during the year and such unspent amount pertains to any ongoing project, the company shall transfer the unspent amount to special bank account to be opened by the company in that behalf for the financial year in any scheduled bank to be called the Unspent Corporate Social Responsibility Account within a period of 30 days from the end of the relevant financial year. The Company have spent all unspent CSR amount of all the earlier years during the financial year 2020-21 and the Company does not have any unspent CSR amount as on 31<sup>st</sup> March, 2021.

## Notes on Financial Statements for the Financial year ended on March 31, 2021

### NOTE NO.49 EVENTS AFTER THE REPORTING PERIOD

The Board of Directors have recommended a final dividend of ₹. 2.75 (55 %) per equity share of ₹ 5/-each.

### NOTE NO.50

Previous year's figures have been regrouped/reclassified wherever necessary to correspond with the current year's classification/disclosure.

As per our report of even date attached

#### For JAYANTILAL THAKKAR & CO.

Chartered Accountants  
(Firm Reg. No. 104133W)

#### VIRAL A. MERCHANT

Partner  
Membership No: 116279

Mumbai: 21<sup>st</sup> May, 2021

#### For ANUH PHARMA LTD.

#### RITESH SHAH

Joint Managing Director  
(DIN: 02496729)

#### DARSHAN RAMPARIYA

Chief Financial Officer  
Mumbai: 21<sup>st</sup> May, 2021

#### VIVEK SHAH

Joint Managing Director  
(DIN: 02878724)

#### ASHWINI AMBRALE

Company Secretary

#### JASVANTLAL SHAH

Chirman  
(DIN: 00372600)







## LIST OF API's MANUFACTURED BY ANUH PHARMA LTD.

### MACROLIDES

- Erythromycin 11, 12 Carbonate
- Erythromycin Base
  - EU GMP AVAILABLE
  - CEP AVAILABLE
- Erythromycin Estolate
  - COFEPRIS CERTIFIED
- Erythromycin Propionate
- Erythromycin Ethyl Succinate
  - EU GMP AVAILABLE
  - CEP AVAILABLE
- Erythromycin Phosphate
- Erythromycin Stearate
  - COFEPRIS CERTIFIED
  - UK MHRA REGISTERED

### ANTI MALARIAL

- Sulfadoxine
  - WHO PREQUALIFIED
  - EU GMP AVAILABLE
- Pyrimethamine
  - WHO PREQUALIFIED
  - EU GMP AVAILABLE

### EXPECTORANT

- Ambroxol HCl
  - CEP AVAILABLE

### QUINOLONES

- Moxifloxacin HCl

### HIGHER MACROLIDES

- Azithromycin
  - CEP APPLIED

### INTERMEDIATES

- Erythromycin Oxime Base
- Iminoether (*Int. of Azithromycin*)
- Silylester (*Int. of Clarithromycin*)

### ANTI TB

- Pyrazinamide
  - EU GMP AVAILABLE
  - CEP AVAILABLE
  - WHO PREQUALIFIED
- Isoniazid
  - WHO PQ APPLIED

### ANTI BACTERIAL

- Chloramphenicol
  - COFEPRIS CERTIFIED
- Chloramphenicol Palmitate
  - COFEPRIS CERTIFIED

### ANTI HYPERTENSION

- Losartan Potassium
- Telmisartan

### ANTI DIABETIC

- Gliclazide

### CORTICOSTEROIDS

- Beclomethasone Dipropionate
- Betamethasone Acetate
- Betamethasone Dipropionate
- Betamethasone Sodium Phosphate
- Betamethasone Valerate
- Clobetasone Butyrate
- Clobetasol Propionate
- Deflazacort
- Dexamethasone Acetate
- Dexamethasone Sodium Phosphate
- Mometasone Furoate
- Prednisolone Acetate
- Prednisolone Sodium Phosphate
- Triamcinolone Base
- Triamcinolone Acetonide
- Methyl Prednisolone

### PRODUCTS UNDER DEVELOPMENT

#### ANTI PSYCHOTIC

- Aripiprazole

#### ANTIHISTAMINE

- Fexofenadine HCl
- Phenylephrine HCl

#### RHEUMATOID ARTHRITIS

- Sulfasalazine

#### ANTI INFLAMMATORY

- Celecoxib

#### ANTIBIOTIC

- Sulfadiazine


#### ANTI DIABETIC

- Sitagliptin
- Vildagliptin

#### ANTI FUNGAL

- CLOTRIMAZOLE

# 1. Confirmation of WHO for Pyrimethamine (Non - Micronised)


  
 26, AVENUE APPA - CH-1211 GENEVA 27 - SWITZERLAND - TEL. CENTRAL +41 22 791 3111 - FAX CENTRAL +41 22 791 3111 - WWW.WHO.INT

**Confirmation of WHO**  
**Active Pharmaceutical Ingredient Prequalification (CPQ)**

**Date:** 25 September 2020  
**WHO prequalification number:** WHOAPI-364a  
**Active pharmaceutical ingredient (API):** Pyrimethamine  
**API specification number:** STPPMT/010-02 (version 02) (non-micronised)  
**Re-test Period:** 36 months  
**Storage conditions:** Do not store above 30°C, protect from moisture, protect from light


**API Manufacturers:**  
 Anah Pharma Ltd.  
 Manufacturing Block: AB-3, AJM - 01, AJM - 02 & Blending Room  
 E-17/3 & 17/4 & E-18, M.I.D.C, Tarapur Boisar, Dist. Thane-401506  
 India  
**API Intermediate manufacturers: (in addition to the API manufacturers above)**  
 Not applicable.

This is to confirm that Pyrimethamine, manufactured by Anah Pharma Ltd, has been prequalified by the World Health Organization (WHO). Further information on the API prequalification procedure can be located on the Prequalification Unit - Medicines Assessment Team web page: [http://www.who.int/prequalinfo\\_applicants/API\\_info\\_applicants.htm](http://www.who.int/prequalinfo_applicants/API_info_applicants.htm).  
 API prequalification provides an assurance that the supplied API is of good quality. The comprehensive evaluation procedure has two components: assessment of the API master file (APMF) to verify compliance with WHO norms and standards, and assessment of the sites of API manufacture to verify compliance with WHO GMP requirements.  
 The decision to prequalify Pyrimethamine, manufactured by Anah Pharma Ltd, is particular to the specific details assessed during evaluation, such as sites of manufacture, method of manufacture, control of the API and retest period.

منظمة الصحة العالمية • 世界卫生组织  
 Organisation mondiale de la Santé • Всемирная организация здравоохранения • Organización Mundial de la Salud

Page 1 of 9

# 2. Confirmation of WHO for Pyrimethamine (Micronised)


  
 26, AVENUE APPA - CH-1211 GENEVA 27 - SWITZERLAND - TEL. CENTRAL +41 22 791 3111 - FAX CENTRAL +41 22 791 3111 - WWW.WHO.INT

**Confirmation of WHO**  
**Active Pharmaceutical Ingredient Prequalification (CPQ)**

**Date:** 25 September 2020  
**WHO prequalification number:** WHOAPI-364b  
**Active pharmaceutical ingredient (API):** Pyrimethamine  
**API specification number:** STPPMT/011-02 (version 02) (micronised)  
**Re-test Period:** 12 months  
**Storage conditions:** Do not store above 30°C, protect from moisture, protect from light



**API Manufacturers:**  
 Anah Pharma Ltd.  
 E-17/3 & 17/4 & E-18, M.I.D.C, Tarapur Boisar, Dist. Thane-401506  
 India  
**API Intermediate manufacturers: (in addition to the API manufacturers above)**  
 Not applicable.

This is to confirm that Pyrimethamine, manufactured by Anah Pharma Ltd, has been prequalified by the World Health Organization (WHO). Further information on the API prequalification procedure can be located on the Prequalification Unit - Medicines Assessment Team web page: [http://www.who.int/prequalinfo\\_applicants/API\\_info\\_applicants.htm](http://www.who.int/prequalinfo_applicants/API_info_applicants.htm).  
 API prequalification provides an assurance that the supplied API is of good quality. The comprehensive evaluation procedure has two components: assessment of the API master file (APMF) to verify compliance with WHO norms and standards, and assessment of the sites of API manufacture to verify compliance with WHO GMP requirements.  
 The decision to prequalify Pyrimethamine, manufactured by Anah Pharma Ltd, is particular to the specific details assessed during evaluation, such as sites of manufacture, method of manufacture, control of the API and retest period.  
 The prequalification status of this API and associated details can be verified from the WHO List of Prequalified API web page: [http://www.who.int/prequalinfo\\_applicants/API\\_PQ\\_List.htm](http://www.who.int/prequalinfo_applicants/API_PQ_List.htm). They are not detailed in this document as they are subject to change over time.

منظمة الصحة العالمية • 世界卫生组织  
 Organisation mondiale de la Santé • Всемирная организация здравоохранения • Organización Mundial de la Salud

Page 1 of 8

# 3. CEP of Ambroxol Hcl



  
 edqm European Directorate for the Quality of Medicines  
 Council of Europe CONSEIL DE L'EUROPE

**Certification of Substances Department**  
**Certificate of suitability**  
**No. R0-CEP 2018-033-Rev 00**

1 **Name of the substance:**  
 2 **AMBROXOL HYDROCHLORIDE**  
 3 **Name of holder:**  
 4 **ANAH PHARMA LTD**  
 5 3-A, Shivsagar Estate, North Wing  
 6 Dr Annie Besant Road, Worli  
 7 India-400 018 Mumbai, Maharashtra  
 8 **Site(s) of production:**  
 9 **SEE ANNEX 1**

10 After examination of the information provided on the manufacturing method and subsequent processes (including purification) for this substance on the site(s) of production listed in annex, we certify that the quality of the substance is suitably controlled by the current version of the monograph **AMBROXOL HYDROCHLORIDE** no. 1489 of the European Pharmacopoeia, current edition including supplements.  
 11  
 12  
 13  
 14  
 15 In the last steps of the synthesis isopropyl alcohol and water are used as solvents. Their residual content is limited by the test for loss on drying described in the monograph with a limit of not more than 0.5%.  
 16  
 17  
 18 A risk management summary for elemental impurities has been provided. (Annex 2)  
 19 The re-test period of the substance is 36 months if stored in double polyethylene bags placed in a polyethylene drum.  
 20  
 21 The holder of the certificate has declared the absence of use of material of human or animal origin in the manufacture of the substance.  
 22  
 23 The submitted dossier must be updated after any significant change that may alter the quality, safety or efficacy of the substance.  
 24  
 25 Manufacture of the substance shall take place in accordance with the Good Manufacturing Practice and in accordance with the dossier submitted.  
 26

Address: 7 Allée Kastner, CS 30036  
 F-67081 Strasbourg (France)  
 Tel: +33 (0) 3 88 41 30 30 - Fax: +33 (0) 3 88 41 27 71 - e-mail: cep@edqm.eu  
 Internet: <http://www.edqm.eu>

# 4. CEP of Erythromycin



  
 edqm European Directorate for the Quality of Medicines  
 Council of Europe CONSEIL DE L'EUROPE

**Certification of Substances Department**  
**Certificate of suitability**  
**No. R1-CEP 2005-205-Rev 08**



1 **Name of the substance:**  
 2 **ERYTHROMYCIN**  
 3 **Name of holder:**  
 4 **ANAH PHARMA LTD**  
 5 3-A, Shivsagar Estate, North Wing  
 6 Dr Annie Besant Road, Worli  
 7 India-400 018 Mumbai, Maharashtra  
 8 **Site(s) of production:**  
 9 **SEE ANNEX 1**

**THIS CERTIFICATE SUPERSEDES THE PREVIOUS CERTIFICATE**  
**R1-CEP 2005-205-REV 07**

10  
 11  
 12 After examination of the information provided on the manufacturing method and subsequent processes (including purification) for this substance on the site(s) of production listed in annex, we certify that the quality of the substance is suitably controlled by the current version of the monograph **ERYTHROMYCIN** no. 179 of the European Pharmacopoeia, current edition including supplements, only if it is supplemented by the test(s) mentioned below, based on the analytical procedure(s) given in annex.  
 13  
 14  
 15  
 16  
 17  
 18 - Test for residual solvents by gas chromatography (Annex 2)  
 19 Methylene chloride not more than 600 ppm  
 20  
 21 In the last steps of the synthesis water is used as solvent.  
 22  
 23 The re-test period of the substance is 3 years if stored in double polyethylene bags, placed in a polyethylene drum.  
 24  
 25 The holder of the certificate has declared the absence of use of material of human or animal origin in the manufacture of the substance.  
 26  
 27 The submitted dossier must be updated after any significant change that may alter the quality, safety or efficacy of the substance.  
 28  
 29 Manufacture of the substance shall take place in accordance with the Good Manufacturing Practice and in accordance with the dossier submitted.

Address: 7 Allée Kastner, CS 30036  
 F-67081 Strasbourg (France)  
 Tel: +33 (0) 3 88 41 30 30 - Fax: +33 (0) 3 88 41 27 71 - e-mail: cep@edqm.eu  
 Internet: <http://www.edqm.eu>

## 5. CEP of Pyrazinamide

**Certification of Substances Department**  
**Certificate of suitability**  
**No. R1-CEP 2005-059-Rev 03**

1 *Name of the substance:*  
 2 **PYRAZINAMIDE**

3 *Name of holder:*  
 4 **ANUH PHARMA LTD**  
 5 3-A, Shivsagar Estate, North Wing  
 6 Dr Annie Besant Road, Worli  
 7 India-400 018 Mumbai, Maharashtra

8 *Site(s) of production:*  
 9 **SEE ANNEX 1**

10 **THIS CERTIFICATE SUPERSEDES THE PREVIOUS CERTIFICATE**  
 11 **R1-CEP 2005-059-REV 02**

12 After examination of the information provided on the manufacturing method and subsequent processes (including purification) for this substance on the site(s) of production listed in annex, we certify that the quality of the substance is suitably controlled by the current version of the monograph **PYRAZINAMIDE** no. 859 of the European Pharmacopoeia, current edition including supplements.

17 In the last steps of the synthesis water is used as solvent.

18 No elemental impurity classified in ICH Q3D is intentionally introduced in the manufacture of the substance.

20 The substance is packed in double polyethylene bags, placed in a polyethylene drum.

21 The holder of the certificate has declared the absence of use of material of human or animal origin in the manufacture of the substance.

23 The submitted dossier must be updated after any significant change that may alter the quality, safety or efficacy of the substance.

25 Manufacture of the substance shall take place in accordance with the Good Manufacturing Practice and in accordance with the dossier submitted.

27 Failure to comply with these provisions will render this certificate void.

Address: 7 Allée Kastner, CS 30026  
 F-67081 Strasbourg (France)  
 Tel: +33 (0) 3 88 41 30 30 - Fax: +33 (0) 3 88 41 27 71 - e-mail: cep@edom.eu  
 Internet: <http://www.edom.eu>

## 6. CEP of Erythromycin Ethyl Succinate




**Certification of Substances Department**  
**Certificate of suitability**  
**No. R1-CEP 2007-235-Rev 07**

1 *Name of the substance:*  
 2 **ERYTHROMYCIN ETHYLSUCCINATE**

3 *Name of holder:*  
 4 **ANUH PHARMA LTD**  
 5 3-A, Shivsagar Estate, North Wing  
 6 Dr Annie Besant Road, Worli  
 7 India-400 018 Mumbai, Maharashtra

8 *Site(s) of production:*  
 9 **SEE ANNEX 1**

10 **THIS CERTIFICATE SUPERSEDES THE PREVIOUS CERTIFICATE**  
 11 **R1-CEP 2007-235-REV 06**

12 After examination of the information provided on the manufacturing method and subsequent processes (including purification) for this substance on the site(s) of production listed in annex, we certify that the quality of the substance is suitably controlled by the current version of the monograph **ERYTHROMYCIN ETHYLSUCCINATE** no. 274 of the European Pharmacopoeia, current edition including supplements, only if it is supplemented by the test(s) mentioned below, based on the analytical procedure(s) given in annex.

18 Any unspecified impurity detected by the test for related substances of the monograph is limited to not more than 0.2%.

20 - Test for residual solvents by gas chromatography (Annex 2)  
 21 Acetone not more than 5000 ppm

22 In the last steps of the synthesis water is used as solvent.

23 The re-test period of the substance is 3 years if stored in a double polyethylene bag, placed in a polyethylene drum.

25 The holder of the certificate has declared the absence of use of material of human or animal origin in the manufacture of the substance.

27 The submitted dossier must be updated after any significant change that may alter the quality, safety or efficacy of the substance.

Address: 7 Allée Kastner, CS 30026  
 F-67081 Strasbourg (France)  
 Tel: +33 (0) 3 88 41 30 30 - Fax: +33 (0) 3 88 41 27 71 - e-mail: cep@edom.eu  
 Internet: <http://www.edom.eu>

## 7. EIR - USFDA

**From:** Jose Martinez@fda.hhs.gov  
**Subject:** [WARNING: MESSAGE ENCRYPTED] FDA PMD146 EIR  
**Date:** 16 November 2019 at 1:23:50 AM IST  
**To:** anuh@ak1932.com

11/15/2019  
 VP - Quality Mr. Bhushan Rajput  
 Anuh Pharma Ltd.  
 E-17/3 & 17/4 Tarapur, Boisar Thane, Maharashtra

Dear Mr. Rajput:

The U.S. Food and Drug Administration (FDA) conducted an inspection at Anuh Pharma Ltd., FEI 3001174909, located at E-17/3 & 17/4 Tarapur, Boisar, Thane, Maharashtra, from 09/16/2019 to 09/20/2019. FDA has determined that the inspection classification of this facility is "no action indicated" ("NAI"). Based on this inspection, this facility is considered to be in an acceptable state of compliance with regards to current good manufacturing practice (CGMP).


This letter is not intended as an endorsement or certification of the facility. It remains your responsibility to ensure continued compliance with CGMP.

An inspection classification of NAI for CGMP compliance will not directly negatively impact FDA's assessment of any pending marketing application referencing this facility. Please note, however, that application approval will depend on a product- and application-specific facility assessment conducted by the appropriate CDER or CVM review office. This letter does not address or reflect FDA's decision making with respect to any potential non-CGMP compliance issues.


FDA has concluded that this inspection is "closed" under 21 CFR 20.64(d)(3), and we are enclosing a copy of the narrative portion of the Establishment Inspection Report (EIR). It may reflect redactions made by FDA in accordance with the Freedom of Information Act (FOIA) and 21 CFR part 20. This, however, does not preclude you from requesting additional information under FOIA.

If you have any questions regarding this letter, you may contact John Diehl, Director Compliance Branch via telephone at 2142535200 or email at [john.diehl@FDA.HHS.GOV](mailto:john.diehl@FDA.HHS.GOV) (Do not Sincerely,

Jose Martinez  
 SUPV CONSUMER SAFETY OFFICE  
 PHARMACEUTICAL QUALITY IS INVESTIGATION BRANCH (PHRM2-IB)



## 8. WHO Pre-qualification


**World Health Organization**  
 26 AVENUE APPA - CH-1211 GENEVA 27 - SWITZERLAND - TEL: GENERAL +41 22 791 2111 - FAX: GENERAL +41 22 791 3111 - WWW.WHO.INT

Tel. direct: +41 22 791 3615  
 Fax direct: +41 22 791 4730  
 E-mail: [prequalinspection@who.int](mailto:prequalinspection@who.int)

Mr Vivek Shah  
 Anuh Pharma Ltd  
 E-17/3 & E-17/4 M.L.D.C. Tarapur  
 Taluka Palghar, District Thane  
 401 506 Boisar, Maharashtra  
 India

In reply please refer to: PS-4473/V5/TK1  
 Your reference:

2 August 2019

Dear Mr. Shah,

**WHO Prequalification Team – Inspection Services**  
**Closing of Inspection**

I refer to the inspection that was performed by Mr Vinal Sachdeva, Dr Manuel Barra Lorente and Dr Sotirios Paraschos the details of which are outlined below:

Site name: Anuh Pharma Ltd  
 Unit: E-17/3 & E-17/4  
 Block: NA  
 Address: M.L.D.C. Tarapur Taluka Palghar, District Thane, Boisar, Maharashtra, India  
 Date: 26 – 28 November 2018

Thank you for your email dated 24 June 2019 and the corrective actions to the deficiencies listed in the inspection report. The actions taken, or proposed to be taken, to correct the deficiencies have been reviewed by the Prequalification Inspection Group.

The Prequalification Inspection Group has recommended that the APIs:

- WHOAPI-158 Pyrazinamide
- WHOAPI-234 Sulfadoxine
- WHOAPI-364 Pyrimethamine



can be considered to be compliant with the standards of Good Manufacturing Practices (GMP) for Active Pharmaceutical Ingredients (APIs) published by the World Health Organization (WHO), for the scope of activities listed below:

- manufacture and packaging of Active Pharmaceutical Ingredients by chemical synthesis.

Furthermore the inspection findings and your response allow us to recommend to the Prequalification Assessment Group that the site inspected may be named/continue to be named as API manufacturing site in dossiers assessed within the WHO Prequalification Team.

منظمة الصحة العالمية • 世界卫生组织  
 Organisation mondiale de la Santé • Всемирная организация здравоохранения • Organización Mundial de la Salud

# 9. EU GMP Certificate

Certificado Nº / Certificate No: ES/125/19

**CERTIFICADO DE CUMPLIMIENTO DE NCF<sup>1,2</sup> /  
CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER<sup>2</sup>**

**Parte 1 / Part 1**

**Emitido en virtud de una inspección según artículo 111(5) de la Directiva 2001/83/CE . / Issued following an inspection in accordance with article 111(5) of Directive 2001/83/EC.**

La autoridad competente de España certifica lo siguiente: *The competent authority of Spain confirms the following:*

El fabricante **ANUH PHARMA LTD** en su planta ubicada en E-17/3 & E-17/4 M.I.D.C. Tarapur District Thane, Boisar, 401 506 Maharashtra India es un fabricante de sustancias activas inspeccionado de acuerdo con: artículo 111(1) de la Directiva 2001/83/CE incorporada en la siguiente legislación nacional: artículo 64, Real Decreto Legislativo 1/2015, de 24 de julio y artículo 108, Real Decreto Legislativo 1/2015, de 24 de julio.

*The manufacturer ANUH PHARMA LTD site address E-17/3 & E-17/4 M.I.D.C. Tarapur District Thane, Boisar, 401 506 Maharashtra India is an active substance manufacturer that has been inspected in accordance with: article 111(1) of Directive 2001/83/CE transposed in the following national legislation: article 64, Royal Legislative Decree 1/2015, of 24th of July and article 108, Royal Legislative Decree 1/2015, of 24th of July.*

En base a la información obtenida en las visitas de inspección a este fabricante, la última de ellas realizada el 26/11/2018, se considera que el mismo cumple con los principios de Normas de Correcta Fabricación para sustancias activas establecidos en artículo 47 de la Directiva 2001/83/CE.

*From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 26/11/2018, it is considered that it complies with the principles of GMP for active substances referred to in article 47 of Directive 2001/83/EC.*

Este certificado refleja la situación de la planta de fabricación en la fecha en que se efectuó la inspección antes citada, y no puede considerarse que acredite el cumplimiento si han transcurrido más de tres años desde esa fecha de inspección. Sin embargo, este periodo de validez podrá verse reducido o ampliado mediante el empleo de la herramienta de análisis de riesgos y su inclusión en el correspondiente campo de Restricciones y Aclaraciones.

*This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field.*

Este certificado es válido sólo cuando se presente con todas las páginas y las Partes 1 y 2.

*This certificate is valid only when presented with all pages and both Parts 1 and 2.*

La autenticidad de este certificado puede ser verificada en EudraGMP. Si no apareciera, por favor contacte con la autoridad emisora.

*The authenticity of this certificate may be verified in EudraGMP. If it does not appear, please contact the issuing authority.*

<sup>1</sup> El certificado al que se hace referencia en el párrafo 111(5) de la Directiva 2001/83/CE y 80(5) de la Directiva 2001/82/CE, es también aplicable para importadores. / The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, is also applicable to importers.  
<sup>2</sup> La guía para la interpretación de este formulario puede encontrarse en el menú de ayuda de la base de datos EudraGMP. / Guidance on the interpretation of this template can be found in the help menu of EudraGMP database.  
<sup>3</sup> Estas siglas están en consonancia con las recomendaciones GMP de la OMS. / These requirements fulfil the GMP recommendations of WHO.

Agencia Española de Medicamentos y Productos Sanitarios


Fecha de la firma: 20/05/2019

Puede comprobar la autenticidad del documento en la sede de la AEMPS: <https://wada.aemps.gob.es>

CORREO ELECTRONICO: [sgcm@aemps.es](mailto:sgcm@aemps.es)


Página 1 de 4

Localizador: X 6 6 5 L O B E 7 C



C/ CAMPEZO, 1 - EDIFICIO B  
06002 MADRID  
Tel: (+34) 91 802 52 01  
Fax: (+34) 91 802 52 43

# 10. GMP Certificate



Office of The Commissioner,  
Food & Drugs Administration M.S.  
Bandra - Kuris Complex,  
Bandra (E),  
Mumbai - 400 051  
Date :-03 Jul 2021

**CERTIFICATE OF GOOD MANUFACTURING PRACTICES**

This Certificate conforms to the format recommended by the World Health Organization.  
(General instructions and explanatory notes attached).

Certificate No.: **NEW-WHO-GMP/CERT/KD/98500/2021/11/35817**

On the basis of the inspection carried out on **09/12/2020 & 10/12/2020** we certify that the site indicated on this Certificate complies with **Good Manufacturing Practices** for the dosage forms, categories and activities listed in Table 1.

1. Name of the Firm : **ANUH PHARMA LTD.**  
Address : **E-17/3, E-17/4 & E-16, OPF, BRUJ ICE FACTORY, M.I.D.C. TARAPUR, BOISAR THANE 401506 MAHARASHTRA STATE, INDIA**  
KD1194 in Form 25,  
KD990 in Form 28

2. Licence No. : **KD990 in Form 28**


Sr.No.	Dosage Form(s)	Category(ies)	Activity(ies)
1	Active Pharmaceutical Ingredients ( Bulk Drugs)	General ( Other than Cephalosporins, Penicillin, Cytotoxic, Hormones )	Production, Filling, Packing, labelling, Quality Control, Quality Assurance

The responsibility for the quality of the individual batches of the pharmaceutical products manufactured through this process lies with the manufacturer.


This certificate remains valid until 29 May 2024 . It becomes invalid if the activities and / or categories certified herewith are changed or if the site is no longer considered to be in compliance with GMP.

Address of certifying authority :  
Food & Drug Administration, M.S.  
Bandra-Kuris Complex,  
Bandra (E), Mumbai - 400 051,  
Maharashtra,INDIA.  
Tel: +91-22-26591959/34  
Fax: +91-22-26591959  
INDIA PHARMA CERT - NEW-WHO-GMP/CERT  
NEW98500/2021/11/35817

Name of the Authorised person : **D. R. GAHANE**




Signature :  
Stamp and Date : **Joint Commissioner (IG) & Controlling Authority**  
Food & Drug Administration, M.S.  
Bandra (E), Mumbai  
Maharashtra State, India  
Date:03 Jul 2021




## Financial Journey so far

(₹ in Lakhs)



## Outflow of Dividend

(₹ in Lakhs)



\* Including Special interim dividend of ₹ 1.25 per share declared on February 14, 2014 on the occasion of completion of 25 years of commencements of production activities.

# Including Interim dividend of ₹ 2.75/- per share declared for the financial year 2019-20.

\*\* The Board of Directors recommended final Dividend of ₹ 1.50/- per share i.e. 30% for the FY 2020-21 subject to the approval of shareholders.

## Journey So Far...

Year	Achievements
1989	Started manufacturing Erythromycin salts with capacity of 150 MTPA, followed by doubling the capacity to 300 MTPA in 1995.
2002	Received WHO-GMP for its facilities.
2006	Doubled the capacity by acquiring new plot of 1800 SQMT to expand the output capacity 600 MTPA.
2010	COS, EU/GMP approval for Erythromycin, Erythromycin ethyl succinate and Pyrazinamide.
2012	Acquired R&D assets of Invent Pharma- a Spanish Company and got DSIR approval.
2013	COS, EU/GMP renewal for Pyrazinamide .
2014	Received approval from COFEPRIS, Mexico for marketing its Erythromycin estolate, Erythromycin stearate and Erythromycin ethyl succinate.
2015	COS renewal for Erythromycin, Erythromycin ethyl succinate and pyrazinamide.
2015	DMF approval received for sulphadoxine (Anti malarial) for Europe for veterinary use.
2015	Received approval from COFEPRIS, Mexico for marketing its Chloramphenicol and Chloramphenicol palmitate.
2015	DMF approval received from WHO Geneva pre qualification authorities for sulphadoxine for human use.
2017	Restoration of COS for Erythromycin, Erythromycin ethyl succinate and pyrazinamide.
2017	Restoration of WHO Geneva pre qualification authorities for sulphadoxine and pyrazinamide.
2017	Written confirmation for sales to EU received from CDSCO (Govt. of India).
2017	DMF approval received from UK MHRA for Erythromycin Stearate.
2018	Received certificate of GMP (WHO GMP) from FDA Maharashtra.
2019	Received EDQM attestation of Inspection for Erythromycin Ethyl Succinate.
2019	Received approval from WHO- Geneva Pre qualification for Pyrazinamide and sulphadoxine.
2019	Enhanced the capacity by acquiring new plot of 7800 SQMT to expand the output capacity by 600 MTPA.
2019	USFDA inspection passed successfully with zero 483 observation.
2020	Received CEP from EDQM for Ambroxol HCL (expectorant cum mucolytic agent) during January, 2020.
2021	Applied for European Directorate for Quality Medicine (EDQM) for application of CEP for Azithromycin (Higher macrolides)
2021	Applied for WHO – Geneva Pre qualification for Isoniazid (Anti TB)



# SERVING SOCIETY..... FOR BETTER TOMORROW



Donated Variant II Hemoglobin Testing System to MCGM – Comprehensive Thalassemia Care, Pediatric Hematology – Oncology & MBT Centre through Sevantilal Kantilal Trust [₹ 20,25,000/-]

Donated Furniture to Sanskar Balmandir School [₹ 4,00,000/-]



CSR Contribution made to Vision Foundation of India for Cataract Surgeries [₹ 4,00,000/-]

Donated Posterior Vitrectomy Machine R. N. C. Free Eye Hospital, Valsad [₹ 16,00,000/-]





**REGISTERED OFFICE:**

CIN: L24230MH1960PLC011586

3-A, Shivsagar Estate, North Wing, Dr. Annie Besant Road, Worli, Mumbai 400 018

Tel: 022 6622 7575 | Fax: 022 6622 7600

Email: anuh@sk1932.com | Web: www.anuhpharma.com

**MANUFACTURING UNIT:**

E 17/3, 17/4, E-18, MIDC, Boisar, Tarapur, Taluka Palghar, Thane 401 506.

Tel: 02525 605361

**R&D:**

A-514, TTC Industrial Area, MIDC, Mahape, Navi Mumbai 400 701

Tel: 022 4119 3333 | Fax: 022 4119 3300 | Email: research@anuhpharma.com

